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ABSTRACT
Significant changes in dietary habits have led to a rampant increase in metabolic
disorders. Non-alcoholic fatty liver disease (NAFLD) is one such disorder characterized
by the excess buildup of fat in hepatocytes of people who drink little or no alcohol. If not
managed, NAFL (simple steatosis) progress into nonalcoholic steatohepatitis (NASH) and
further deteriorate to cirrhosis leading to severe illness or even death. Drug disposition
proteins (enzymes and transporters) in liver control the systemic exposure of drugs and
xenobiotics in human and drive the efficacy as well as adverse events in the body.
Therefore, it is critical to address the effect of NAFLD on the abundance of these proteins.
A variation would result in an altered pharmacokinetic and/or pharmacodynamic profile of
substrate drugs in patients with NAFLD. Most studies were performed in preclinical
species (rat, mice) and only a few reports are available in human. The primary objective of
this doctoral project was to investigate the effect of NALFD on the abundance of hepatic
drug disposition proteins (DDP) in a human liver-bank. The levels of proteins were
determined using an LC-MS/MS based label-free, global proteomics method. In addition,
CYP3A4 enzyme kinetics parameters were determined using midazolam as a probe
substrate. Considerable changes in the protein expression and activity of CYP3A4 and
CYP1A2 were found in NAFL and NASH. Only marginal alterations were observed for
other cytochrome P450 enzymes in this study. Levels of uridine 5'-diphosphoglucuronosyltransferases (UGT) and sulfotransferases (SULT) in NAFLD were mostly
unaltered. Dysregulation of mitochondrial proteins involved in lipid metabolism
(ACADSB, ACSM3/5, CPS1) was also observed. A significant downregulation of
CYP3A4 protein and activity but not mRNA in NAFLD was observed suggesting that post-

transcriptional changes may play a more significant role in the observed phenotypic
perturbations for the isoform. Overall, enzyme kinetics and quantitative protein abundance
data from this project will be important in the development of physiologically based
pharmacokinetic (PBPK) models for prediction of drug disposition in the NAFLD
population
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PREFACE
This dissertation was prepared according to the University of Rhode Island
Thesis/Dissertation Process: From Proposal to Defense standards for the manuscript
format. This dissertation consists of five manuscripts that have been combined to satisfy
the requirements of the Department of Biomedical and Pharmaceutical Sciences, College
of Pharmacy, University of Rhode Island. Two of the manuscript have already been
published while three others would be submitted in future.
Manuscript I: Nonalcoholic fatty liver disease and hepatic drug metabolism enzymes
and transporters.
This manuscript reviews the current literature on alterations in drug metabolism enzymes
in NAFLD with focus on human studies. The work has been prepared as a research article
for submission to Drug Metabolism Reviews, Taylor & Francis Online.
Manuscript II: Multiplex and Label-Free Relative Quantification Approach for
Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver
Microsomes Using SWATH-MS.
This manuscript described the development of a mass spectrometry-based method for
simultaneous quantification of CYP450 enzymes in human liver microsomes. The protein
abundance was further correlated with mRNA and activity. It was found that for most CYP
enzymes, protein levels correlated stronger with activity than the mRNA. The work was
published in the Journal of Proteome Research, 2017 Nov 3;16(11):4134-4143. PMID
28944677
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Manuscript III: Nonalcoholic fatty liver disease and diabetes is associated with
decreased CYP3A4 protein expression and activity in human liver
This work determined the effect of NAFLD and diabetes on the enzyme kinetic parameters
and protein abundance of CYP3A4, one of the most important drug metabolism enzymes.
A PBPK model was developed for NAFLD population with study generated in vitro
kinetics and protein expression data. The results suggested an almost two-fold decrease in
CYP3A4 activity and protein expression but not mRNA suggesting the involvement of
post-transcriptional alterations. The manuscript published as a research article in Molecular
Pharmaceutics, 2018 June 11; PMID 29792708
Manuscript IV: Effect of non-alcoholic fatty liver disease (NAFLD) on the protein
abundance and activity of hepatic drug metabolizing enzymes in human.
This manuscript determined the effect of NAFLD on the protein abundance of major drug
disposition proteins in the human liver. The results suggest downregulation of CYP1A2
and CYP3A4 activity while the levels of other CYP450 and drug metabolizing enzymes
were similar. This manuscript has been prepared as a research article for submission to the
Journal of Pharmacology and Experimental Therapeutics, ASPET Publications
Manuscript V: SWATH-MS based method for simultaneous relative quantification
of 25 clinically important drug transporters in human liver.
This manuscript describes the development of a SWATH-MS based method for
quantification of human xenobiotic transporters. The manuscript has been prepared as a
research article for submission to the Journal of Proteomics, Elsevier
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Other manuscripts authored during PhD program but not included in the
dissertation
Rohitash Jamwal, Ariel R Topletz, Bharat Ramratnam, Fatemeh Akhlaghi F. Ultra-highperformance liquid chromatography tandem mass-spectrometry for simple and
simultaneous quantification of cannabinoids. J Chromatogr B Analyt Technol Biomed
Life Sci. 2017 Mar 24;1048:10-18. PMID: 28192758
This project aimed to develop and validate a LC-MS/MS based method for simultaneous
quantification of cannabinoids in human plasma.
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Abstract
Significant lifestyle and diet changes in last few decades have led to a rampant increase in
metabolic diseases in human. Nonalcoholic fatty liver disease (NAFLD) is characterized
by the excessive buildup of fats in the liver. The disease can range from simple steatosis
(fat accumulation) to nonalcoholic steatohepatitis (NASH) which represents a severe form
of NAFLD and is accompanied with inflammation, fibrosis and hepatocyte damage in
addition to significant steatosis. Hepatic proteins involved in metabolism (enzymes) and
uptake/efflux (transporters) of xenobiotics are collectively known as drug disposition
proteins (DDPs). While the expression of DDPs is well studied in healthy volunteers, our
understanding of the alterations of these proteins in NAFLD is limited. Much of the
existing knowledge on the subject is derived from pre-clinical species, and clinical
translation of these findings is poor. The effect of NAFLD on these proteins in human is
debatable and currently lacks a consensus among different reports. Global label-free, massspectrometry-based quantitative proteomics is a promising tool to study the changes
associated with NAFLD without the need for protein-specific targeted quantification.
Protein expression is important in vitro physiological parameter controlling the
pharmacokinetics. The last decade has also seen a rise in the use of physiologically based
pharmacokinetic (PBPK) modeling for prediction of drug pharmacokinetics in special
populations. Here, we present a review of current literature on the alterations in human
hepatic DDPs in NAFLD.

Keywords: NAFLD, NASH, Cytochrome P450, LC-MS/MS, Proteomics, PBPK
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Introduction
Substantial changes in the dietary habits of our generation are fueling an epidemic
of various metabolic disorders. Nonalcoholic fatty acid liver disease (NAFLD) is one such
metabolic syndrome which is rising at an alarming rate (Ahmed 2015; Mikolasevic et al.
2016). The prevalence of NAFLD is higher in patients with diabetes, obesity, hyperlipemia,
hypertension and hypertriglyceridemia (Lonardo et al. 2016; Younossi, Koenig, et al.
2016). NAFLD is characterized by the presence of greater than 5% of hepatic fat in people
without significant alcohol intake (<20 g per day for women, <30 g per day for men)
(Chalasani et al. 2012; Leoni et al. 2018). Fat-accumulation in hepatocytes is triggered by
various mechanisms which include the increased hepatic uptake of circulating fatty acids,
increased hepatic de novo fatty acid synthesis, decreased hepatic beta-oxidation and
decreased hepatic lipid export (Geisler and Renquist 2017). The disease is characterized
by the accumulation of free fatty acids and triglycerides in the hepatocytes, and severity
ranges from benign steatosis to nonalcoholic steatohepatitis (figure 1) (McCullough 2006).
NASH, characterized by significant lobular inflammation, hepatic fibrosis, and hepatocyte
necrosis, can progress to life-threatening liver cirrhosis and hepatocellular carcinoma
(HCC) (Farrell and Larter 2006).
Pathogenesis, epidemiology and risk factors
The current “multiple hit” theory for the pathogenesis of NAFLD proposes first hit
as the accumulation of lipid droplets (triglycerides) in >5% of liver hepatocytes (Takaki et
al. 2014). A successive second hit characterized by excessive free radical and proinflammatory cytokine formation leading to inflammation, necrosis and consequently,
fibrosis (Takaki et al. 2014). A number of histologic scoring systems have been introduced
3

in the past decade for diagnostic evaluation of different stages of NAFLD (Brunt E. M. et
al. 1999; Kleiner et al. 2005; Bedossa et al. 2012). Pathologists commonly differentiate
different stages of NAFLD using semi-quantitative evaluation based on steatosis, lobular
inflammation, hepatocellular ballooning, and/or fibrosis (Brunt E. M. 2016). Liver biopsy
is the gold standard for the diagnosis of NAFLD but ethical, and feasibility constraints limit
the direct assessment of its prevalence. The global prevalence of NAFLD diagnosed by
imaging was estimated to be 25.2%, and it was >30% in the Middle East and South
America (Chalasani et al. 2018). The lowest prevalence of NAFLD was reported from
Africa (13.5%). The prevalence of NAFLD diagnosed with ultrasonography was 24.13%.
The overall prevalence of nonalcoholic steatohepatitis (NASH) in general populations is
estimated to be between 1.5-6.5% (Chalasani et al. 2018). In the USA, NAFLD is also
associated with significant economic (~$103 billion) and clinical burden (~64 million
people projected to have NAFLD) (Younossi, Blissett, et al. 2016). Ethnic differences
exist in the prevalence of NALFD and Hispanics are more susceptible to the disease as
compared to Caucasians and Afro-Americans (Kalia and Gaglio 2016). The disease was
initially thought to be present only in obese adults; however recent studies have shown its
prevalence in people with normal BMI as well as children (Margariti et al. 2012; Anderson
et al. 2015; Bush et al. 2017). Certain genetic factors are also responsible for predisposition
of carriers to NAFLD. PNLA3 (Patatin-like phospholipase domain-containing protein 3)
is a multifunctional enzyme involved in the hydrolysis of triacylglycerol (TAG) in the liver,
and rs738409 variant is the strongest genetic risk factor for NAFLD (Romeo et al. 2008).
Recent genome-wide association studies (GWAS) have identified increased NAFLD
susceptibility in variants of TM6SF2 (rs58542926; transmembrane 6 superfamily member
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2), GCKR (rs780094, Glucokinase regulator), NCAN (rs2228603, Neurocan), LYPLAL1
(rs12137855, Lysophospholipase-like 1) (Sookoian and Pirola 2017; Sliz et al. 2018). The
association of rs641738 variant of MBOAT7-TMC4 locus (membrane bound Oacyltransferase domain-containing 7, transmembrane channel-like 4) is controversial and
inconclusive (Mancina et al. 2016; Sookoian et al. 2018).
Physical findings show that patients with NAFLD often have obesity and
hepatomegaly (enlarged liver) due to fat infiltration of the liver. NAFLD patients show
mild or moderate elevations in the aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), although normal aminotransferase levels do not exclude NAFLD.
When elevated, the AST and ALT are typically 2 to 5 times the upper limit of normal with
an AST to ALT ratio of less than one (>1.5 for alcoholic liver disease) (Sattar et al. 2014).
Alkaline phosphatase may also be elevated 2-3 times the upper limit of normal and patients
may have an elevated serum ferritin concentration or transferrin saturation. Decreased
hepatic attenuation on computed tomography (CT) and an increased fat signal on magnetic
resonance imaging (MRI) are generally evident in radiographic findings (Decarie et al.
2011).
Classification systems for NAFLD
NAFLD is a complex disease and differentiating definite NASH from NAFL can
be equally complicated for basic researchers as well as for pathologists. The gray zone of
distinction between NAFL and NASH is precarious, and diagnosis often varies
dramatically among pathologists due to the heterogenous histopathologic spectrum of
NAFLD and its progression over time (Younossi et al. 2011). Controversy exists over the
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use of these classifications has led to misuse of scoring systems (Kleiner et al. 2005;
Angulo Paul 2011; Brunt Elizabeth M. et al. 2011). The categorical nature of the
histopathological scoring system adds to the discrepancies in the diagnosis of the type of
NAFLD. Since the categories are not well-defined, it eventually leads to varying
interpretations and conclusions from researchers and pathologists (Brunt E. M. 2016).
Additive nature of recent scoring systems (NAS or SAF) deconvolutes the contribution of
each histologic legion. Interestingly, NAS scoring system was not designed to be used as
a diagnostic tool for determination of NASH versus NAFL (Kleiner et al. 2005; Brunt
Elizabeth M. et al. 2011). It was intended to evaluate the changes in histological lesions
(steatosis, inflammation, hepatocyte ballooning, fibrosis) that can occur over time (Angulo
P. 2011). Fatty liver inhibition of progression (FLIP) algorithm was proposed to improve
the consistency in the diagnosis of NASH in adults and takes into account fibrosis along
with steatosis and activity score (inflammation, ballooning) (Younossi et al. 2011). The
use of different classification systems may, therefore, contribute to significant variability
seen in the literature on the subject. Surgical hepatitis and potential differences between
the biopsy site (right or left lobe) also confound the diagnosis of histologic lesions and
subsequently the proper classification of disease (Brunt E. M. 2016).
Treatment strategies to manage NAFLD
Hepatic pathological conditions have been known to impact the abundance of DMEs and
transporters in the liver, leading to altered drug profiles and often to side-effects (Gandhi
et al. 2012). Despite the widespread prevalence of NAFLD/NASH, currently, there are no
pharmacological therapies available for its treatment and involves the management of
associated conditions including obesity, diabetes and hyperlipidemia (Takei 2013; Barb et
6

al. 2016; Sumida et al. 2016). Weight loss is usually the first and most common
intervention recommended for any metabolic syndrome (Marchesini et al. 2016). Similarly,
lifestyle modifications through exercise and dietary restriction are considered vital in the
management of NAFLD (Vilar-Gomez et al. 2015). Patients with the disease are advised
to avoid intake of positive calorie foods like soda and sweetened drink which are rich in
simple carbohydrates which are readily absorbed (Zivkovic et al. 2007). Patients are also
asked/recommended to avoid diets rich in cholesterol, fructose and other saturated fats
which are often linked with progression of NAFLD (Musso et al. 2009; Abdelmalek et al.
2010).
Interestingly, consumption of fructose-sweetened and non-glucose sweetened beverages
has been associated with elevated insulin resistance and an increase in visceral adiposity
and lipids in overweight and obese humans (Stanhope et al. 2009). Ryan et al. found that
the Mediterranean diet improved insulin sensitivity and reduced hepatic steatosis in
NAFLD patients with insulin-resistance (Ryan et al. 2013). A considerable effort is
currently underway in the development of therapeutic agents for the treatment of NAFLD,
and multiple molecular pathways are now being targeted for drug development (Perazzo
and Dufour 2017). Pioglitazone, vitamin E and, GLP-1 and SGLT2 inhibitors have shown
some efficacy in NASH. New therapies in development target one or more of the following
pathways; a) hepatic fat accumulation and insulin resistance, b) oxidative stress,
inflammation and apoptosis, and c) hepatic fibrosis (Sumida and Yoneda 2018). An
overview of some of the therapeutic agents in clinical development is given in table 1.
Leoni et al. recently published a review analyzing the current guidelines in the diagnosis
of NAFLD as well as the areas of therapeutic focus.
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Drug metabolism enzymes and NAFLD
Human liver, facilitated by several drug metabolizing enzymes (DMEs), is the
primary organ responsible for the elimination of xenobiotics and endogenous compounds.
DMEs are responsible for the metabolism of diverse chemicals which include xenobiotics
like drugs, pesticides and endogenous substrates like steroids and bile acids (Zanger and
Schwab 2013). DMEs are broadly classified into phase I enzymes which are mostly
oxidative, reductive or hydrolytic; and phase II enzymes which are conjugative. Major
proteins involved in oxidative biotransformation belongs to cytochrome P450 (CYP450s),
flavin-monooxygenases (FMOs), monoamine oxidases (MAOs), alcohol and aldehyde
dehydrogenases, and aldehyde and xanthine oxidase (Appendix: Drug Metabolizing
Enzymes and Biotransformation Reactions 2012). Aldo-keto reductases (AKRs), azo- and
nitro-reductases constitute reductive enzymes involved in metabolism whereas epoxide
hydrolases, esterases, and peptidases are responsible for the bulk of hydrolysis reactions in
the liver (Appendix: Drug Metabolizing Enzymes and Biotransformation Reactions 2012).
Cytochrome P450 superfamily enzymes are involved in the majority of reductive
reactions and are reported to be responsible for the metabolism of ~70-80% of all the
available drugs in the market (Zanger and Schwab 2013). Conjugation reactions in the liver
are carried out by uridine diphosphate-glucuronosyltransferases (UGTs), sulfotransferases
(SULTs), N-acetyltransferases (NATs), glutathione S-transferases (GSTs), amino acid
conjugation enzymes and methyltransferases (Jancova et al. 2010; Appendix: Drug
Metabolizing Enzymes and Biotransformation Reactions

2012). Majority of studies

evaluating the effect of NAFLD on drug disposition proteins draw their conclusions from
studies performed in preclinical animal models. A careful interrogation often suggests a
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complex and heterogeneous alteration in drug metabolizing enzymes and transporters in
human. Such discrepancies are partly due to species differences and lack of animal models
which accurately reflect the complexity and pathophysiology of human disease.
Studies in preclinical species
Preclinical species have played a key role in our understanding of NAFLD
(Santhekadur et al. 2018). Genetic as well as dietary animal models have been developed
to understand the disease. Common genetic mice models of NAFLD include leptindeficient (ob/ob), leptin receptor-deficient (db/db) and low-density lipoprotein deficient
mice. Even though low leptin levels are not observed in human NAFLD, leptin-deficient
mice (ob/ob) represents obesity, hyperlipidemia and insulin resistance, steatosis but
without fibrosis (Trak-Smayra et al. 2011; Canet et al. 2014).
However, fibrosis can be induced in leptin receptor-deficient mice (db/db) from
external stimuli. Low-density lipoprotein receptor-deficient mice (LDLR) exhibit a
pathology similar to db/db mice and can develop fibrosis. But not all studies in mice models
are consistent among different models, the results have shown to vary according to the diet
and species. (Kim et al. 2004; Yoshinari et al. 2006; Fisher et al. 2008). Dietary models
are developed using methionine and choline-deficient (MCD) and hypercaloric diets
(Stephenson et al. 2018). MCD models exhibit steatosis, inflammation, fibrosis similar to
human disease but significantly differ in metabolic phenotype of the disease. MCD-fed
mice show increased insulin sensitivity, significant weight loss, and low blood glucose.
Similarly,

hypercaloric diet (Western-like

diet) model show steatosis,

inflammation, fibrosis but take a significant time for disease induction. DIAMOND (diet-
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induced animal model of alcoholic fatty liver disease) and STAM (Stelic Animal Model)
models are proposed to exhibit considerable similarity with human NAFLD in pathology
and phenotype (Fujii et al. 2013; Asgharpour et al. 2016). Both the models gain weight and
develop insulin resistance, steatosis, fibrosis, and hepatocellular carcinoma. Dietrich et al.
have extensively discussed the pros and cons of different animal models of NAFLD
(Dietrich et al. 2017).
Given the complexity of human disease, no single animal model to date fully
recapitulates the human disease state (Dietrich et al. 2017). The failure of some compounds
which showed a significant promise in preclinical studies has raised a concern about the
inadequacies of animal models for the disease. ASP9831, a potent PDE4 inhibitor was
being developed by Astellas Pharma to modulate cyclic adenosine monophosphate activity.
Compared to placebo, ASP9831 drug failed to improve the biochemical parameters
associated with NASH in a 12-week phase-II clinical trial (Ratziu et al. 2014). Similarly,
resveratrol was unable to improve hepatic steatosis and insulin sensitivity at
pharmacological doses in an 8-week study (Chachay et al. 2014).
Studies in human
Disease-mediated changes have been known to impact the abundance of drug
disposition proteins in the liver, hence leading to altered drug profiles (Merrell and
Cherrington 2011; Gandhi et al. 2012; Cobbina and Akhlaghi 2017; Evers et al. 2018).
Theoretically, an alteration in DDPs could lead to undesirable pharmacokinetic and
pharmacodynamic outcomes (figure 2). Clinical studies in NAFLD are currently limited
but are critical to understanding the implication of altered drug metabolizing enzyme
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profile on therapeutic result in the disease state. Current literature on studies with human
tissue is confounding with reports of increase, decrease or non-significant change in the
activity, protein, and/or mRNA levels of clinically relevant hepatic cytochrome P450
enzymes (table 2). Genome-wide studies (GWAS) in NAFLD patients found no significant
changes in ADME proteins between normal and steatotic livers at mRNA expression level
(Greco et al. 2008; Lake et al. 2011). However, mRNA-based studies do not account for
the potential contribution of post-transcriptional and post-translational changes relevant to
protein expression or enzyme activity. A comprehensive table of alteration in drug
metabolism enzyme expression or activity is given in table 1. In general, a decrease in
CYP3A4 and CYP2E1 activity appears to be dominant in the studies in subjects and human
tissue (Merrell and Cherrington 2011; Woolsey et al. 2015; Cobbina and Akhlaghi 2017).
Even though the effect of NAFLD on CYP450s has been extensively studied in vitro, our
understanding of the disease associated impact on other DMEs is limited due to the scarcity
of studies. Similar to CYP450s, differential regulation appears to be at play for other DMEs
including UGT and SULTs in human NAFLD. Studies in human tissue found the minimal
effect of NAFLD on UGT enzymes while a significant alteration was reported in hepatic
sulfotransferase expression and activity (Hardwick et al. 2013). NASH mediated
upregulation of UGT1A9, 2B10, and 3A1 mRNA was reported in human liver (Hardwick
et al. 2013). It was also noteworthy that the protein expression of UGT1A9 and 1A6
decreased in NASH (Hardwick et al. 2013). Elevated SULT1C4 mRNA was seen in NASH
whereas SULT1A1 and 2A1 protein levels were lower in disease samples compared to
control samples (Hardwick et al. 2013).
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Label-free mass spectrometry-based proteomics
Traditionally, the level of expression is determined using Western blotting, but last
decade has seen a rise in mass-spectrometry-based methods for quantification of proteins.
Omics technologies have been used extensively in the quest to identify novel biomarkers
for NAFLD (Pirola and Sookoian 2018). Targeted proteomics (SRSM, MRM) based
approaches have also proven to be useful in quantification of DDPs. While the targeted
quantification represents the most robust method of choice for absolute quantification, cost
and significant time for optimization of mass spectrometer conditions for each targeted
peptide limit its application to a few target proteins.
In contrast, label-free quantification or more commonly known as LFQ has
emerged recently as an alternative approach for comparative analysis of protein expression
across different samples owing to fast and low-cost of this technique (Wong and Cagney
2010). LFQ approaches are relatively inexpensive as compared to targeted MRM methods
as there is no need to synthesize unique peptides for each protein and isotopically labeled
isoforms of this peptide as the internal standard. Accurate and robust quantification with
LFQ approaches is intricate, and different strategies for extracting quantitative data from
LFQ analysis has been developed (Wong and Cagney 2010). A comprehensive cost
comparison of various mass spectrometry-based techniques reported significant cost
savings with label-free based quantitative proteomics (Al Feteisi et al. 2015).
Studies have shown that protein expression is a better surrogate than mRNA for
prediction of functional activity of cytochrome P450 enzymes. Data-dependent (DDA) and
data independent analysis (DIA) are two common data collection modes in shotgun
proteomics. In DDA mode, most abundant ion species from a precursor scan (MS1) at a
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given retention time are selectively selected for fragmentation (MS/MS). Alternatively, the
precursors are selected in a specific m/z range and are fragmented without any
prioritization to their relative abundance. This approach offers a more comprehensive and
complete analysis of samples than traditional DDA. SWATH-MS (sequential window
acquisition of all theoretical mass spectra) is one such DIA technique that provides an
alternative to DDA and targeted approaches for protein estimation (Gillet et al. 2012). As
mentioned previously, SWATH is a DIA technique in which all the precursors within a
predefined m/z are fragmented, and product ions of these precursors are recorded as a
digital repository (Rosenberger et al. 2014). However, coeluting precursors and fragments
at any given RT in DIA data make it difficult to select the correct peak without a robust
spectral library. Therefore, a reference spectral library is often used for DIA and data are
further deconvoluted and extracted using software like OpenSWATH, SWATH 2.0 and
Skyline (Navarro et al. 2016). A significant advantage of SWATH-MS over the other mass
spectrometry methods is related to the ability to perform retrospective mining of the data.
The targeted protein extraction can be improved by expanding the coverage of reference
spectral library and remining the DIA data. For instance, if the researcher comes up with a
new hypothesis in the future, SWATH-MS data would allow interrogation of the existing
data for additional protein/s of interest without the need for sample digestion or data
reacquisition (figure 3). Such a strategy offers a tremendous benefit concerning the saving
of sample, time and money.
Absolute protein concentrations are vital to simulate drug exposure using
physiologically based pharmacokinetic (PBPK) models. However, despite all the
advantages, DIA approaches are relative, and hence absolute protein concentration levels
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can’t be determined using techniques like SWATH-MS. Alternatively, a spike in standard
or targeted approach for a protein of interest would be needed to determine the protein
levels. Global proteomics using DDA data and “total protein approach (TPA)” can be
instead used to estimate protein concentrations. TPA is widely accepted and delivers
protein concentrations without the need for the isotope-labeled spike in reference peptides
(Wisniewski et al. 2014). TPA assumes that a protein’s abundance with a cell as a fraction
of total protein is approximately the same as the proportion of its MS signal to the total MS
signal of the cell.

𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 =

𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑚𝑎𝑠𝑠
~
𝑇𝑜𝑡𝑎𝑙 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑚𝑎𝑠𝑠

The absolute protein concentration (p), expressed as mol/g of total protein can further be
calculated using equation 2 (Wisniewski and Mann 2016). MW (p) is the molar mass of
protein.

𝑝=

𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑝)
𝑇𝑜𝑡𝑎𝑙 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 × 𝑀𝑊(𝑝)

Physiologically based pharmacokinetic (PBPK) model
While there is a significant amount of literature is available for the levels of these
proteins in healthy people, little is known about how NAFLD changes the concentration of
these enzymes in the human liver. The information is essential to determine the influence
of the disease on the drug disposition, but clinical studies in NAFLD subjects are limited.
The use of physiologically based pharmacokinetic models for prediction of
pharmacokinetic and drug metabolism in populations which present clinical challenges is
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increasing in popularity (Sager et al. 2015). PBPK modeling is a bottom-up simulation
approach which takes in account multiple parameters specific to the drug, physiology of
the species (different organs represented as compartments) and an understanding of the
pharmacokinetic properties of the drug of interest (Zhuang and Lu 2016). System or
dependent population parameters which are essential for prediction of exposure and include
hepatic blood flow and enzyme or transporter abundance among others. Drug-dependent
parameters are derived from physicochemical properties of the molecules and rest are
determined from in vitro studies (protein binding, metabolism, enzyme kinetics, intrinsic
clearance, etc.). An exhaustive list of different parameters required for building a PBPK
model is discussed elsewhere (Zhuang and Lu 2016).
In vitro and in vivo parameters which accurately reflect the human disease are vital
to predict and simulate in silico drug exposure. Some commercial PBPK platforms like
GastroPlus (Simulation Plus Inc.), Simcyp (Certara L.P.) PKSIM (Bayer), CloePK (Evotec
A.G.) are currently available. PBPK models for NAFLD are presently not available in
different simulation platforms. A lack of sufficient in vitro and in vivo data is a significant
hurdle in the development of PBPK models for NAFLD.
Hepatic blood flow is a critical parameter determining the rate of presentation of
the drug for its metabolism in the liver. Hepatic portal vein (HPV) supplies 70% whereas
hepatic artery (HA) is responsible for ~30% of the blood reaching the liver. HPV supplies
liver with nutrients and xenobiotics (drugs) absorbed in the GI tract and HA is responsible
for carrying oxygen. Fat-accumulation in hepatocytes was found to correlate with
decreased HPV blood flow in NAFLD patients (Shigefuku et al. 2014). Hepatocyte
ballooning associated with NASH cause sinusoidal distortion leading to reduced
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intrasinusoidal volume and microvascular blood flow (Farrell et al. 2008). Impaired
systemic circulation and modification of cellular membrane may also interrupt oxygen
availability in NAFLD leading to hypoxia and accelerated lipid droplet formation (Anavi
et al. 2017). Blood flow change in early fibrosis was attributed to outflow blockage in the
liver sinusoidal area (Hirooka et al. 2015). The changes in hepatic blood flow during
different stages of NAFLD is given in table 3 (Shigefuku et al. 2012).
Concluding remarks
The epidemic of NAFLD is upon us, and a widespread effort is currently underway
to address different aspects of this multifaceted and complex metabolic disease. A lack of
good preclinical models to recapitulate the spectrum of the disease remains a significant
challenge and care should be taken when extrapolating results from preclinical species to
human. Risk of alterations in the drug disposition proteins remains high in NAFLD due to
significant structural and pathophysiological changes in the liver, the primary organ for
drug disposition. PBPK has been used in recent past to simulate the exposure of various
drugs in special populations. However, most of our understanding of these models comes
from research done in healthy individuals, but little is known about the physiological as
well as pharmacokinetic parameters of drugs in NAFLD. Moreover, after drug
administration, there is also a need to understand how drug disposition proceeds in these
disease/target populations. Two of the critical parameters governing the exposure include
enzyme kinetics and expression of proteins involved in the disposition of the compound.
There is also a need of predictive biomarkers for NAFLD to delineate NASH from NAFL
in human and mass spectrometry-based proteomics may hold promise to fill this gap. In
summary, it's of paramount importance to determine how disease alters the expression of
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the proteins involved in the disposition of the drugs. Additionally, to improve translation
ability and accuracy of simulation models, it is essential to understand how the
pharmacokinetics and other physiological parameters change in NAFLD.
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Figures and tables
Figure 1: Hematoxylin and Eosin staining of liver samples (A) Normal liver with
uniform chord-like arrangements of hepatocytes, (B) Nonalcoholic fatty liver (NAFL) liver
with lipid droplets, and (C) Nonalcoholic steatohepatitis (NASH) with significant hepatic
steatosis and infiltration of lymphomononuclear inflammatory cells.
Figure 2: Effect of altered CYP3A4 on systemic midazolam exposure. The systemic
exposure of a substrate may increase if the CYP450 responsible for its metabolism and
clearance is reduced. The opposite is true when the expression is increase. The illustration
shown here for CYP3A4 mediated midazolam (MDZ) in normal and altered states. 1’OHMDZ: 1-hydroxy midazolam.
Figure 3: Graphical illustration of the advantage of SWATH-MS over traditional
MRM based quantification method. MRM, Multiple reaction monitoring; SWATH-MS,
Sequential windowed analysis of all the theoretical mass spectra.
Table 1: Therapeutic agents currently being developed for treatment of NAFLD.
ACC, Acetyl-CoA Carboxylase; AOC, amine oxidase, copper containing; ASK, Apoptosis
signal-regulating kinase; FGF, fibroblast growth factor; FXR, Farnesoid X receptor;
PPAR, peroxisome

proliferator-activated receptors; mTOT, mitochondrial target of

thiazolidinediones; SGLT, Sodium-dependent glucose cotransporter; GLP, Glucagon-like
peptide; ASBT, apical sodium–bile acid transporter; ASK, apoptosis signal-regulating
kinase; THB, thyroid hormone receptor
Table 2: Altered expression and activity levels of CYP450 enzymes in NAFLD. CYP,
cytochrome P450; NASH: Nonalcoholic steatohepatitis
Table 3: Hepatic blood flow changes in different stages of NAFLD. Liver blood flow
in the disease state were studied using xenon computed tomography. THBF: Total hepatic
blood flow; PVBF: Portal vein blood flow; HABF: Hepatic artery blood flow
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Figure 1: Hematoxylin and Eosin staining of liver samples. (A) Normal liver with
uniform chord-like arrangements of hepatocytes, (B) Nonalcoholic fatty liver (NAFL) liver
with lipid droplets, and (C) Nonalcoholic steatohepatitis (NASH) with significant hepatic
steatosis and infiltration of lymphomononuclear inflammatory cells.
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Figure 2: Effect of altered CYP3A4 on systemic midazolam exposure. The systemic
exposure of a substrate may increase if the CYP450 responsible for its metabolism and
clearance is reduced. The opposite is true when the expression is increase. The illustration
shown here for CYP3A4 mediated midazolam (MDZ) in normal and altered states. 1’OHMDZ: 1-hydroxy midazolam.
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Traditional MRM method

Develop new MS method for new analyte of interest and repeat the process

Data
collection

Data
interpretation

Data
processing

New
hypothesis

SWATH-MS method
Develop library for analytes of interest and
remine the data without need for sample acquisitions

Figure 3: Graphical illustration of the advantage of SWATH-MS over traditional
MRM based quantification method. MRM, Multiple reaction monitoring; SWATH-MS,
Sequential windowed analysis of all the theoretical mass spectra.
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Therapeutic
candidate
GFT505
Obeticholic
acid
BMS-986036
GS-0976
PF-05221304
Selonsertib
GR-MD-02
Aramchol

Company
Genefit
Pharmaceuticals
Intercept
Pharmaceuticals
Bristol-Myers
Squibb
Gilead Sciences
Inc.
Pfizer Inc.
Gilead Sciences
Inc.
Galectin
Therapeutics
Galmed
Pharmaceuticals

Mechanism of
action
PPARα/δ
agonist
FXR agonist
FGF21 analog
ACC inhibitor
ACC inhibitor
ASK1 inhibitor
Galectin
inhibitor
SCD1 inhibitor

Cenicriviroc

Allergan plc

CCR2/5
antagonist

NGM282

NGM
Biopharmaceutical
s Inc.

FGF19 analogue

Volixibat
(SHP626)

Shire

ASBT inhibitor

Novartis
Pharmaceuticals
Novartis
Pharmaceuticals
Cirius
Therapeutics

SGLT1/2
inhibitor
FXR agonist

Novo Nordisk

GLP-1 analogue

LIK066
LJN452
MSDC 0602k
Liraglutide
(NN2211)
Emricasan
MGL-3196

Conatus and
Novartis
Pharmaceuticals
Madrigal
Pharmaceuticals

mTOT
modulator

Target

Ref.

Lipid
metabolism
Lipid
metabolism
Lipid
metabolism
Lipid
metabolism
Lipid
metabolism
Lipid
metabolism

Lipid
metabolism
Inflammation/
cell death

(Ratziu et al.
2016)
(NeuschwanderTetri et al. 2015)
(Sanyal et al.
2017)
(Lawitz et al.
2018)
(Bergman et al.
2018)
(Loomba et al.
2017)
(Harrison et al.
2016)
(Hashmonai et al.
1974)
(Friedman et al.
2018)

Lipid
metabolism

(Harrison SA et
al. 2018)

Bile acid
synthesis
Glucose
reabsorption
Lipid
metabolism
Insulin
signaling
Insulin
signaling

(Tiessen et al.
2018)

Fibrosis

(HE et al. 2018)
(Tully et al.
2017)
(Colca et al.
2018)
(Armstrong et al.
2016)

Pan-caspase
inhibitor

Apoptosis

(Shiffman et al.
2015)

THR β-selective
agonist

Lipid
metabolism

(Harrison S et al.
2018)

Table 1: Therapeutic agents currently being developed for treatment of NAFLD.
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Enzyme

Disease stage
NAFLD

CYP2E1

CYP3A4/5

CYP1A2

CYP2A6

CYP2B6

CYP2C8
CYP2C9
CYP2C19

NAFLD
NAFLD
NAFLD
progression
NASH
NASH
NASH
NASH
NASH
NASH
NAFL
NAFL
NASH
NAFL
NAFLD
progression
NAFLD
Hepatocytes
Steatosis
NASH
NASH
NAFL
NAFLD
progression
NAFL
NAFL
NAFLD
progression
NASH
NASH
NAFLD
progression
NASH
NASH
NAFLD
progression
NAFLD
progression
NAFLD
progression

mRNA
expression
↑

Protein
expression

Activity

Ref.
(Kohjima et al. 2007)

↓

↓

↔
↓

(Prompila et al. 2008)
(Nakamuta et al. 2005)

↔

(Fisher et al. 2009)

↑

↑
↔
↔

↓
↓

↓
↓

(Baker et al. 2010)
(Chalasani et al. 2003)
(Orellana et al. 2006)
(Orellana et al. 2006)
(Weltman et al. 1998)
(Niemela et al. 2000)
(Donato et al. 2006)
(Emery et al. 2003)
(Jamwal et al. 2018)
(Jamwal et al. 2018)

↔

↔

↔

(Fisher et al. 2009)

↑
↑
↑
↑
↑
↔

↔

↔

↑
↓
↔

↓

(Bell et al. 2010)
(Donato et al. 2006)
(Donato et al. 2007)
(Niemela et al. 2000)
(Weltman et al. 1998)
(Kolwankar et al. 2007)

↔

↓

↓

(Fisher et al. 2009)

↓

(Donato et al. 2006)
(Greco et al. 2008)

↑

(Fisher et al. 2009)

↔
↔

↓
↑

↑

↓

(Rubio et al. 2007)
(Niemela et al. 2000)

↑
↑

↔

↔

↓
↓

(Fisher et al. 2009)
(Stepanova et al. 2010)
(Yoneda et al. 2008)

↔

↔

↔

(Fisher et al. 2009)

↔

↔

↑

(Fisher et al. 2009)

↔

↓

↓

(Fisher et al. 2009)

Table 2: Altered expression and activity levels of CYP450 enzymes in NAFLD.
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ml/min/100 g

Normal

NAFL

THBF

94.0±17.8

66.4±10.6

Early
NASH
52.4±12.3

PVBF

72.4±16.2

41.6±5.6

33.6±7.0

28.4±6.3

HABF

21.2±7.4

24.8±8.5

18.7±7.0

18.7±8.4

(Carlisle et al. 1992)

Advanced NASH
47.1±13.2

(Shigefuku et al. 2012)

Table 3: Changes in hepatic blood flow in different stages of nonalcoholic fatty
liver disease.
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ABSTRACT
We describe a sequential windowed acquisition of all theoretical fragment ion mass spectra
(SWATH-MS) based method for label-free, simultaneous, relative quantification of drug
metabolism enzymes in human liver microsomes (HLM; n=78).

In-solution tryptic

digestion was aided by a pressure cycling method which allowed a 90-min incubation time,
a significant reduction over classical protocols (12-18 h). Digested peptides were separated
on an Acquity UHPLC Peptide BEH C18 column using a 60-min gradient method at a flow
rate of 0.100 mL/min. The quadrupole-time-of-flight mass spectrometer (ESI-QTOFMS)
was operated in positive electrospray ionization mode and data was acquired by DataDependent Acquisition (DDA) and SWATH-MSALL mode. A pooled HLM sample was
used as quality control to evaluate variability in digestion and quantification among
different batches, and inter-batch %CV for various proteins was between 3.1-7.8%.
Spectral library generated from the DDA data identified 1,855 distinct proteins and 25,601
distinct peptides at a 1% global false discovery rate (FDR). SWATH data were queried and
analyzed for 10 major cytochrome P450 (CYP) enzymes using Skyline, a targeted data
extraction software. Further, correlation analysis was performed between functional
activity, protein and mRNA expression for ten CYP enzymes.

Pearson correlation

coefficient (r) between protein and activity for CYPs ranged from 0.314 (CYP2C19) to
0.767 (CYP2A6). A strong correlation was found between CYP3A4 and CYP3A5
abundance and activity determined using midazolam and testosterone (r>0.600, p<0.001).
A moderate protein-to-activity correlation (r>0.500, p<0.01) was also observed for
CYP2A6, CYP1A2, CYP2C9, CYP2B6 and CYP2E1. The correlation for CYP2C8,
CYP2D6 and CYP2C19 was significant but poor (r<0.400, p<0.05). The findings suggest
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the suitability of SWATH-MS based method as a valuable and relatively fast analytical
technique for relative quantification of proteins in complex biological samples. We also
show that protein abundance is a better surrogate than mRNA to predict the activity of CYP
activity.
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INTRODUCTION
Hepatic drug metabolizing enzymes (DMEs) are responsible for the clearance of
pharmacological agents and xenobiotics. The abundance of these enzymes in liver tissue
determines the rate and extent to which drugs are metabolized and cleared from systemic
circulation. Cytochrome P450s (CYPs) and uridine diphosphate glucuronyltransferases
(UGTs) constitute the majority of phase I and phase II DMEs, respectively (1). CYPs are
primarily involved in the oxidation of endogenous steroids, xenobiotics, and drugs (2, 3).
Expression of CYPs thus impacts drug disposition, pharmacokinetics and adverse drug
reactions (1).

Characterization of expression and activity of DMEs in human liver

microsomes and hepatocytes is a pivotal part of drug development. Moreover, induction
potential of new chemical entities is typically screened using primary or cryopreserved
hepatocyte culture (4).
It is important to understand how the level of different DMEs changes from one
individual to another or how different disease states influence the abundance of these
enzymes. Classical methods for protein quantification include Western blotting and ELISA
(5). Western blotting is semi-quantitative, low throughput, labor intensive, and require the
use of expensive antibodies (6). ELISA methods can be higher throughput and more
quantitative than Western analysis, but this approach is also labor intensive, suffers from
limited concentration range and can lack specificity (6). In the recent years, protein mass
spectrometry has proved to be a powerful technique in different areas of biomedical
research including in drug development (7).

“Targeted” or “absolute” protein

quantification methods use liquid chromatography coupled with a triple quadrupole mass
spectrometer (LC-MS/MS) and consist of quantification of one or more signature peptides
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per protein (8). These peptides are custom synthesized and are often paired with an isotopelabeled peptide as an internal standard. Several groups have used high-resolution mass
spectrometry methods to analyze the expression of drug-metabolizing enzymes and
transporters in human tissue (3, 9). Traditionally, in the drug metabolism field, multiplereaction monitoring (MRM) method has been used for absolute quantification of clinically
relevant CYPs and UGTs in human liver tissue (10-12). Others have measured the
concentration of drug transporters using quantitative targeted proteomics (13). However,
significant upfront assay development with 1-2 synthetic peptides for each protein is often
required for targeted MRM methods developed to ensure detection of multiple transitions.
Label-free quantification (LFQ) techniques are now becoming common for analysis of
proteins using mass spectrometry. Neilson et al. published a comprehensive review on
LFQ approaches and compared it with other labeling based techniques (14). Sequential
windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) is a cost
efficient, LFQ method that combines data-independent acquisition (DIA) and multiple
reaction monitoring-like data processing for accurate peptide quantitation. It provides an
advantage when compared to traditional mass spectrometry-based proteomics methods like
shotgun (high throughput) and SRM (high reproducibility and consistency). The technique
enables a complete and permanent recording of all fragment ions of the detectable peptide
precursors present in a digested biological sample that can be interrogated retrospectively
for peptide features for SRM-like quantitative information, time-consuming design of
acquisition method (15). Data are acquired on the high-resolution time of flight mass
spectrometer (TOF/MS) in consecutive continuous cycles through precursor isolation
windows which collect fragment ion spectra for all analytes in a sample. The collected

46

data contain the spectra of fragment ions for all precursor ions that appear within the
defined precursor retention time and m/z space. The combination of all the high-resolution
spectra collected at ≥25,000 resolution (FWHM) generates a fragment ion map which
generates extracted ion chromatogram (XIC) measurements with high specificity derived
by low mass error (15). This provides an unbiased quantification method which is
reproducibly collected across all samples for relative quantitation and does not require a
protein or sample specific method development. Peptide spectral library can be used for
extraction of peptides of interest from the SWATH data and further statistical analysis.
The purpose of this work was to develop a SWATH-MS method for relative
quantification of proteins in the microsomal fraction of 78 human liver tissue samples.
Enzyme activities of DMEs as provided by the vendor were correlated with protein level
determined in the human liver microsomes by using the current method. Additionally, we
performed correlation analysis between protein and mRNA expression with enzyme
activity of 10 major CYPs.
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MATERIALS AND METHODS
Chemical and Reagents
Trypsin digested β-galactosidase (E. coli), protein preparation kit and TPCK-treated
trypsin were procured from AB Sciex, Framingham, MA. Mass spectrometry grade
acetonitrile and formic acid were from ThermoFisher Scientific, Waltham, MA. Acquity
UHPLC Peptide BEH C18 analytical column and VanGuard pre-columns were from
Waters Corp., Waltham, MA. RNeasy Mini Kit was purchased from Qiagen Inc., Valencia,
CA.

Human liver microsomes
Human liver tissues retrieved from brain dead individuals by Sekisui Xenotech were
used in this study. A brief overview of the donor demographics was given in table 1.
Human liver microsomes (HLM) were prepared as described previously, with
modifications (16).
Briefly, human liver samples were carefully thawed on ice and weighed. Tissue was
immediately transferred to a pre-cooled 7 mL homogenization bead-mill tube containing
50 mM Tris-HCl (pH 7.4) buffer having 0.5 mM EDTA, 0.25 M sucrose and 20 µM
BHT (3 mL/g wet liver weight) and homogenized using a bead homogenizer (Bead
Ruptor 24, Omni International, Kennesaw, GA). Homogenate was centrifuged at 10,000
g for 20 min at 4°C (Eppendorf 5810R, Eppendorf AG, Hamburg, Germany). The pellet
containing cell debris was discarded, and supernatant (S9 fraction) was ultra-centrifuged
at 100,000 g for 1 hour at 4°C (Beckman Coulter, Brea, CA). Further, the supernatant
was separated and stored as a cytosolic fraction for future use. The pellet on the walls
of the tubes was washed (50 nM sodium pyrophosphate, pH 7.4) and re-suspended in
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homogenization buffer containing 20% glycerol (pH 7.4, 0.66 mL/g of tissue). The
contents were carefully transferred to a 1 mL Dounce homogenizer for fine
homogenization. The resulting microsomal fraction was stored at -80°C until analysis.
Microsomal protein concentration was estimated using a bicinchoninic acid method
(Pierce-Fisher, Rockford, IL) with bovine serum albumin as a standard. The samples
were diluted to 2.5 mg/mL in phosphate-buffered saline (pH 7.4) before protein
digestion as described below. XTreme 200 pool HLM was purchased from Sekisui
XenoTech, LLC, Kansas City, KS.

Pressure cycling technology (PCT) based protein digestion
In-solution trypsin digestion was performed on each biological sample in duplicates
according to a published method with modifications (17). Denaturation, reduction, and
alkylation were performed in centrifuge tubes while digestion was carried out in
MicroTubes (Pressure BioSciences Inc., South Easton, MA) under oscillating highpressure cycles in a Barocyler NEP2320-45k (Pressure BioSciences Inc.). Briefly, 150
µg of microsomal protein was denatured and reduced for 1 h at 60°C in a shaking water
bath (75 rpm). Reduced samples were alkylated for 10 min at room temperature to
prevent free cysteine residues from the reformation of peptide bonds. Subsequently,
samples were diluted with equal volume of 100 mM Tris buffer (pH 8) containing 4 mM
MgCl2 and digested with TPCK-treated trypsin (protease: protein, 1: 20) in the
barocycler. PCT-aided digestion was performed at 50 °C for 90 cycles, 50 s at 35 kpsi
and 10 s at ambient pressure for every cycle. Further, samples were transferred to a
centrifuge tube, and digestion was stopped by addition of formic acid at a final
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concentration of 0.1%. The mixture was vortex-mixed for 10 s before centrifugation at
5,000 rpm for 1 min at 10°C. The supernatant was collected and transferred to a clean
micro-insert for further analysis. Two technical replicates for each HLM sample were
digested and analyzed by mass spectrometry. XTreme 200 pool sample was used as
digestion control to monitor the batch-to-batch variation of protein digestion carried out
in 6 batches. Approximately 12 samples and one digestion control sample were digested
and run in every batch along.

LC-QTOF/MS analysis
All experiments were performed on a Sciex 5600 TripleTOF® mass spectrometer
equipped with a DuoSpray™ ion source (AB Sciex, Concord, Canada) coupled to
Acquity UHPLC HClass system (Waters Corp., Milford, MA, USA).

The mass

spectrometer was operated in positive electrospray ionization mode for the analysis. The
peptides were separated on Acquity UHPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å,
1.7 µm) equipped with Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm).
Digested samples were maintained at 10°C in the autosampler and the analytical column
temperature was kept at 40°C. The amount of protein per injection on the column was
10 µg. The chromatographic separation was achieved with a runtime of 60 min at 100
µL/min with a gradient method using mobile phase A (98% water, 2% acetonitrile, 0.1%
formic acid) and mobile phase B (98% acetonitrile, 2% water, 0.1% formic acid). A
linear gradient scheme was used with solvent composition as follows; 98% A from 0-3
min: 60% to 90% A from 3-48 min: 20% A held from 49-52 min to flush the column,
98% A at 53 min. The column was allowed to equilibrate at 98% A from 53 to 60 min
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before the start of next run. In each batch, trypsin-digested β-galactosidase peptides were
injected (~30 pmol/injection) every 10 samples during the analysis to monitor mass
calibration of the TOF detector and normalization of intensity during relative
quantification. The average intensity of all the β-galactosidase peptide samples in a
batch was used for data normalization of the respective batch of samples.

Standard DDA and SWATH-MS data acquisition
Mass spectrometry analysis was performed according to a previously described
method with modifications (18). Analyst® TF 1.7 was used to acquire data during the
study (AB Sciex, Framingham, MA). DDA was used to acquire data for generation of
peptide ion library, and SWATH-MSALL mode for relative quantification of the proteins.
Positive ionization monitoring was utilized for all the experiments during the study.
DDA experiments were performed over a mass range of m/z 350-950 and all ions
exceeding 350 cps, with a charge state 2 to 4, and quadrupole resolution of 0.7 AMU
was used for automated MS/MS analysis. The mass tolerance was set at 50 mDa during
the initial 250-milliseconds (ms) survey scan, and 8 ions were selected for product scan
per cycle (total cycle time: 900-ms). A DuoSpray™ ion source was used for all the
experiments. Source specific parameters settings for the analysis were ion source gas 1
(GS1): 55 psi, ion source gas 2 (GS2): 60 psi, curtain gas (CUR):25 psi, source
temperature (TEM): 500°C, and ionspray voltage floating (ISVF):5500 V. Compoundspecific parameters for acquisition were declustering potential (DP): 120, and collision
energy (CE): 10 (product ion experiments were carried out using rolling collision
energy). SWATH-MS based spectra were acquired for mass range m/z 400-900 Da with
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SWATH window width of 25 m/z resulting in 20 overlapping mass windows per cycle.
Accumulation time of 109 ms per window was used which resulted in a total cycle time
of 2.29 s. Rolling collision energy for +2 and +3 charges with collision energy spread
of 15 V was applied to each SWATH window upon automatic calculation of the collision
energy center value, dependent on the m/z range according to this rolling collision
energy equation; CE = 0.044*(m/z)+9 (19).

Generation of spectral library
Protein database searching was performed against reference UniProt human
proteome library (July 2015) by ProteinPilot 5.0 (AB Sciex; Framingham, MA, USA)
using Paragon™ algorithm (5.0). A comprehensive spectral library of protein and
peptides from DDA runs of the HLM samples was prepared. Data were uploaded to
ProteinPilot Software to carry out protein identification against a Human Uniprot
FASTA database. Search parameters in ProteinPilot were as follows: Cys alkylationMMTS; digestion-Trypsin; instrument, TripleTOF ® 5600; ID focus-Biological
modifications, search effort-Thorough ID, detected protein threshold-0.05 (10%), and
false discovery rate analysis - yes. The resulting library file (*.group) was uploaded to
Skyline and label-free analyses of data was performed as described below. The spectral
library is available on PeptideAtlas (Identified number PASS01078).

Data processing using Skyline
Skyline is an open source, Windows-based software for creating and analyzing data
from proteomic experiments (20). Reviewed protein sequence of DMEs of interest was
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retrieved from Uniprot and uploaded onto Skyline. Detailed Skyline and data processing
settings are given in supplementary information I.
Briefly, spectral library generated from DDA files was uploaded in Skyline, and
SWATH-MS data files were processed using the full scan MS/MS filtering at a resolution
of 10,000. Unique, non-repetitive peptides were refined and curated for reproducible
fragment ions, and peak boundaries for each selected peptide were manually supervised
and when necessary, adjusted. The reproducibility and reliability of selected peptide and
transitions were verified visually by looking at the peak area ratio of the ion across the
samples. We used 2 peptides per protein and 3 fragment ions per peptide for every protein.
Selected peptides for each protein for the relative quantification of the CYPs described in
this study were also correlated (protein specific) to validate the selection of peptides
(supplementary figure 1).
The total area of representative peptides for a protein was summed, and resulting
intensity was normalized by total intensity of tryptic peptide of β-galactosidase.
MultiQuant v 3.0 (AB Sciex, Framingham, MA) was used to retrieve intensity for
APLDNDIGVSEATR peptide [(M+2H)2+: 729.365] and was subsequently used for
normalization among different batches as described above (supplementary information II)
(21). Percent coefficient of variation (CV%) of the proteins of interest (CYPs) between 6
batches was calculated and plotted using Prism 6.0 (GraphPad Inc., La Jolla, CA). Peptides
used for relative quantification and the transitions for precursor and product ions are given
in supplementary information II.
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Quantification of hepatic mRNA expression
Total cellular RNA was isolated from the samples using RNeasy Mini Kit (QIAGEN
Inc., Valencia, CA). The total RNA was reverse‐transcribed, and the single-stranded
DNA was used for real‐time PCR. The mRNA expression of hepatic CYP was quantified
in duplicates by real‐time PCR using an Applied Biosystems 7500 real-time PCR system
(Applied Biosystems) according to the manufacturer’s instructions. 18S ribosomal RNA
(rRNA) was also quantified as an internal control. The primers used for CYPs are given
in supplementary information III.
Correlation and statistical analysis: Enzyme activity, protein, and mRNA expression
Enzymatic activity for 10 CYPs provided by Xenotech was used for correlation with
the relative protein abundance estimated in HLM using the current method. The correlation
analysis was also performed with mRNA levels determined from liver samples using
method as described above. The incubation conditions, probe substrates and other details
of the enzymatic assays performed by Xenotech on the livers are given in supplementary
information IV. Information on mRNA probes is provided in supplementary information
III. A three-way correlation analysis was conducted between enzyme activity, protein
levels, and mRNA (described below).
Normality tests were performed before statistical analysis and to address the skewness,
the data were natural log transformed (ln) before correlation analysis. Pearson correlation
coefficient was used to determine the relationship between activity, protein and mRNA
level. Correlation coefficient (r)>0.600 was considered strong while between 0.400-0.600
was considered moderate. Additionally, any correlation with r<0.400 was considered poor
in this work. Statistical values (p<0.05) were considered significant for the analysis. All

54

statistical analysis was performed with SPSS 24 (IBM Corp., Armonk, NY) and graphs
were plotted on Prism 6.0 (GraphPad Inc., La Jolla, CA).
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RESULTS
Targeted data extraction using Skyline
At a critical FDR of 1.0%, we detected 1855 distinct proteins and 25,681 distinct
peptides from global FDR fit (Figure 1 (a-b). The in-house generated spectral library was
imported into Skyline, and data extraction was performed. The list of peptides and their
transitions along with charge state is provided in supplementary information II. The
correlation analysis of two peptides for a protein is given in supplementary figure 1. Out
of the 15 hepatic CYPs reported for xenobiotic metabolism, we were able to find 12 CYPs
in this study (22). Inter-batch %CV for all the DMEs evaluated from quality control sample
ranged from 3.1 to 7.8% (supplementary figure 2).
Correlation between protein expression and enzyme activity
Pearson correlation coefficient (r) for CYPs ranged from 0.314 (CYP219) to 0.767
(CYP2A6). All the major CYP enzymes showed a significant (p<0.05) correlation between
enzyme activity and protein levels (Figure 2 (a-l). CYP3A4 and CYP3A5 abundance, and
activity determined using midazolam and testosterone showed a significant association
(r>0.650, p<0.001). A moderate protein-to-activity correlation (r=0.400-0.600, p<0.001)
was also observed for CYP2A6, CYP1A2, CYP2C9, CYP2B6 and CYP2E1. The
correlation for CYP2C8, CYP2D6 and CYP2C19 was significant but poor (r<0.400,
p<0.05). A detailed correlation between activity and protein is provided in Table 2.
Correlation between mRNA expression and enzyme activity
The correlation coefficient for mRNA and activity ranged from -0.067 to 0.729 (Figure
3 (a-l). CYP2C19 and CYP2E1 showed a slightly negative correlation but were not
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significant. The correlation between mRNA expression and activity for CYP3A4,
CYP1A2, CYP2A6, CYP2C8, and CYP2B6 showed a significant and moderate correlation
(r=0.400-0.600, p<0.01). CYP3A5 mRNA correlated significantly only with midazolam
hydroxylation activity. CYP2D6 exhibited a poor but significant correlation (r=0.306,
p<0.05). The correlation was poor and insignificant for other CYP isoforms. A detailed
correlation table is provided in Table 2.
Correlation between mRNA and protein expression
We found that only CYP2A6 (r=0.395), CYP1A2 (r=0.271), CYP3A4 (r=0.577) and
CYP2B6 mRNA (r=0.431) levels showed a correlation which was statistically significant
(Figure 4 (a-j). There was some correlation (r<0.200) between CYP2C9 and CYP2C19
mRNA and protein level but did not reach statistical significance. All other isoforms
showed a poor correlation between mRNA and protein which was again not significant
(p>0.1). A detailed correlation table is provided in Table 2.
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DISCUSSION
Studies involving drug metabolizing enzymes (DMEs) are critical for evaluating drug
efficacy and safety. Thus, an understanding of the biological variation of these DMEs could
provide useful insight into pharmacokinetics or drug interaction potential of new chemical
entities. Conventional targeted methods for protein quantification rely on the use of 1 or 2
unique peptides per protein. The data are further acquired using MRM, and a ratio of
unlabeled (light) to labeled peptide (heavy) is used to determine the level of that peptide
present in a digested sample (23). However, a researcher would require a separate isotopelabeled peptide for each target peptide, and this leads to a significant cost. These highpurity isotope-labeled synthetic heavy peptides cost anywhere from $700 to $1,000 for ∼1
mg of peptides with concentration certification by amino acid analysis.

For the

development of small numbers of assays, this is a reasonable investment. However, the
cost can be prohibitive when the numbers of proteins of interest exceed a limited number
or for experiments intended for biomarker discovery. In drug metabolism, usually only
high abundance CYPs are measured using targeted approach and the low abundance CYPs
or other microsomal enzymes are neglected.
SWATH-MS has found an important application is the discovery of novel biomarkers
(24, 25). Drawbacks of traditional MRM based approaches of protein quantification make
it unsuitable for the research area (26). Ortea and colleagues used SWATH-MS for mining
potential protein biomarkers of lung adenocarcinoma (27). Quantitative mapping of ErbB2,
a receptor tyrosine kinase biomarker was recently demonstrated using SWATH-MS
approach and highlights the application of technique (28).
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Pressure cycling technology (PCT) based digestion along with SWATH-MS
acquisition (PCT-SWATH) was used to reduce the sample preparation time (17). The
typical incubation time for digestion with trypsin is time-consuming and range from 12-18
h (usually overnight). PCT enhances proteolytic action by inducing denaturation of
proteins, therefore allowing better access to trypsin for cleavage sites (29). This also
significantly reduces the digestion and overall sample preparation time.
Skyline is a popular tool used for targeted data analyses of mass spectrometry data. It
supports spectral library generation as well as data analyses of SWATH-MS files (20). Like
other LFQ approaches, it relies on retention time (RT) alignment between the data files and
the spectral library. A commonly used method for retention time normalization relies on
the use of synthetic iRT peptides which are spiked to ever sample before analysis and has
few drawbacks (30). Complex and widely different matrix might significantly affect the
ionization and retention time reproducibility of these peptides within their LC retention
time space and would compromise the evaluation of peptide peak area and FDR calculation
in the case of a low signal within background noise. After thorough literature review and
taking into consideration the costs associated with insertion of standards for RT
normalization, we used the method suggested by Parker et al. (2016) and Nakamura et al.
(2016) in recent articles (21, 30). A retention time predictor was created from endogenous
peptides present in our sample using Skyline allowing integration of fragment intensity
over different batches.
Correlation between mRNA expression, protein abundance, and functional activity are
not always tight due to complex regulation mechanisms involving pre and posttranscriptional events, translational modifications and subsequent protein localization
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events (31). Among other mechanisms, stability and half-life of protein and mRNA in their
in vitro conditions also contribute to poor correlation (31). Similar mechanisms also dictate
the correlation between protein and activity. Further, a poor selection of peptides for
quantification can also affect the outcome of correlation analysis.
In this work, we found that protein levels are better surrogates for estimating the
activity of major xenobiotic CYP isoforms than mRNA. Additionally, we observed that
both protein, as well as mRNA, can be used to access the functional activity of CYP2A6,
CYP1A2, CYP2B6, CYP2C8 and CYP3A4. Interestingly, apart from CYP3A4, CYP1A2,
CYP2B6 and CYP2A6, protein expression of none of the other six CYP isoforms showed
a significant correlation with the mRNA expression. Pre-translational regulation of
CYP1A2, CYP3A4 and CYP2B6 expression has already been reported to be responsible
for good correlation between mRNA expression and enzyme activity (32).
Al Koudsi et al. found that CYP2A6 protein determined by Western blotting
significantly correlate with nicotine C-oxidation activity in human livers (33). We also
observed a significant correlation between protein, activity, and mRNA for CYP2A6. The
correlation was in general stronger between activity and protein expression, followed by
activity and mRNA. Similar correlations have been published previously for microsomal
CYP2A6 (33).
CYP3A activity for testosterone and midazolam hydroxylation correlated strongly with
mRNA as well as protein. There was a good correlation between CYP3A4 mRNA, protein,
and activity suggesting that both protein, as well as mRNA could be used to estimate the
functional activity of this enzyme. Similar results on the correlation of CYP3A4 activity
with mRNA and protein has been previously published (34). CYP3A5 protein expression
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correlated strongly with midazolam and as well as testosterone hydroxylation (r>0.600,
p<0.05). In contrast, the correlation between CYP3A5 mRNA and activity was poor for
testosterone activity (r<0.188, p>0.10) while it was significant for midazolam activity
(r=0.330, p<0.01). There was no relationship observed between protein levels and mRNA
(r<0.100, p>0.10).
As previously reported, CYP2E1 activity correlated strongly with protein level but not
with the mRNA expression (34, 35). This again highlights the role of post-translational
modifications of protein on the enzyme activity. Conversely, a pharmacogenomics study
of CYP1A2 in human liver samples (n=150) found that mRNA and protein correlated with
the functional activity of this enzyme (36). The results are in line with the significant
correlation observed for CYP1A2 in our studies also.
CYP2C9 metabolic activity was shown to have a higher correlation with protein than
mRNA (32). This agrees with our findings for strong CYP2C9 protein and activity
correlation (r=0.620, p<0.001). However, we insignificant correlation for mRNA with
CYP2C9 activity and protein levels. Interestingly, CYP2B6 and CYP2C8 activity showed
a better correlation with mRNA than protein levels. It was not unexpected as Ohtsuki and
colleagues have earlier reported that mRNA is a better surrogate than protein level for
prediction of CYP2B6 activity (3). For CYP2B6, our data agree with finding as we also
found a strong correlation (r=0.729, p<0.001) between mRNA and activity while there was
a moderate correlation (r=0.533, p<0.001) between activity and protein. The correlation
between CYP2B6 protein and mRNA was also moderate (r=0.431, p<0.001). Genetic
polymorphisms were previously suggested to be responsible for such correlation
(Spearman r=0.44) between CYP2B6 mRNA and protein expression (37). Studies have
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also reported that the genetic polymorphism in CYP2C8, CYP2C19, and CYP2D6 account
for major variability in the activity of these enzymes (38). Protein stability in isolated
microsomes could also be attributed to poor correlation with mRNA.
Rodríguez-Antona et al. observed a moderate correlation between CYP2C8 protein
abundance and enzyme activity (39). CYP2C8 activity correlated moderately with protein
(r=0.331, p<0.01) but a strong correlation was observed with mRNA (r=0.524, p<0.01)
suggesting the role of post-translational modifications. A significant correlation between
mRNA and activity for CYP2C8 and CYP2D6 suggests the utility of mRNA for studying
the functional activity of these CYP isoforms. Poor correlation of CYP2C19 mRNA and
activity suggest towards major post-translational changes influencing its activity in human
and makes a case for use of protein levels to predict the activity for this enzyme.
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CONCLUSIONS
SWATH-MS exemplify a powerful LFQ technique, which addresses the limitations of
the shotgun and targeted proteomics to provide a permanent digital repository of all
peptides present in a sample. This method can serve as a valuable post hoc tool for studying
new hypothesis and ideas without the need to re-acquire data.

To the best of our

knowledge, this is the first report demonstrating the use of SWATH-MS and pressurecycling based digestion for relative quantification of drug metabolizing enzymes in human
liver microsomes and the correlation with their functional activity and mRNA expression.
The studies also highlight the importance of protein levels for prediction of the functional
activity of CYP enzymes.
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Tables
Table 1: Brief demographic summary of donors
Total number of donors (Male/Female)

78 (41, 37)

Ethnicity (C/AA/H)

66, 9, 3
Mean ± SD

Age (years)

51.5 ± 12.9

Weight (kg)

90.6 ± 27.2

Height (cm)

169.6 ± 10.9

C: Caucasian, AA: African-American, H: Hispanic
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Figure legends
Figure 1 : Identified proteins and peptides at 1% false discovery rate (FDR). The graph
depicts identification of 1855 proteins and 25681 peptides in the spectral library at 1%
FDR.
Figure 2 (a-l): Correlation plots for relative protein expression and enzyme activity.
Protein abundance values were expressed relative to APLDNDIGVSEATR peptide from
E. coli β-galactosidase. The enzyme activity was represented as CYP-specific product
formation/min/mg protein. All values are natural logarithm (ln) transformed and Pearson
correlation analysis was performed.
Figure 3 (a-l): Correlation plots for mRNA and enzyme activity. Messenger RNA
(mRNA) was expressed relative to β-actin. Protein abundance values were expressed
relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. The enzyme activity
was represented as CYP-specific product formation/min/mg protein. All values were
natural logarithm (ln) transformed and Pearson correlation analysis was performed.
Figure 4 (a-j): Correlation plots for mRNA and protein expression. Messenger RNA
(mRNA) was expressed relative to β-actin. Protein abundance values were expressed
relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. All values are
natural logarithm (ln) transformed and Pearson correlation analysis was performed.
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Figure 1: Identified proteins and peptides at 1% false discovery rate (FDR). The graph
depicts identification of 1855 proteins and 25681 peptides in the spectral library at 1%
FDR.
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Figure 2 (a-l): Correlation plots for relative protein expression and enzyme activity.
Protein abundance values were expressed relative to APLDNDIGVSEATR peptide from
E. coli β-galactosidase. The enzyme activity was represented as CYP-specific product
formation/min/mg protein. All values were natural logarithm (ln) transformed before
Pearson correlation analysis.
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Figure 3 (a-l): Correlation plots for mRNA and enzyme activity. Messenger RNA
(mRNA) was expressed relative to GAPDH and β-actin. Protein abundance values were
expressed relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. The
enzyme activity was represented as CYP-specific product formation/min/mg protein. All
values were natural logarithm (ln) transformed before Pearson correlation analysis.
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Figure 4 (a-j): Correlation plots for mRNA and protein expression. Messenger RNA
(mRNA) was expressed relative to β-actin. Protein abundance values were expressed
relative to APLDNDIGVSEATR peptide from E. coli β-galactosidase. All values are
natural logarithm (ln) transformed before Pearson correlation analysis.
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Abstract graphic. Liver microsomes were prepared from human liver samples and
trypsin-based digestion was carried out on samples after denaturation and alkylation.
Furthermore, tryptic peptides were analyzed using LC-MS/MS in data dependent and
SWATH-MS mode. The in-house spectral library was prepared from the using Protein Pilot
and targeted data extraction for CYPs was performed in SWATH files using Skyline. Total
intensity of CYPs in each batch was normalized using average intensity of β-galacotosidase
for that batch. Subsequently, the relative protein abundance protein values were correlated
with enzymatic activity and mRNA.
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Supplementary information III: Quantification of hepatic CYP mRNA expression
Total cellular RNA was isolated from the samples using RNeasy Mini Kit (QIAGEN Inc.,
Valencia, CA). The total RNA was reverse‐transcribed, and the single stranded DNA was
used for real‐time PCR. The mRNA expression of hepatic CYP was quantified by real‐
time PCR using an Applied Biosystems 7500 Real‐Time PCR system (Applied
Biosystems) at least two times according to the manufacturer’s instructions. The primers
for CYP were shown in table below. 18S ribosomal RNA (rRNA) was also quantified as
an internal control.
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Sequence

Position

CYP1A2
Forward
primer
Reverse primer
CYP2A6
Forward
primer
Reverse primer
CYP2B6

GCTTCTACATCCCCAAGAAAT

1257-1277

TCCCACTTGGCCAGGACT

1464-1447

Forward
primer
Reverse primer

ATGGGGCACTGAAAAAGACT
GA
AGAGGCGGGGACACTGAATG
AC

1257-1278

AGATCAGAATTTTCTCACCC

665-684

AACTTCGTGTAAGAGCAACA

822-803

CYP2C8
Forward
primer
Reverse primer
CYP2C9
Forward
primer
Reverse primer
CYP2C19
Forward
primer
Reverse primer
CYP2D6
Forward
primer
Reverse primer
CYP2E1
Forward
primer
Reverse primer
CYP3A4
Forward
primer
Reverse primer
CYP3A5
Forward
primer
Reverse primer
18S rRNA
Forward
primer
Reverse primer

Accession
number
NM000761

NM000762
AGCAACAGGCCTTTCAGTT

722-740

CCCAATGAAGAGGTTCAAC

924-906
NM000767

1539-1518

Ref.
Katoh et al.,
2004

Katoh et al.,
2004

Wilkening et al.,
2004

Katoh et al.,
2004
NM000770

NM000771
CAGATCTGCAATAATTTTTCTC

665-686

CTTTCAATAGTAAATTCAGAT
G

882-861

ATTGAATGAAAACATCAGGAT
TG
GAGGGTTGTTGATGTCCATC

600-622

Katoh et al.,
2004

Katoh et al.,
2004
NM000769

781-762
NM000106

GGTGTGACCCATATGACATC

1207-1226

CTCCCCGAGGCATGCACG

1428-1411

GACTGTGGCCGACCTGTT

906-923

ACTACGACTGTGCCCTTGG

1202-1184

CTTTTATGATGGTCAACAGCC
TGTG
CTTTTCATAAATCCCACTGGA
CCA

326-350

CCCACACCTCTGCCTTTG

223-240

CAGGGAGTTGACCTTCATACG

343-323

NM000773

Wilkening et al.,
2004

NM000940

He et al., 2006

NM000777

Busi et al., 2005

NM003286

Jigorel et al.,
2006

454-431

CGCCGCTAGAGGTGAAATTC

948-967

TTGGCAAATGCTTTCGCTC

1009-991
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Supplementary information IV: Enzyme assay conditions as provided by Seksui
Xenotech LLC, Kansas City, MO

Enzymatic assay conditions
• HLM protein concentration: 50 µg/mL
• Incubation temp: 37°C
• Reaction time: 10 min
• Potassium phosphate buffer (50 mM, pH 7.4) containing 3.0 mM MgCl2, EDTA
(1.0 mM), NADP (1.0 mM), glucose-6-phosphate (5.0 mM), glucose-6-phosphate
dehydrogenase (1 Unit/mL)
• Probe substrates were incubated at a final concentration mentioned in the table below.

Probe substrate

Probe reaction

CYP1A2

Phenacetin

Phenacetin O-alkylation

Substrate
conc. (µM)
80

CYP2A6

Coumarin

Coumarin 7-hydroxylation

50

CYP3A4/3A5

Midazolam

30

CYP3A4/3A5

Testosterone

CYP2B6

Bupropion

Midazolam 1hydroxylation
Testosterone 6βhydroxylation
Bupropion hydroxylation

CYP2C8

Amodiaquine

CYP2C9

Diclofenac

CYP2C19

S-Mephenytoin

CYP2D6

Dextromethorphan

CYP2E1

Chlorzoxane

Amodiaquine Ndealkyation
Dicofenace 4hydroxylation
S-Mephenytoin 4hydroxylation
Dextromethorphan 6hydroxylation
Chlorzoxane 6hydroxylation

250
500
20
100
400
80
500

Reference: Pearce et al., Effects of freezing, thawing, and storing human liver
microsomes on cytochrome P450 activity. Arch Biochem Biophys. 1996, 15;331(2):14569.
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ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease in the
Western population. We investigated the association of nonalcoholic fatty liver disease
(NAFLD) and diabetes mellitus on CYP3A4 activity in human liver tissue from brain dead
donors (N=74). Histopathologically graded livers were grouped into normal (n=24),
nonalcoholic fatty liver (NAFL, n=26) and nonalcoholic steatohepatitis (NASH, n=24)
categories. The rate of conversion of midazolam to its 1-hydroxy metabolite was used to
assess in vitro CYP3A4 activity in human liver microsomes (HLM). A proteomics
approach was utilized to quantify the protein expression of CYP3A4 and related enzymes.
Moreover, a physiologically based pharmacokinetic (PBPK) model was developed to allow
prediction of midazolam concentration in NAFL and NASH patients. CYP3A4 activity in
NAFL and NASH was 1.9 and 3.1-fold (p<0.05) lower than normal donors, respectively.
Intrinsic clearance (CLint) was 2.7 (p<0.05) and 4.1 (p<0.01) fold lower in donors with
NAFL and NASH, respectively. CYP3A4 protein expression was significantly lower in
NAFL and NASH donors (p<0.05) and accounted for midazolam hydroxylation variability
in a multiple linear regression analysis (β=0.869, r2=0.762, P<0.01). Diabetes was also
associated with decreased CYP3A4 activity and protein. Both midazolam CLint and
CYP3A4 protein abundance decreased significantly with increase in hepatic fat
accumulation. Age and gender did not exhibit any significant association with the observed
alterations. Predicted midazolam exposure was 1.7 and 2.3-fold higher for NAFL and
NASH, respectively, which may result in a longer period of sedation in these patients. Data
suggests that NAFLD and diabetes are associated with the decreased hepatic CYP3A4
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activity. Thus, further evaluation of clinical consequences of these findings on the efficacy
and safety of CYP3A4 substrates is warranted.
Keywords:
CYP3A4, diabetes, drug metabolism, midazolam, nonalcoholic fatty liver disease,
nonalcoholic steatohepatitis, PBPK, pharmacokinetics, proteomics
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INTRODUCTION
The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising at an alarming
rate in populations with diabetes and obesity. The clinical diagnosis of NAFLD is based
on limited or no consumption of alcohol, evidence of hepatic steatosis based on either
biopsy or imaging, and the exclusion of other causes of liver disease. NAFLD is subcategorized histopathologically as non-alcoholic fatty liver (NAFL), which is characterized
by lipid accumulation in hepatocytes, or non-alcoholic steatohepatitis (NASH), which is
associated with hepatic steatosis with inflammation and ongoing inflammatory or
degenerative injury to hepatocytes

1, 2

. Significant lobular inflammation, hepatic fibrosis,

and hepatocyte necrosis present in NASH can progress to life-threatening liver cirrhosis
and hepatocellular carcinoma (HCC).3
Over 64 million people in the United States are projected to have NAFLD, with an
estimated economic burden of about $103 billion, and these costs are highest among
patients aged 45-65 year.4 Presence of NAFLD is highly correlated with insulin resistance
and diabetes.5

Diabetes and NAFLD share common underlying pathophysiological

processes including insulin resistance, hyperglycemia, dyslipidemia, inflammation and
other cardiovascular conditions.6 A retrospective analysis of the hospital admission of
patients with type 2 diabetes showed that the relative risk of NAFLD among these patients
was 3-times higher in men and 5-times higher in women than those without diabetes.7
Despite the widespread prevalence of NAFLD, no specific pharmacological
therapies are available for its treatment; however, management of associated conditions
including obesity, diabetes, and hyperlipidemia are often achieved pharmacologically or
through lifestyle intervention.8-10 CYP3A enzymes metabolize most of the drugs prescribed
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for these comorbidities.11 Moreover, CYP3A enzymes are also responsible for the
metabolism of 30-50% of all drugs available in the market.11, 12 CYP3A4 and CYP3A5
proteins of this superfamily of enzymes are expressed in human liver as well as
extrahepatic tissues including intestine.13 Moreover, CYP3A4 plays a significant role in
the catabolism of carcinogens (aflatoxin B1), and various endogenous steroids
(progesterone, testosterone, cortisol and bile acids).14-17 Additionally, the enzyme is
involved in the biotransformation of cholesterol, and the plasma concentration of
cholesterol 4β-hydroxy has been used as an endogenous marker of CYP3A4 activity.18
CAR, PXR, HNFα, and PPARα are some of the transcription factors which has been
reported to modulate the expression of CYP3A4.19, 20
A perturbation in CYP3A4 activity associated with diabetes, NAFLD or both is
likely to alter the clearance of some drugs thereby changing the efficacy or safety of
CYP3A substrates. Current studies in rodent models of the disease are conflicting as it has
been widely known that most models fail to recapitulate the complex pathophysiology of
human NAFLD fully.21-23 In rat models, reduced or elevated expression and activity of
Cyp3a in steatosis and NASH has been reported 24-28. Similarly, studies in mice models are
inconsistent, and results vary with diet and species 29-31.
Genome-wide studies (GWAS) in human NAFLD patients found no significant
changes in drug metabolism genes between normal and steatotic livers at mRNA
expression level.32, 33 However, these results don’t capture the post-transcriptional and
post-translational changes which may alter protein expression or activity. The results of
studies in human liver examining the impact of NAFLD on CYP3A4 activity are
heterogeneous and lacks agreement.34-37 Fisher et al. found a trend of decreasing CYP3A4
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protein expression with severity of NAFLD, but no change in enzyme activity was
observed. 34 However this study was done in a small sample size (steatosis =10, NASH=10)
and no information on the ethnicity was provided. In contrast, Woolsey et al. found
significantly lower activity CYP3A4 activity in human NASH subjects.

37

Diabetes was

found to be associated with significant reduced CYP3A4 activity in human livers.

38

However, the sample size in this study investigation was small, and presence of NAFL or
NASH status was unknown.
Therefore, using a large human liver tissue repository (N=74), well-characterized
with respect to the presence of diabetes and NAFLD, we aimed to verify which disease
condition influence the expression and activity of CYP3A4. The goal of studies using
microsomes it to determine the intrinsic clearance and in vitro in vivo extrapolation
(IVIVE). CYP3A4 functional activity and intrinsic clearance of midazolam was evaluated
in HLM. As protein expression is an important factor for IVIVE, we determined the
expression of CYP3A4 and related proteins in HLM using mass spectrometry.
Furthermore, we developed a physiologically based pharmacokinetic (PBPK) model and
predicted midazolam exposure in virtual populations of NAFL and NASH patients.
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EXPERIMENTAL SECTION
Materials and reagents. Midazolam (MDZ), 1-hydroxy midazolam (1′-OH MDZ), and 1hydroxy midazolam-D4 (1′-OH MDZ-D4) were purchased from Cerilliant Corporation
(Round Rock, TX). MS-grade formic acid, acetonitrile, and methanol were obtained from
ThermoFisher Scientific (Waltham, MA). NADPH tetrasodium salt was from Calbiochem
(EMD Millipore, Billerica, MA). OxiSelect TBARS assay kit (Malondialdehyde
quantification) was purchased from Cell Biolabs, Inc., San Diego, CA and Amplex® Red
Cholesterol Assay Kit was from ThermoFisher Scientific, Waltham MA. All other reagents
and solvents used in the study were of analytical grade.

Human liver bank. A novel human liver tissue repository (N=106) was created in our
laboratory from hepatic tissue purchased from Sekisui XenoTech LLC (Kansas City, KS).
The identity of donors was not known thereby the study was designated as Institutional
Review Board (IRB) exempt category 4. Age, gender, ethnicity, the cause of death, cold
ischemia time, liver and body weight was available for ≥95% of the samples. While being
accessible, smoking and alcohol consumption was not assessed for effect on CYP3A4
activity due to reasons discussed later in the text. Detailed donor demographics are given
in Table 1. The primary objective of the work was to study the effect of NAFLD and
diabetes on CYP3A4 activity and protein levels. Therefore, only samples that were
homozygous for CYP3A5*3/*3 (n=74) were included in this study. The results and findings
of this study are thus limited to Caucasian male and female population. Moreover, five
donors were identified with CYP3A4*22 variant and one possessed CYP3A4*1B (Table
1).
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Histological grading and study grouping. Liver tissue was graded for steatosis, lobular
inflammation, hepatocyte ballooning, and fibrosis by a physician specializing in
histopathology (Suzanne Delamonte, MD). The standardized scoring protocol assessed the
presence and severity of hepatocellular steatosis, lobular inflammation, ballooning
degeneration, and fibrosis.39 Formalin-fixed paraffin-embedded histological sections (5
µm thick) of the liver, stained with hematoxylin and eosin dyes, were used to grade the
severity of the disease. In brief, the slides were coded and scored concerning the abundance
and distribution of hepatic steatosis, lobular inflammation, hepatocellular ballooning
degeneration, and fibrosis. Steatosis was graded as 0 (<5%), 1 (5-33%), 2 (34-66%), or 3
(>66%), reflecting the cross-sectional areas of the section showing hepatocytes with
steatosis. Lobular inflammation was graded as 0 (absent), 1 (<2 foci/200x microscopic
field), 2 (between 2 and 4 foci/200x microscopic field), or 3 (>4 foci/200x microscopic
field). Hepatocyte ballooning degeneration was graded as 0 (absent), 1 (rare, scattered
cells) or 2 (readily detected). Fibrosis grading was simplified relative to the original report
and graded as 0 (absent), 1 (mild and delicate in the perisinusoidal regions), 2
(conspicuously present in perisinusoidal and periportal regions), 3 (bridging fibrosis), or 4
(cirrhosis, which requires bridging fibrosis and regenerative nodules). The final scores
represent the summed sub-scores. Steatosis was confirmed by Oil Red O staining of
cryostat sections (10 microns) of the same liver samples, and fibrosis was confirmed by
Sirius red staining of adjacent formalin fixed paraffin-embedded tissue sections.40 A
composite of different histological sections of representative liver samples from different
groups is given in Fig. 1.
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Subsequently, livers were categorized as normal, NAFL, and NASH based on the
scoring algorithm described in supplemental figure I.41 Detailed histological
characteristics of donors are given in supplemental table I.

Malondialdehyde and cholesterol estimation. Quantification of malondialdehyde
(MDA) in donor liver homogenate was determined using OxiSelect TBARS assay kit
according to manufacturer instructions (Cell Biolabs, Inc., San Diego, CA). Total liver
cholesterol was estimated using Amplex® Red cholesterol assay kit according to
manufacturer’s instruction (ThermoFisher Scientific, Waltham, MA).

Quantification of mRNA. Total RNA from liver tissues was isolated using the RNeasy
mini kit (Qiagen Inc., Valencia, CA). Subsequently, the total cellular RNA was reversetranscribed, and the cDNA was used for real-time PCR analysis. The mRNA expression of
hepatic CYP3A4 and the relevant transcription factors were quantified by real-time PCR
using SYBR Green Master Mix on 7500 Real‐Time PCR system (Applied Biosystems,
ThermoFisher Scientific, MA). Human 18S ribosomal RNA (rRNA) was used as an
internal control for relative expression of data. The information on PCR primers used is
available in supplemental table II.

CYP3A4 activity assay. Microsomes were prepared from liver samples as described
previously in detail.42

CYP3A4 activity was assessed by formation of 1-hydroxy

midazolam in HLM using midazolam as probe substrate.43 Enzymatic incubations were
carried out in 100 mM potassium phosphate buffer containing 3 mM MgCl2 (pH 7.4).
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Microsomal protein concentration used was 50 µg/mL and concentrations of midazolam
were 0, 0.2, 1, 2.5, 5, 10, 25 µM. The addition of NADPH initiated the reaction, and the
incubations were carried out in a shaking water bath (75 rpm) kept at 37°C. After 20 min,
the reaction was terminated by addition of ice-cold acetonitrile containing 0.5% formic
acid and internal standard (1-hydroxymidazolam-D4, 50 ng/mL). Subsequently, samples
were centrifuged at 2000 g for 5 min at 4°C. The supernatant was collected, and 5 µL was
injected for quantification of 1-hydroxy midazolam using the UPLC-MS method described
below. CYP3A4 activity (Vmax; maximum rate of reaction) was expressed as pmol/mg
microsomal protein.

Quantification of 1-hydroxy midazolam. Samples were analyzed using a previously
published method with some modifications to chromatography method as described below
43

. Chromatographic separation was performed using a gradient elution mode using 10 mM

ammonium acetate and 10% methanol (A) and acetonitrile (B) at the flow rate of 400
µL/min. The linear gradient started with 25% B until 0.5 min, 60% B at 1.5 min, 90% B at
3 min before returning to 25% B at 4 min. All other mass spectrometer parameters were
same as previously described.43

Quantification of proteins using mass spectrometry. Protein levels of CYP3A4,
NADPH-cytochrome P450 reductase (CPR), and Cytochrome b5 (Cyb5) in human liver
microsomes were determined using mass spectrometry and “Total Protein Approach”.44
Microsomal fractions were digested with trypsin and analyzed in Data-Dependent
Acquisition (DDA) mode on SCIEX TripleTOF 5600+ mass spectrometer (SCIEX,
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Concord, CA). The raw data files from one of our previous study were analyzed using
MaxQuant (ver 1.5.2.10).42 The specifics of protein digestion and mass spectrometry
analysis were previously described in the literature.42, 44 The proteins were searched on
Andromeda search engine against UniProt human protein database (updated Oct 2016) at
1% false discovery rate (FDR).45 Cysteine carbamidomethylation was selected as fixed
modifications for the search. Label-free quantification (LFQ) was performed with a ratio
count of 1 and maximum of two missed cleavages were allowed. All the other MaxQuant
settings were kept as default values. The absolute protein levels were calculated using
“Total Protein Approach” from LFQ intensities obtained from MaxQuant using the
equations given below44.
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝑝) =

𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝) =

𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑝)
𝑇𝑜𝑡𝑎𝑙 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙

𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑝)
[mol/gram total protein]
𝑇𝑜𝑡𝑎𝑙 𝑀𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 𝑥 𝑀𝑊(𝑝)

where MS signal (p) refers to total LFQ signal intensity for CYP3A4, CPR or Cyb5. Total
MS signal refers to the total LFQ intensity of all the proteins and MW represents the
molecular weight of respective protein.

Modeling of enzyme kinetics data. In vitro CYP3A4 kinetics data were fitted using
Prism® version 6 (GraphPad Software Inc., La Jolla, CA) into a nonlinear least-squares
regression equation given below 46.
𝑣=

𝑉𝑚𝑎𝑥 × 𝑆
𝑆
𝐾𝑚 + 𝑆 × (1 + 𝐾 )
𝑠
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Where S represents the concentration of substrate, v is the velocity of 1-OH midazolam
formation; Km is Michaelis-Menten constant (substrate concentration required for an
enzyme to reach one-half its maximum velocity), and Ks is inhibition constant. Vmax
(maximum rate of product formation) and Km were estimated from the equation, and
apparent in vitro intrinsic clearance (CLint, app) was calculated as Vmax/Km. Intrinsic
clearance for whole liver (CLint, whole liver) was calculated using the equations given
below and was expressed as L/min. MPPGL denotes the yield of membrane proteins per
gram of liver.
𝐶𝐿𝑖𝑛𝑡 (𝑤ℎ𝑜𝑙𝑒 𝑙𝑖𝑣𝑒𝑟) = 𝐶𝐿𝑖𝑛𝑡, 𝑎𝑝𝑝 × 𝑀𝑃𝑃𝐺𝐿 × 𝐿𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
SimCYP based PBPK simulation. A physiologically based pharmacokinetic (PBPK)
model was developed in SimCYP population-based simulator (ver 15, Certara LP,
Sheffield, UK) using CYP3A4 protein and midazolam enzyme kinetic parameters. A
virtual Caucasian population (Sim-NEurcaucasian) with an equal proportion of males and
females, 20-65 year old, was selected for simulations. A minimal PBPK model was utilized
for estimating plasma concentration-time profiles. Portal and arterial blood flow were the
same for all the populations given a lack of data on hepatic blood flows in NAFL and
NASH. An intravenous bolus dose of 5 mg midazolam was given, and default SimCYP
compound file was used. In vitro Vmax and Km values were substituted for a respective
study group in the “whole organ metabolic clearance” tab implemented in SimCYP.
Default CYP3A4 phenotype values for the Caucasian population was replaced with protein
concentrations determined in this study. Five virtual trials with 50 subjects per study were
used for prediction of systemic midazolam concentration. All other parameters were kept
as the default values.
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Statistical analysis. Statistical analysis was performed with SPSS version 24 (IBM
Analytics, Armonk, NY), and Prism® version 6 (GraphPad Software Inc., La Jolla, CA)
was used for graphs, Vmax and Km calculations. Descriptive statistical values in tables are
reported as mean ± standard error (SE) unless otherwise stated. Mann-Whitney U test (2tailed) was used to compare the effect of gender. Non-parametric Kruskal-Wallis test (2tailed) without multiple corrections was used when studying three or more groups. The
correlation was analyzed using nonparametric Spearman correlation analysis. Linear and
multiple regression analysis were used to determine the contribution of predictors toward
explaining variability in CYP3A4 activity. P <0.05 was considered significant for all the
statistical tests and correlation analysis.
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RESULTS
CYP3A4 activity and protein expression are decreased in NAFLD. Significantly lower
CYP3A4 activity (Vmax expressed as pmol/min/mg protein) was observed in microsomes
from NAFLD donors (Fig. 2).

HLM from NASH donors exhibited 3.1-fold lower

midazolam Vmax as compared with normal donors (Table 2). Midazolam Vmax was 1.9fold lower in HLM from NAFL donors, but the effect was not statistically significant
(P>0.05). CLint (L/min) was significantly lower intrinsic clearance in NAFL (2.7±0.9,
P<0.05) and NASH (1.8±0.6, P<0.01) as compared to normal (7.3±1.8, Fig. 3). MichaelisMenten constant (Km) was comparable in different study groups and ranged from 1.6 to 2.3
µM (Table 2).
Mean protein levels of CYP3A4 decreased with progression of disease (P<0.05,
Fig. 3). CPR and Cyb5 protein levels were significantly lower (P<0.05) in HLM from
NAFLD donors (Table 3). The progression of disease from NAFL to NASH reduced the
CYP3A4 mRNA expression (Fig. 4). However, the decrease was not significant. The levels
of transcription factors, PXR, CAR, HNF4α and PPARα mRNA, decreased with disease
progression (Fig. 4). The reduction in CAR mRNA level was significantly different
between normal and NASH donors (P<0.05).

CYP3A4 activity and protein expression are decreased in diabetes and NAFLD. Given
the high prevalence of NAFLD in patients with diabetes, we further studied the combined
effect of the insulin resistance and fatty liver on CYP3A4 protein and activity. The levels
of CYP3A4 activity, protein and mRNA expression and relevant transcription factors are
summarized in Table 4. We observed that the effect of NAFLD was more prominent and
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statistically significant in HLM from diabetic donors. For non-diabetic donors, the study
parameters showed a trend of reduction in disease state but were not statistically significant
except CPR. In contrast, CYP3A4 activity and Clint was significantly lower in HLM from
diabetic NAFL and NASH donors. Similarly, a significant decrease in CYP3A4, CPR, and
Cyb5 was also observed in diabetic donors with NAFLD. Interestingly, while mRNA
expression decreased in both disease states, the mean differences failed to achieve
statistical significance.

CYP3A4 activity and protein expression decrease with increase in liver fat. The impact
of varying grades of steatosis on CYP3A4 activity, protein and mRNA levels was also
evaluated. When the donors were categorized based on the severity of steatosis, a
significant reduction in CLint was observed (Fig. 5). CYP3A4 activity decreased with
increase in liver fat content, but the decline was not significant due to extensive variability.
CYP3A4, CPR, and Cyb5 protein levels also reduced with an increase in the severity of
steatosis (Fig. 5, supplemental figure III).

Effect of age. The average age of normal donors was similar in NAFL and NASH donors
(Table 1). Donor age showed no significant correlation with CYP3A4 activity (r=-0.143,
P >0.1), CYP3A4 protein (r=-0.101, P >0.1), and CLint (r=-0.228, P >0.1, Supplemental
figure IV). The association with age was also insignificant for CYP3A4 mRNA.

Effect of gender. Almost equal number of male and female donors were included in this
study (males=36, females=38, Supplemental table III). In general, males exhibited
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marginally higher CYP3A4 activity, CLint, protein and mRNA levels than female donors.
However, no significant association (P>0.1) was observed between gender and CYP3A4
activity, Clint as well as CYP3A4, CPR and Cyb5 protein abundance. The relationship
between gender and CYP3A4 and related proteins was also examined, and no significant
correlations were found (Supplemental table III).

Correlation between activity, mRNA and protein levels. The rate of 1hydroxymidazolam formation showed a significantly positive correlation with CYP3A4
protein and mRNA levels. Similarly, CYP3A4 protein and mRNA expression levels
exhibited significant positive correlation (supplemental figure V). A significant but
moderate correlation was found between CPR protein and CYP3A4 activity (r=0.446, P
<0.01), and CYP3A4 protein (r=0.547, P <0.01). The correlation between Cyb5 protein
and CYP3A4 activity (r=0.463, P <0.01), and CYP3A4 protein (r=0.592, P <0.01) was
moderate and significant. The association between two CPR and Cyb5 was significant as
well (r=0.607, P <0.01). Correlation plots can be found in supplemental figure V.

Linear regression analysis of protein and activity. Univariate linear regression analysis
was used to determine how much of the variability in CYP3A4 activity was accounted by
CYP3A4, CPR, and Cyb5 protein levels. We found that CYP3A4 (r2=0.761, P<0.01), CPR
(r2=0.331, P<0.01) and Cyb5 (r2=0.197, P<0.01) protein levels were significant predictors
of the CYP3A4 activity in HLM. However, multiple linear regression analysis returned a
regression coefficient (r2=0.762, P<0.01) which was marginally better than the coefficient
returned by univariate linear regression between CYP3A4 protein and activity (r2=0.761).
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Standardized beta coefficients of multiple regression models for CYP3A4 protein
(β=0.869, P<0.01) explained most of the variability in midazolam hydroxylation activity,
whereas CPR protein (β =0.062, P>0.1) and Cyb5 protein (β =-0.069, P>0.1) revealed the
minimal contribution of each predictor to the model.

SimCYP based PBPK model. The simulated plasma profile of midazolam was in good
agreement with the observed profiles previously reported in the literature so as the values
of area under the concentration-time curve (AUC0-24), maximum midazolam
concentration (Cmax) and clearance (CL).47 A 1.8 and 2.3-fold increase in exposure (based
on AUC) was found for NAFL and NASH populations, respectively (supplemental table
IV). Predicted plasma concentration of midazolam in a Caucasian population with
CYP3A4 phenotype and enzyme kinetic parameters is shown in Fig. 6. . The predicted
intravenous clearance (CL) of midazolam in normal, NAFL and NASH group was 16.6,
9.4 and 8.6 L/h, respectively (supplemental table IV). The pharmacokinetic parameters
when accounting for insulin resistance (diabetes) and fatty liver (NAFLD) are given in
supplemental table V.
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DISCUSSION
Our studies suggest downregulation of CYP3A4 protein and activity in NAFLD. While
some findings were not statistically significant for NAFL, a trend of reduction was
observed. This pattern achieved significance for HLM from NASH donors suggesting that
the decrease in CYP3A4 activity and CYP3A4 protein continues with the severity of
disease as it progresses from benign stage to NAFL and NASH. We also found that insulin
resistance along with steatosis appears to provide a double-blow leading to decreased
CYP3A4 protein and activity. Similar substrate affinity (Km) among the groups indicate
that the differences seen in the velocity of the reaction (1-hydroxy midazolam formation)
were in fact due to an altered enzyme level rather than its affinity for the substrate. Multiple
linear regression modeling showed that the variability in midazolam hydroxylation was
accounted mainly by CYP3A4 protein in HLM. SimCYP based PBPK model was in good
agreement for the healthy population when in vitro parameters from this study were used.
Woolsey and colleagues found that midazolam concentrations in human subjects
with NASH were significantly higher as compared to control subjects (indicating reduced
CYP3A activity).37 Fisher and colleagues suggested a decrease in CYP3A4 expression and
functional activity with the progression of NAFLD, but this difference was not statistically
significant.34 The same study reported that the mRNA expression was not different between
NAFLD groups. We found that the mRNA expression of CYP3A4 and its transcription
factors (CAR, PXR, HNF4α, and PPARα) was reduced in livers from NAFLD donors, but
the effect was statistically insignificant except for CAR mRNA. In contrast, the level of
protein expression was significantly lower in such donors possibly indicating the
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involvement of transcriptional and translational mechanisms in down-regulation of
CYP3A4 activity.
Two primary inducible nuclear transcription regulators of CYP3A4 mRNA
expression in human, PXR and CAR, are widely affected by dietary, genetic,
environmental and pathological factors.48 Similar PXR mRNA levels between fatty and
normal human liver microsomes were previously reported.35 HNF4α was identified as a
critical constitutive regulator of PXR and CAR-mediated transcriptional induction of
CYP3A4.49 Conversely, we found a decrease in HNF4α levels, but the alteration was
statistically insignificant between the three groups. Interestingly, a study on PXR-knockout
rat model indicated that down-regulation of hepatic CYP450s via a PXR-independent
mechanism.50 It could partially explain why the PXR mRNA levels were not significantly
different in our study despite a discernible decrease in the disease state. Recently, Woolsey
et al. reported that CYP3A4 down-regulation might be due induced fibroblast growth factor
21 (FGF21) leading to reduced PXR localization and binding to the CYP3A4 proximal
promoter.51 While some have reported elevated CAR in the pathogenesis of NASH in mice,
other studies suggest a downregulation of CAR.52, 53 We also found that CAR mRNA
expressed was decreased with progression of NAFLD. PPARα governs transport and βoxidation of fatty acid in the liver in addition to regulation of inflammatory response. We
found different levels of PPARα in our groups, but the effect was insignificant. Due to lack
of data, we speculate that tandem decrease in levels of transcription factors may result in
significant downregulation of some target proteins.
Diabetes and insulin resistance are associated with NAFLD with up to 70% patients
having been reported to share both these comorbidities.54, 55 Our lab has reported the effect
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of diabetes on CYP3A4 expression and activity in human liver, but the impact of NAFLD
was not studied.38 In this study, we found that while there was a decrease in CYP3A4
activity and protein, the effect was statistically insignificant in HLM from non-diabetic
donors. In contrast, NAFL and NASH donors with diabetes showed a statistically
significant decrease in activity, protein expression, and midazolam clearance. Interestingly,
we found that diabetic, normal donors exhibited marginally higher CYP3A4 activity and
Clint as compared to non-diabetic normal donors. We speculate that this anomaly could be
possibly attributed to pharmacological agents that these diabetic donors might be receiving.
Our lab is currently pursuing a challenging project to find out the exposure to different
drugs at the time of death in our liver bank. Based on the data, we speculate that the
heightened reduction of activity and midazolam Clint in diabetic subjects may be due to
the double-punch which insulin resistance appears to trigger in steatotic livers. It is also
supported in part by lack of statistically significant decrease in CYP3A4 activity in nondiabetic livers.
Kolwankar and colleagues found an independent association between hepatic
steatosis and reduced CYP3A activity which decreased with the severity of steatosis.35
Another study in human hepatocytes isolated from macrosteatosis livers found a significant
reduction in CYP3A4 activity without any alteration in CPR levels in microsomes from
steatotic and nonsteatotic livers.56 We also found that livers with >5% hepatic fat were
associated with the low CYP3A4 activity and intrinsic clearance of midazolam in HLM.
Previous studies have reported a higher amount of protein, mRNA and CYP3A4
activity in female livers.13 In contrast, we found that males exhibited slightly higher
CYP3A4 level than females. A few clinical studies have reported that women have higher
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CYP3A4 activity than men based on pharmacokinetic studies with cyclosporine,
erythromycin, and midazolam.57, 58 Conversely, studies with cyclosporine and midazolam
suggest an insignificant gender difference in metabolism of these drugs. As CYP3A4 and
P-glycoprotein 1 (Pgp) share a large number of common substrates; increased metabolism
in females may in part be due to lower Pgp activity in canalicular membrane rather than
the CYP3A4 activity in the endoplasmic reticulum.59 Schuetz reported that Pgp in women
was almost half the levels of that in men.60 Moreover, another study in HLM found that
median CYP3A4 content was 2-fold higher in women than men with the
CYP3A5*3/*3 livers (P<0.05).61
Reports on the effect of NAFLD on NADPH-cytochrome P450 reductase (CPR)
are lacking. The expression of CPR reduced significantly with progression of disease from
NAFL to NASH. Multiple linear regression analysis with CYP3A activity as the dependent
variable revealed that CPR protein content does not account for additional variability when
CYP3A4 protein is present as a predictor variable. These results are in line with a previous
report which found that CYP3A variability was independent of CPR protein level.62
Oxidative stress has been found to be a critical factor associated independently with
NAFLD.63, 64 We found that livers from NAFLD donors had higher malondialdehyde levels
compared to normal donors suggesting increased oxidative stress (Table 1). Additionally,
liver samples from NALFD donors exhibited a significantly higher amount of cholesterol
as compared to normal donors (Table 1). Increased liver cholesterol leads to activation of
Kupffer and stellate cells in the liver, thereby promoting inflammation and fibrogenesis.65
Production of reactive oxygen species during NAFLD may lead to lipid peroxidation which
stimulates subsequent activation of stellate cells resulting in fibrogenesis 66, 67.
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Studies in the last decade have suggested a strong relationship between metabolic
diseases like NAFLD and microRNA expression in human liver.68, 69 These miRs can
regulate expression and mRNA stability function, in addition to the regulation of lipid
metabolism, inflammation, and apoptosis.70, 71 Significantly, upregulated miR-155 levels
in cirrhotic livers showed a strong negative correlation with CYP3A activity.72 Moreover,
miR-27b was found to suppress the translation of CYP3A4 protein without affecting the
mRNA levels of the enzyme.73 We speculate elevated miR species to be one of the factors
responsible for a contrast of mRNA and protein expression levels in NAFLD.
The information on any other underlying disease or drug use by donors at the time
of their death was not available. The data on prior drug usage, alcohol consumption, and
smoking can be challenging to interpret, and it is naïve to assume that such information
provided by the vendor is accurate.74 Contrary to this, data on age and gender can be
considered reliable. Therefore, we did not evaluate the effect of smoking and alcohol
consumption on the CYP3A activity and clearance of midazolam.
The performance of PBPK model in the normal population was used to estimate
the accuracy of predictions made in the normal population.47 Compared to normal
population, a 2.3 fold higher midazolam exposure was predicted by the model for NASH
population (supplemental table IV), which is consistent with 2.4-fold higher systemic
midazolam concentration reported in a clinical study with subjects with NASH.37 PBPK
model also suggested prolonged sedation in NAFLD patients with compromised liver
function. An average midazolam effective concentration (EC50) of 68.7 ng/mL (10.9165.0, 95% CI) for a Ramsay score between 3-5 was recently reported in a populationbased pharmacodynamic model in Caucasians.75 Considering this, PBPK simulation in
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NAFLD population showed that the midazolam concentration would remain over EC50 for
extended time compared to the normal population (Fig. 6). It was reported that subjects
with alcoholic cirrhosis had a significantly higher elimination half-life of midazolam
compared to healthy subjects.76 Indeed, Li et al. have reported that patients with the severe
liver disease were more sensitive to midazolam and achieved loss of consciousness at much
lower systemic concentration compared to subjects with normal hepatic function.77
Therefore, we can speculate that NAFL and NASH patients may also be more sensitive to
midazolam that non-NAFLD patients.
Further studies with different probes and population cohorts are warranted to
corroborate these findings and understand the underlying mechanism/s responsible for
perturbations in CYP3A4 expression. A well-planned in vivo trial would be an ideal study
to address the discrepancies in literature but has its limitations. For instance, obtaining a
biopsy sample from healthy individuals remains an ethical challenge for researchers. Given
these results are largely limited to Caucasian population, care should be taken for
interpolation of the results. Efforts are currently underway in our lab to study different
pathways involved in regulation of CYP3A4 expression at protein level.
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Table 1: Overview of Caucasian donor demographics
Normal

NAFL

NASH

n (Male, Female)

24 (13, 11)

26 (10, 16)

24 (11, 13)

Ethnicity# (n)

24, 0, 0

26, 0, 0

22, 1, 1

Age1 (years)

50.2±3.0

52.4± 2.1

53.1±2.1

Body-mass index1

31.4±3.0

33.9±2.5

32.5±1.6

11, 13

14, 12

11, 13

Liver weight1 (kg)

1.6±0.1

2.0±0.2

1.9±0.1

Body weight1 (kg)

88.7±7.2

97.1±6.6

94.0±4.7

Malondialdehyde 1

0.7±0.1

1.2±0.2**

1.5±0.2**

16.3±1.3

21.0±1.7*

22.6±1.9**

CYP3A5*3/*3 (n)

24

26

24

CYP3A4*22 (n)

23, 1

23, 3

23, 1

24, 0

26, 0

23, 1

C, AA, H

(kg/m2)
Diabetes mellitus
(no, yes)

(nmol/mg protein)
Cholesterol1
(µg/mg liver)

*1/*1, *1/*22
CYP3A4*1B (n)
*1/*1, *1/*1B

#

C-Caucasian, AA-Afro-American, H-Hispanic; 1All descriptive statistics values

represent mean ± SE. *P < 0.05, **P < 0.01 as compared to normal. P-values reported
from non-parametric Kruskal-Wallis test (2-sided) without adjustment for multiple
comparisons.
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Table 2: Effect of nonalcoholic fatty liver disease on midazolam hydroxylation
parameters

Vmax
(pmol/min/mg protein)
Km (µM)
CLint, whole liver
(L/min)

Normal

NAFL

NASH

553.8±134.9

281.2±80.9

176.2±40.4*

1.6±0.1

2.0±0.2

2.3±0.4

7.3±1.8

2.7±0.9*

1.8±0.6**

All descriptive statistics values represent mean±SE. *P < 0.05, **P < 0.01 as compared
to normal. P-values reported from non-parametric Kruskal-Wallis test (2-sided) without
adjustment for multiple comparisons.
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Table 3: Effect of nonalcoholic fatty liver disease on protein abundance

CYP3A4
(pmol/mg protein)
CPR
(pmol/mg protein)
Cyb5
(pmol/mg protein)

Normal

NAFL

NASH

131.8±20.4

68.0±18.0*

59.9±7.3*

51.1±2.3

39.3±2.4**

36.6±1.9**

654.5±41.2

506.5±26.3*

515.3±24.6*

All descriptive statistics values represent mean±SE. *P<0.05, **P < 0.01 as compared to
normal. P-values reported from nonparametric Kruskal-Wallis test (2-sided) without
adjustment for multiple comparisons.

Table 4: Effect of diabetes and NAFLD on CYP3A4 activity, protein and mRNA
expression, and relevant proteins and transcription factors

138

Table 4: Effect of diabetes and NAFLD on CYP3A4 activity, protein and mRNA
expression, and relevant proteins and transcription factors
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Figure legends
Figure 1. Histological staining of liver sections. (A, D) normal controls, (B, E) patients
with diabetes mellitus and hepatic steatosis, i.e. non-alcoholic fatty liver (NAFL), and (C,
F) patients with diabetes mellitus and non-alcoholic fatty liver disease with inflammation,
i.e. non-alcoholic steatohepatitis (NASH) were stained with (A-C) Hematoxylin and Eosin
or (D-F) Sirius Red. (A) Control livers exhibited uniform chord-like arrangements of
hepatocytes, (A-Inset) homogeneous cytoplasm, and (D and D-inset) minimal delicate
Sirius red staining of sinusoidal collagen. (B) In diabetes, NAFL was associated with (B,
B-inset) macrovesicular (large vacuoles filling cytoplasm) and microvesicular (clusters of
small cytoplasmic vacuoles) lipid droplets (clear circumscribed structures in cytoplasm)
and (E, E-inset) predominantly delicate but focally moderate Sirius red labeling of
sinusoidal and pericellular collagen. (C) In patients with diabetes and NASH, the livers
showed abundant (C, C-inset) macrovesicular and microvesicular lipid vacuoles in
hepatocytes, conspicuous lymphomononuclear inflammatory cell infiltrates among
hepatocytes, and (F) prominent Sirus red staining of bridging fibrosis and (F-inset) perihepatocyte collagen. (Original magnifications x625)
Figure 2. Effect of nonalcoholic fatty liver disease on CYP3A4 activity. (A) CYP3A4
activity, (B) CLint (whole liver). Column and error bars represent mean±SE. *P<0.05 as
compared to normal. P-values reported from nonparametric Kruskal-Wallis test (2-sided)
without adjustment for multiple comparisons.
Figure 3. Effect of nonalcoholic fatty liver disease on protein expression. (A) CYP3A4,
(B) cytochrome P450 reductase and (C) Cytochrome b5 protein. Column and error bars
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represent mean±SE. *P<0.05 as compared to normal. P-values reported from
nonparametric Kruskal-Wallis test (2-sided) without adjustment for multiple comparisons.
Figure 4. Effect of nonalcoholic fatty liver disease on relative mRNA expression. (A)
CYP3A4 mRNA, (B) CAR mRNA, (C) PXR mRNA and (D) HNF4α mRNA. Column and
error bars represent mean±SE. *P<0.05 as compared to normal. P-values reported from
nonparametric Kruskal-Wallis test (2-sided) without adjustment for multiple comparisons.
Messenger RNA data expressed relative to 18S rRNA
Figure 5. Effect of different grades of steatosis. (A) CYP3A4 activity, (B) CLint (whole
liver), (C) CYP3A4 protein. Column and error bars represent mean±SE. *P<0.05 as
compared to <5% liver fat. P-values reported from nonparametric Kruskal-Wallis test (2sided) without adjustment for multiple comparisons.
Figure 6. SimCYP predicted plasma concentration of midazolam in virtual Caucasian
population indicating a higher concentration and longer sedation time with respect to
disease state (A) in a virtual population of normal, NAFL or NASH patients irrespective
of diabetes status (B) without diabetes normal versus NAFL or NASH (C) with diabetes
normal versus NAFL or NASH.
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Supplemental table files
Supplemental table 1: Histological characteristics of the donors.
Supplemental table II: PCR primers used in the study.
Supplemental table III: Effect of gender on CYP3A4 activity, protein and mRNA
expression.
Supplemental table IV: Predicted pharmacokinetic parameters (Geometric mean, 95%
CI) after 5 mg intravenous dose in populations accounting for fatty liver.
Supplemental table V: Predicted pharmacokinetic parameters (Geometric mean, 95% CI)
after 5 mg intravenous dose in populations accounting for fatty liver and insulin resistance.

Supplemental figure files
Supplemental figure I. Scheme of the histological scoring system used for group
formation in the study.
Supplemental figure II. Correlation of CYP3A4 activity with (A) CYP3A4 mRNA and
(B) CYP3A4 protein. (C) Correlation between CYP3A4 mRNA and protein expression.
P<0.05 were considered significant. Correlation coefficient represents Spearman r.
Messenger RNA data expressed relative to 18S rRNA. Some parameters were log10
transformed for graphical representation.
Supplemental figure III. Effect of different grades of steatosis (A) NADPH cytochrome
P450 reductase protein, and (B) Cytochrome b5 protein. Column and error bars represent
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mean ± SE. *P<0.05 as compared to <5% liver fat. *P-values reported from nonparametric
Kruskal-Wallis test (2-sided) without adjustment for multiple comparisons.
Supplemental figure IV: Spearman correlation analysis of age with (A) CYP3A4 activity
(pmol/min/mg protein), (B) CLint (L/min), (C) CYP3A4 protein (pmol/mg protein) and
(D) CYP3A4 mRNA. P<0.05 was considered significant. Correlation coefficient
represents Spearman r. Messenger RNA data expressed relative to 18S rRNA. Closed
circles represent normal, open circles represent NAFL and triangles represent NASH
samples.
Supplemental figure V. Association of NADPH-cytochrome P450 reductase with (A)
CYP3A4 activity (pmol/min/mg protein) and (B) CYP3A4 protein (pmol/mg protein).
Correlation of cytochrome b5 with (C) CYP3A4 activity (pmol/min/mg protein) and (D)
CYP3A4 protein (pmol/mg protein). (E) Correlation between NADPH-cytochrome P450
reductase and cytochrome b5 proteins. P<0.05 was considered significant. Correlation
coefficient represents Spearman r. Messenger RNA data expressed relative to 18S rRNA.
Some parameters were log10 transformed for graphical representation.
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Supplemental tables
Supplemental table 1: Histological characteristics of donors
Histological score
Normal
NAFL
NASH
n=24
n=26
n=24
Steatosis
0
24
0
0
1
0
12
7
2
0
7
7
3
0
7
10
Hepatocyte
ballooning
0
23
19
0
1
1
6
18
2
0
1
6
Lobular
inflammation
0
9
9
0
1
12
13
18
2
3
4
6
Fibrosis
0
12
10
8
1
9
11
12
2
2
4
3
3
1
1
1
Diabetic
11
14
11
Non-diabetic
13
12
13
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Supplemental table III: Effect of gender on activity, protein and mRNA
expression
Gender
Female
Male
Sample size (n)

38

36

Vmax
(pmol/min/mg protein)
Km (µM)

303.95±84.21

368.95±74.42

1.96±0.18

1.96±0.25

Clint, whole liver
(L/min)
CYP3A4
(pmol/mg protein)
CPR
(pmol/mg protein)
Cyb5
(pmol/mg protein)
CYP3A4 mRNA1

3.03±0.96

4.79±1.17

73.71±13.54

100.66±14.71

40.60±2.01

44.15±2.12

505.66±19.32

618.40±33.41

5.41±1.88

6.03±1.62

CAR mRNA1

1.94±0.24

2.76±0.73

PXR mRNA1

1.98±0.25

1.87±0.24

HNF4α mRNA1

1.81±0.31

1.56±0.24

PPARα mRNA1

1.33±0.20

1.21±0.24

All descriptive statistics value represent mean±SE. *P<0.05 as compared to normal liver.
P-values reported from non-parametric Mann-Whitney U test (2-sided). 1Messenger RNA
data expressed relative to 18S rRNA
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Supplemental table IV: Predicted pharmacokinetic parameters (Geometric
mean, 95% CI) after 5 mg intravenous dose in virtual populations (n=250 in
each group) accounting for fatty liver.

Cmax (ng/mL)

AUC0-24 (ng/mL.h)

CL (L/h)

Normal

NAFL

NASH

114.8

114.8

114.8

(107.7-122.4)

(107.7-122.4)

(107.7-122.4)

301.3

533.5

680.7

(280.3-323.9)

(492.2-578.3)

(634.9-729.7)

16.6

9.4

8.6

(15.4-17.8)

(8.6-10.2)

(6.8-7.9)
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Supplemental figures

Supplemental figure I
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Supplemental figure II.

156

Supplemental figure III.

157

Supplemental figure IV.

158

Supplemental figure V.

159

MANUSCRIPT IV
This manuscript has been prepared as a research article for submission to the Journal of
Pharmacology and Experimental Therapeutics, ASPET Publications

Effect of non-alcoholic fatty liver disease (NAFLD) on the protein abundance and
activity of hepatic drug metabolizing enzymes in human

Rohitash Jamwal, Benjamin B Barlock, Fatemeh Akhlaghi*
Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode
Island, Kingston, RI,

Running title: NAFLD is associated with altered CYP activity and protein

Corresponding author at:
Fatemeh Akhlaghi, Ph.D.
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island,
495A College of Pharmacy, 7 Greenhouse Road, Kingston, RI 02881, United States.
Email address: fatemeh@uri.edu

160

The number of words in the abstract: 231
The number of words in the introduction: 782
The number of words in the discussion: 1517
The number of figures: 6
The number of tables: 3
The number of references: 62

Conflict of interest:
None of the authors have any conflict of interest to declare.

161

Abstract
Differential basal expression of drug disposition proteins (DDP) in the disease state can
contribute to significant changes in systemic exposure to xenobiotics. The changes in
abundance of drug-metabolizing enzymes (DME) is vital for accurate in vivo extrapolation
and prediction of hepatic clearance from in vitro data. To gain insight into the alterations
of phase-I and phase-II DDPs during non-alcoholic fatty liver disease (NAFLD), we
compared the protein abundance and activity in 106 human liver samples (control=42,
nonalcoholic fatty liver; NAFL=34 and nonalcoholic steatohepatitis; NASH=30). Insolution trypsin digestion of proteins in whole tissue lysate was carried out using pressurecycling technology. Data were acquired in data-dependent acquisition (DDA) mode on a
triple-time of flight (TOF) mass spectrometer, and absolute protein levels were determined
using total protein approach. Functional activity data from the tissue vendor were used to
evaluate the effect of disease on activity and further correlated with protein abundance.
CYP1A2 and CYP3A4/5 protein abundance and activity were downregulated in the
NAFLD whereas minor changes were observed for other CYPs. UGT and SULTregulation were mostly similar between the different groups except for SULT1A1 and
SULT1A2. Mitochondrial proteins (ACADSB, ACSM3/5) involved in lipid metabolism
were also dysregulated in NAFLD. Levels of CPS1 were significantly lower in the disease
state. Here, we provide a quantitative protein abundance data which would allow
development of PBPK models for prediction of drug disposition in the NAFLD population.
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Introduction
Human liver, facilitated by several drug metabolizing enzymes (DMEs) and
transporters, is the primary organ responsible for the elimination of xenobiotics and
endogenous compounds. Nonalcoholic fatty liver disease (NAFLD), a chronic liver
condition is defined as the presence of >5% of macrovascular steatosis in individuals
without high alcohol intake (<20 g per day for women, <30 g per day for men) and ranges
from the benign fatty liver to severe nonalcoholic steatosis (NASH) (Vuppalanchi and
Chalasani, 2009). A recent meta-analytic report estimated higher prevalence in the Middle
East and South America with a global NAFLD prevalence of 25.24% (95%CI 22.1-28.7)
(Younossi et al., 2016b). The prevalence of NAFLD in the United States was found to be
30% with 10.3% of patients with advanced fibrosis (Le et al., 2017). In the USA, NAFLD
is also associated with significant economic (~$103 billion) and clinical burden (~64
million people projected to have NAFLD) (Younossi et al., 2016a). NAFLD is commonly
associated with hepatic fat accumulation, lipotoxicity, insulin resistance, obesity and
cardiovascular diseases (Brunt and Tiniakos, 2010). The disease is characterized by the
presence of significant hepatic steatosis in patients without the considerable intake of
alcohol (Chalasani et al., 2012)., NAFLD is associated with the histopathological features
including steatosis, hepatocyte ballooning and lobular inflammation (Younossi and Henry,
2016). Recent studies have shown significant dysregulation of hepatic DMEs in S9
fractions from cirrhotic liver samples (Prasad et al., 2017). NAFLD was associated with
substantial downregulation of CYP3A4 protein and activity in liver from CYP3A5*3/*3
expressers (Jamwal et al., 2018). However, the information on the expression of other
DMEs in NAFLD is limited, and wherever available, lacks consensus (Cobbina and
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Akhlaghi, 2017). The current literature suggests alteration in hepatic cytochrome P450
(CYP) expression, activity or both, however, the directionality of change lacks agreement
(Niemela et al., 2000; Kolwankar et al., 2007; Fisher et al., 2009; Woolsey et al., 2015).
One potential explanation for such a wide discrepancy in literature can be attributed to the
interindividual variability, and sample size used to derive the inferences. Misuse of
classification systems and incorrect characterization of study samples may have also lead
to different conclusions (Brunt et al., 2011).
The last decade has seen a rise in the use of mass spectrometry (MS) based
techniques for quantification of the protein expression (Prasad and Unadkat, 2014; Fallon
et al., 2016). Despite being the gold standard, targeted methods of protein quantification
are costly and need significant time for optimization of mass spectrometer conditions.
Label-free quantification (LFQ) has emerged recently as an alternative approach for
comparative analysis of protein expression across different samples (Wong and Cagney,
2010). Accurate and robust quantification with LFQ approaches is complex, and different
strategies for extracting quantitative data has been developed (Wong and Cagney, 2010).
A comprehensive cost comparison of different mass spectrometry-based techniques
reported significant cost savings with label-free based quantitative proteomics (Al Feteisi
et al., 2015).
Disease conditions have been known to impact the abundance of drug disposition
proteins (DDPs) in the liver, hence leading to altered drug profiles and often to side-effects
(Gandhi et al., 2012; Dietrich et al., 2017; Evers et al., 2018). However, it is not always
practical to measure the impact of hepatic impairment on clinical outcomes in special
population. Physiologically based pharmacokinetic (PBPK) models for prediction of
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pharmacokinetic and drug metabolism in populations are gaining popularity for
populations which represent clinical challenges (Sager et al., 2015; Jamei, 2016). The
patients with metabolic syndrome are often on multiple medications and alterations in
expression of DMEs carries a potential of significant drug-drug interactions (DDI). PBPK
models can be used in such cases to predict DDI once representative clinical parameters
are available (Marsousi et al., 2017). Along with physicochemical properties of a drug,
physiological information is vital for accurate prediction of drug exposure. Quantification
of DDPs is therefore important for development of simulation models. Due to the lack of
clinical studies in NAFLD patients, PBPK models should be qualified for the normal
population before using them for prediction in special population groups (Shebley et al.,
2018). Availability of clinical study data in the future would help to validate these models.
Traditionally, the expression and activity of DMEs have been measured in a human
liver microsomal fraction. However, the quantification of DMEs in subcellular fractions
usually suffers from batch-to-batch variability in recovery and enrichment of proteins (Xu
et al., 2018). Therefore, we developed a simple whole tissue lysate method for
simultaneous quantification of hepatic drug metabolism enzymes in human liver using LCMS/MS. The method was applied to study the effect of NAFLD on the expression of
clinically important drug disposition proteins (phase-I and phase-II proteins). The effect of
disease on the functional activity of 8 CYP enzymes was also studied.
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Materials and Methods
Chemicals and Reagents
Protein preparation kit, TPCK-treated trypsin, trypsin digested β-galactosidase, and
mass spectrometer tuning solution was from AB Sciex, Framingham, MA. Aquity UPLC
Peptide BEH C18 analytical column and VanGuard pre-columns were procured from
Waters Corp. (Waltham, MA). Calbiochem ProteoExtract Native Membrane Protein
Extraction Kit was purchased from EMD Millipore (Billerica, MA). 1,4-Dithiothreitol
(DTT) was obtained from Roche Diagnostics (Indianapolis, IN). Sodium deoxycholate and
iodoacetamide (IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade
acetonitrile and formic acid were purchased from ThermoFisher, Waltham, MA. Aquity
UPLC Peptide BEH C18 analytical column and VanGuard pre-columns were procured
from Waters Corp., Waltham, MA.
Human liver and homogenate preparation
Frozen human liver samples from brain dead donors were purchased from Sekisui
XenoTech LLC, Kansas City, KS. The detailed demographics of the donors are given in
table 1. Livers were graded by a histopathologist as previously described and were
categorized as control, NAFL (steatosis) or NASH (Jamwal et al., 2018). Samples were
randomly ordered, and the liver homogenate was prepared in homogenization buffer (8 M
urea, 50 mM Triethylammonium bicarbonate, 10 mM DTT’, v/v). Briefly, liver tissue (~50
mg) was weighed and homogenized in 1000 µl of HB. Tissue was homogenized on an
Omni bead homogenizer as described previously (Jamwal et al., 2017). Further, samples
were spun at 1,000 g for 5 min, and the supernatant was collected. The total protein
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concentration of the resulting sample was determined using Pierce BCA protein assay kit
(ThermoFisher Scientific, Waltham, MA). Lipid peroxidation and total cholesterol were
measured as described previously (Jamwal et al., 2017).
Pressure-cycling technology (PCT) aided trypsin digestion
Protein digestion was conducted as described previously, with few adaptations
(Prasad et al., 2014; Jamwal et al., 2017). Protein samples (250 µg protein) were spiked
with 2 µg BSA and denatured with 25 µL DTT (100 mM) at 35°C for 30 min in a shaking
water bath (100 rpm). After denaturation, samples were alkylated in the dark with 25 µL
IAA (200 mM) for 30 min at room temperature. Samples were subsequently concentrated
using the cold water, methanol and chloroform (1:2:1) precipitation method (centrifugation
at 10000 rpm, 5min at 10°C). The protein pellet was washed with ice-cold methanol and
then suspended in 100 µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v
sodium deoxycholate (DOC). Further, TPCK-treated trypsin (10 µg) was added to samples
at a ratio of 1:25 (trypsin: protein) and samples were transferred into digestion tubes (PCT
MicroTubes, Pressure Biosciences Inc., Easton, MA). The barocycler was run at 35°C, for
75 cycles with 60 sec per pressure-cycle (50-sec high pressure, 10-sec ambient pressure,
25 kpsi). Subsequently, 10 µg trypsin was again added to each sample and barocycler based
digestion was repeated at the specifications mentioned above.
Further, to 110 µL of digested peptides sample, 10 µL of ACN/water (1:1, v/v containing
5% formic acid) was added to precipitate detergent (snow white pellet). Samples were spun
to remove the pellet and 100 µL supernatant was collected (10,000 rpm for 5 min at 10°C).
The collected supernatant was spiked with 5 µl trypsin-digested β-galactosidase peptides
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(∼15 pmol). Samples were spun (10,000 rpm for 5 min at 10°C) again to remove pellet if
any. Subsequently, twenty-five microliters of the resulting peptide solution was injected
on the analytical column and samples were analyzed using LC-MS/MS method described
below.
LC-MS/MS Analysis
Data-dependent analysis (DDA) was performed in positive ionization mode using
a DuoSpray™ ion source on a Sciex 5600 TripleTOF™ mass spectrometer (AB Sciex,
Concord, Canada) equipped with an Acquity UPLC HClass system (Waters Corp.,
Milford, MA, USA). Gas 1 (GS1), gas 2 (GS2) and curtain gas (CUR) were maintained
at 55, 60 and 25 psi, respectively. Ion spray voltage floating (ISVF) was kept at 5500 V
while the source temperature (TEM) was 500°C. Declustering potential (DP), collision
energy (CE) and collision energy spread (CES) were set at 120, 10 and 5 respectively.
During the survey scan, all the ions with a charge state of 2 to 4, mass range of m/z 3001250 and exceeding 25 cps were used for MS/MS analysis. Former target ions were
excluded for 8 sec and the mass tolerance for TOF-MS was 50 mDa with a 100 milliseconds
accumulation time. For product scan, data was acquired from 100 to 1250 m/z with an
accumulation time of 75 millisecond with a total cycle time of 3.5 sec. Product ion analysis
was done under dynamic accumulation and rolling collision energy dependent on the m/z
of the ion.
Chromatographic separation was achieved over 180 min gradient method at 100
μL/min on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) preceded
by an Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). Mobile phase A
was 98% water, 2% acetonitrile, 0.1% formic acid and mobile phase B was 98%
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acetonitrile, 2% water, 0.1% formic acid). Gradient conditions used were 98% A from
0 to 5 min, 98% to 70% A from 5 to 155 min, 70% to 50% A from 155 to 160 min, 50%
to 5% A from 160 to 170 min, 5% to 98% A held from 170 to 175 min. The gradient
was held at initial conditions from 175 min until the end of the run to equilibrate the
column before the start of next run. The flow was diverted to waste for the first 8 minutes
and last 20 minutes of the acquisition. Autosampler was maintained at 10°C, and the
column was kept at 50°C. Trypsin-digested β-galactosidase peptides were injected to
monitor TOF detector mass calibration every four sample.
Data processing
The absolute level of proteins was determined from DDA data using “Total Protein
Approach”(Wisniewski and Rakus, 2014). Homogenate samples were analyzed as
previously described using MaxQuant (ver 1.5.2.10) (Wisniewski and Rakus, 2014;
Jamwal et al., 2017). The proteins were searched on Andromeda search engine against the
Swiss-Prot human protein database (updated Apr 2018) at 1% false discovery rate
(FDR)(Cox and Mann, 2008). Cysteine carbamidomethylation was selected as fixed
modifications for the search. Oxidation (M) and acetyl (protein N-term) were used as a
variable modification in protein quantification. Label-free quantification (LFQ) was
performed with a ratio count of 1, and a maximum of two missed cleavages was allowed.
Unique peptides were selected for protein quantification while all the other MaxQuant
settings were kept as default values. The absolute protein levels were calculated using
“Total Protein Approach” from raw intensities obtained from MaxQuant (Wisniewski and
Rakus, 2014). The protein concentrations were expressed as picomoles of protein per gram
liver tissue (pmol/g liver).
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Total protein (p) =

Protein conc. (p) =

MS signal (p)
Total MS signal

MS signal (p) × 106
[pmol/mg homogenate protein]
Total MS signal × MW(p)

Normalized Protein conc. (p) = Protein conc (p) × PPGL × NF [pmol/g liver]

where MS signal (p) refers to total LFQ signal intensity for a protein of interest. Total MS
signal indicates to the total LFQ intensity of all the proteins in the sample and MW
represents the molecular weight of respective protein. PPGL denotes the yield of
milligrams of total protein per gram of liver tissue.

Statistical analysis
Q-Q plot was used to determine the normality of the protein samples. After
determining that the protein samples violated the assumption of normal distribution, nonparametric tests were used for all the analyses. Non-parametric Mann-Whitney U test was
used to compare the differences for two groups and Kruskal-Wallis for comparison of three
or more groups. The vendor provided functional activity was used for correlation analysis
with protein concentration. The details of the assay’s conditions are described elsewhere
(Jamwal et al., 2017). Spearman-correlation analysis was performed between the
functional activity and protein levels. Correlation was expressed as strong (r>0.7),
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moderate (r=0.5-0.7) or weak (r=0.3-0.5). P < 0.05 was considered significant throughout
the analysis. Data are reported as geometric mean and 95% confidence interval unless
stated otherwise. Prism 6 (GraphPad Inc., La Jolla, CA) and SPSS 23 (IBM Corp., Armonk,
NY) were used for graphing and statistical testing, respectively.
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Results
NAFL and NASH liver samples exhibited significantly elevated levels of malondialdehyde
and cholesterol (Table 1). The livers from NAFL and NASH donors were larger in weight
than the control group. The total protein yield from samples with NAFLD was marginally
lower as compared to the control. Donors with NAFLD also showed a trend of increased
body weight and body mass index. The geometric mean of ????? for the control group was
marginally lower than the NAFLD groups. The yield of protein per gram liver (mg/g) was
slightly lower from NAFL and NASH groups as compared to control.
Effect of NAFLD on the expression and activity
The protein expression of CYP1A2 was significantly lower in NAFLD samples
(p<0.05). There was a discernible decrease in CYP3A4 and CYP3A5 levels in NAFL and
NASH livers but the effect was not significant due to high interindividual variability (figure
1). We observed no change in the protein levels of CYP2E1, CYP2D6, CYP2C8, and
CYP2C9 among different study groups (table 2). A trend of lower expression was observed
for CYP2B6; however, the reduction was not significantly different from control samples.
Cytochrome b5 was downregulated considerably as the severity of disease increased. There
was no change observed for the amount of CPR between the different groups. The protein
levels of CYP8B1, CYP27A1, and CYP51A1 were also similar among three study groups.
Similar to protein abundance, CYP1A2 phenacetin O-dealkylation activity was
significantly lower in NAFL and NASH (figure 2). CYP3A4 mediated testosterone
hydroxylation was moderately decreased in NAFLD group. The activity of other CYP450
enzymes remained mostly similar between control and disease state.
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Furthermore, we did not see any significant differences in the protein expression of any of
the UGTs included in the study (table 3, figure 3). Interestingly, SULT1A1 and SULT2A1
expression were lower in NAFL, but levels were similar for NASH and control livers (table
3). No significant alteration in SULT1C1 and SULT1A2 levels was observed (figure 4).
A comprehensive list of other hepatic proteins studied, and the effect of NAFLD is given
in supplementary table 1.
Correlation of CYP450 enzyme activity and protein expression
Non-parametric Spearman correlation analysis was performed between the
determined protein levels and vendor provided enzyme activity (figure 5). A significant
correlation with varying strength was observed for all the 9 CYP450 enzymes. CYP1A2,
2A6, 2B6, 3A4 exhibited strong correlation (r>0.7) while it was moderate (r=0.5-0.7) for
CYP2C8, 2D6 and 3A5. Interestingly, the association between CYP2C9 protein and
activity was weakest (r=0.48) among all the proteins.
Biomarker proteins in NAFLD
Carbamoyl-phosphate synthase (CPS1), acyl-CoA dehydrogenase short/branched
chain (ACADSB) and acyl-CoA synthetase medium-chain family member 5 (ACSM5)
were significantly downregulated in NAFLD (table 3). In contrast, acyl-CoA synthetase
medium-chain family member 3 (ACSM3) levels were significantly lower in NAFL but
not NASH. The protein expression of fatty acid synthase (FASN) was unchanged in NAFL
but was elevated in NASH (Fig 6). Hepatic glyoxalase 1 (GLO1) levels were moderately
lower in NAFLD but the difference was statistically not significant.
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Discussion
Variable effects were observed on the expression of most proteins suggesting involvement
of complex transcriptional, translational, epigenetic and/or polymorphic regulatory events.
Oxidative stress and lipid peroxidation play a significant role in the pathogenesis of
NAFLD (Masarone et al., 2018). Studies in human have found elevated levels of
malondialdehyde (MDA) and other markers of oxidative stress in NAFLD (Kumar et al.,
2013). Higher cholesterol is also a significant risk factor for development and progression
of the disease (Ioannou, 2016). The protein expression of CYP8B1 and CYP27A1 (bile
acid synthesis) and CYP51A1 (cholesterol synthesis) was similar among three groups
suggesting other mechanisms (uptake or efflux) for cholesterol accumulation may be at
play in NAFLD. Suppressed cholesterol efflux capacity has been reported in NAFLD
patients (Fadaei et al., 2018). No downregulation of CYP51A1 and CYP8B1 in NASH
biopsy samples was reported in the Japanese population (Kakehashi et al., 2017). CYP4F2
level initially increased during acute lipid insult (hepatoprotective mechanism) but was
found to be downregulated during chronic stimulation (hepatotoxicity) (Bartolini et al.,
2017).
Studies in human liver microsomes have shown downregulation of CYP3A activity
with the progression of disease and severity of steatosis (Kolwankar et al., 2007; Fisher et
al., 2009). The plasma midazolam concentration in NASH patients was 2.4-fold higher
than the control subjects (Woolsey et al., 2015). A recent study from our group found
almost a 2-fold decrease of CYP3A4 protein expression and activity in liver microsomes
from NAFLD donors (Jamwal et al., 2018). Studies in microsomal fractions from diabetic
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livers found significant downregulation of CYP3A4 protein and activity but not mRNA
(Dostalek et al., 2011).
Downregulation of CYP1A2 protein and activity has been reported in human liver
microsomes and hepatocytes from fatty liver grafts (Donato et al., 2006; Fisher et al.,
2009). Dysregulated cytokine and the chemokine-mediated inflammatory response is
typical in NAFLD and plays a pivotal role in its pathophysiology (Braunersreuther et al.,
2012). Elevated proinflammatory cytokines in NAFLD have been reported, and this may
partially explain the downregulation of CYP1A2 and CYP3A4 activity and protein
observed in our study (Liptrott et al., 2009). In contrast to other reports of significant upregulation of CYP2A6 in NAFLD, we found a marginal decrease in the protein expression
of the enzyme (Wang et al., 2018). The coumarin hydroxylation activity of the enzyme was
similar between control and NAFLD livers. Donato et al. found significant downregulation
of CYP2A6 mRNA and activity in a hepatocyte model of cellular steatosis (Donato et al.,
2006).
CYP2E1 mediated biotransformation reactions in liver generate a significant
amount of reactive oxygen species which further promote the oxidative stress in NAFLD
(Aubert et al., 2011). In contrast to reports of elevated CYP2E1 in NAFL and NASH, we
found that the protein expression and functional activity was similar among the three
groups (Leung and Nieto, 2013). CYP2E1 mRNA and protein expression were found to be
lower in another study in livers from NAFLD patients whereas activity was unaltered
(Fisher et al., 2009). Fatty acid treatment in cultured HepG2 cells did not induce CYP2E1
expression (Aljomah et al., 2015). CHZ test (6-hydroxychlorzoxazone/chlorzoxazone
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ratio) in patients with NAFLD was unable to distinguish NASH from NAFL (Chtioui et
al., 2007).
CYP2C8 protein expression was downregulated in NASH-associated liver biopsy
while CYP2C9 levels were unchanged compared to control (Kakehashi et al., 2017). Other
studies in human tissue also observed no changes in the expression of either isoforms
(Chtioui et al., 2007). CYP2C8 activity was similar in different stages of NAFLD and
control livers whereas CYP2C9 activity was reported to be higher (Fisher et al., 2009). A
recent study in 3-dimensional hepatocyte culture model of NAFLD, CYP3A4 activity was
found to be upregulated while CYP2C9 decreased (Kostrzewski et al., 2017). We could
not determine the levels of CYP2C19 in our study and is one of the limitations of the
homogenate-based method in which low abundance proteins are not measured due to a
limited dynamic range of quantification.
CYP2B6 is one of most polymorphic enzymes which accounts for significant
variability in its expression and activity (Zanger and Klein, 2013). Fisher et al. observed
elevated CYP2B6 mRNA without any change in protein and activity during the progression
of NAFLD (Fisher et al., 2009). Similar to CYP2B6, CYP2D6 is another highly
polymorphic enzyme responsible with varying phenotypes and degree of metabolism of its
substrates (Zhou, 2009). Current literature reports no significant alterations in CYP2D6
expression and activity in human liver (Fisher et al., 2009). A revisit to protein and activity
data with information of polymorphism may help to ascertain the changes associated with
these enzymes in NAFLD.
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UDP glucuronosyltransferases (UGTs) are involved in phase-II metabolism
(glucuronidation) of 40–70% of all clinical drugs in human and also detoxify endogenous
compounds (Jancova et al., 2010; Rowland et al., 2013). While the effect of NAFL on
CYP450 enzymes has been extensively studied, only limited information on the regulation
of UGTs is available in human (Hardwick et al., 2013). Hardwick and colleagues identified
significant alterations in mRNA of different UGT isoforms, but the acetaminophen
glucuronidation activity was unchanged (Hardwick et al., 2013). UGT2B17 and UGT2B7
were identified to have similar protein levels between control and NASH biopsy samples
(Kakehashi et al., 2017) . Yalcin et al. also found that SULT1A1 protein expression and
activity were significantly decreased in steatosis (Yalcin et al., 2013). Other have reported
downregulation of human SULT1A2 in NAFLD (Younossi et al., 2005; Stepanova et al.,
2010). In contrast, the elevated SULT1A1 protein was observed in steatosis, but it was
found to be downregulated in NASH (Hardwick et al., 2013). Similar to reports for
CYP450 enzymes, regulation of UGT and SULT is as heterogeneous; however, there is a
scarcity of data for the later.
Mitochondrial distress and oxidative stress are common in NASH (Simoes et al.,
2018). Studies have reported reduced anti-oxidant defense capacity in NASH (Koliaki et
al., 2015).

Significant suppression of numerous mitochondria associated proteins was

observed in NAFLD samples. Differential expression of FASN has been reported in
literature with common consensus on the increase in the levels of enzyme with the
progression of steatosis (Dorn et al., 2010). Acyl-CoA dehydrogenase short/branched chain
(ACADSB) is a mitochondrial enzyme involved in the metabolism of fatty acid and
branched chain amino acids in mitochondria. Gene expression of ACADSB was almost 2177

fold lower in patients with NASH versus obese controls (Younossi et al., 2005).
Concurrently, a decrease in the mitochondrial enzymes (ACSM3, ACSM5) involved in
fatty acid oxidation was observed.
GLO1 is involved in metabolism of reactive glyoxyal and methylglyoxal
metabolites thereby preventing glycation of proteins. Decreased levels of GLO1 were
recently identified in pediatric NAFLD biopsy samples (Spanos et al., 2018). A decrease
in GLO1 (as observed in our study) may be responsible for elevated levels of
methylglyoxal-derived advanced glycation end product observed in serum of NAFLD
patients (Spanos et al., 2018). Downregulation of CPS1 and dysregulation of the urea cycle
in NAFLD has been described in literature (De Chiara et al., 2018). Accumulation of urea
leads to scar tissue development, one of the complications of NAFLD. The gradual
decrease from control to NAFL and NASH samples in CPS1 expression was reported
previously (Rodriguez-Suarez et al., 2010).
The sampling of human liver tissue is critical in the identification of the
perturbations in the expression of DDPs. We speculate that the differences in the sampling
may have presented some of the observed results in our study. Histopathological
differences were found in liver biopsies from the right and left lobes of bariatric patients
(Merriman et al., 2006). Given these results are primarily limited to Caucasian population,
care should be taken for extrapolation of the results. The availability of human liver tissue
for studying the hepatic xenobiotic transporters remains a challenge for researchers due to
ethical consideration and the availability of tissue with adequate clinical information. Our
knowledge of the drugs which the donors were taking at the time of death is limited only
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to the information passed on by the vendor. Furthermore, there was no data available on
the duration of hospitalization of donors before the organs were harvested.
NAFLD is often accompanied by other comorbidities (obesity, diabetes) which
may confound the observations and could partially explain the wide discrepancy in the
literature. While we accounted for the NAFLD with and without diabetes, small sample
size deterred us from conducting statistical analysis of any sort (supplementary table 2-6).
Therefore, the results and discussion of this work are mainly restricted to the effect of
NAFLD on the expression of DMEs without any focus on underlying comorbidities.
To summarize, our research suggests that most drug metabolizing enzymes apart
from CYP1A2 and CYP3A appears to be largely unaffected by NAFL and NASH. A lack
of adverse clinical reports also indicates that most drugs appear to be well-tolerated by
these patients despite the changes in the expression of drug metabolism enzymes. An
understanding of metabolism, as well as transport protein, may provide a better picture of
the clinical manifestations of the perturbed proteins in NAFLD. Multiple factors in NAFLD
may affect the expression and activity of DDPs, and comprehensive study needs to be
conducted to answer some of the questions around the discrepancies observed in the
literature.
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Figure 1: Effect of NAFLD on protein expression of various CYP450 proteins.
Figure 2: Effect of NAFLD on functional activity of various CYP450 proteins.
Figure 3: Effect of NAFLD on protein expression of UGT proteins.
Figure 4: Effect of NAFLD on protein expression of SULT proteins.
Figure 5: Correlation of protein expression and activity of CYP enzymes.
Figure 6: Effect of NAFLD on protein expression of some marker proteins in NAFLD.

Table 1: Demographic characteristics of study groups.
Table 2: Effect of NAFLD on the expression of major CYP450 enzymes and auxiliary
proteins.
Table 3: Effect of NAFLD on the expression of major UGT enzymes.
Table 4: Effect of NAFLD on the expression of NAFLD specific marker proteins.
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Figure 1: Effect of NAFLD on protein expression of various CYP450 proteins. Graphs
represent Tukey box plots with median (horizontal line); + represent mean; P-value from
non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent
p-value <0.05 and <0.01, respectively.
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Figure 2: Effect of NAFLD on functional activity of various CYP450 proteins. Graphs
represent Tukey box plots with median (horizontal line); + represent mean; P-value from
non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent
p-value <0.05 and <0.01, respectively.
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Figure 3: Correlation of protein expression and functional activity of CYP enzymes.
Non-parametric Spearman correlation analysis.
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Figure 4: Effect of NAFLD on protein expression of UGT proteins. Graphs represent
Tukey box plots with median (horizontal line); + represent mean; P-value from nonparametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent pvalue <0.05 and <0.01, respectively.
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Figure 5: Effect of NAFLD on protein expression of SULT proteins. Graphs represent
Tukey box plots with median (horizontal line); + represent mean; P-value from nonparametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent pvalue <0.05 and <0.01, respectively.
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Figure 6: Effect of NAFLD on protein expression of some marker proteins in NAFLD.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; P-value
from non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and **
represent p-value <0.05 and <0.01, respectively.
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Table 1: Demographic characteristics of control, NAFL and NASH groups. BMI:

Body-mass index; PPGL: Protein per gram liver. P-value from non-parametric Kruskal-

Wallis and Dunn’s multiple comparison test. * and ** represent p-value <0.05 and <0.01,

respectively.
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Malondialdehyde
(nmol/mg
protein)
Cholesterol
(µg/g liver)
PPGL (mg/g)
Non-diabetic
Diabetic

N
Age (y)
Female
Male
Caucasian
Afro-American
Hispanic
Body weight
(kg)
BMI (kg/m2)
Liver weight (g)

1.2 (1 - 1.6) **

20.8 (17.9 - 24.1) **

18.7 (16 - 21.9) **
78.9 (71.8 - 86.8)
19
15

14.2 (12.4 - 16.2)
83.1 (77.4 - 89.3)
21
21

79.8 (72.1 - 88.3)
13
17

32.2 (29.9 - 34.7)
1839 (1678.4 - 2014.9) **

31.2 (28 - 34.8)
1798.5 (1603.2 2017.6) *
0.9 (0.8 - 1.2) **

29.3 (26.5 - 32.3)
1482.4 (1374.9 1598.3)
0.6 (0.5 - 0.7)

NASH
30
50.8 (47.3 - 54.5)
15
15
28
1
1
92.7 (86 - 99.9)

NAFL
34
52.8 (49.5 - 56.4)
19
15
20
1
3
89.8 (80.6 - 100.1)

Control
42
46.5 (41.9 - 51.6)
16
26
33
8
1
83.5 (76.2 - 91.5)

Table 2: Effect of NAFLD on the expression of major CYP450 enzymes and
auxiliary proteins. P-value from non-parametric Kruskal-Wallis test and Dunn’s
multiple comparison test. * and ** represent p-value <0.05 and <0.01, respectively.
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Table 3: Effect of NAFLD on the expression of major UGT enzymes. P-value from

non-parametric Kruskal-Wallis test with Dunn's multiple comparisons. * and ** represent

p-value <0.05 and <0.01, respectively.
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387.8 (324.9 - 462.8)
79.2 (67.4 - 93.2)

141.1 (111.5 - 178.8)
308.9 (260.3 - 366.6)

123 (105 - 144.1)
4000.4 (3026 - 5288.6)

465.8 (390.5 - 555.6)
395.2 (340.4 - 458.9)
86.5 (74.1 - 101)
109 (93.6 - 127.1)
78.9 (62.6 - 99.5)
124.2 (93.8 - 164.4)
271.6 (229.8 - 320.9)
801.6 (698.9 - 919.4)
1543.2 (1300.2 - 1831.6)
396.3 (308.6 - 509) *
207.3 (176.5 - 243.4)
119 (99.5 - 142.4)
3654.7 (2720.7 - 4909.3) *

556.5 (491.7 - 629.8)
355.6 (316.7 - 399.3)
76 (65.9 - 87.5)
110 (93.5 - 129.3)
63.2 (52.6 - 76)
132.6 (104.9 - 167.7)
292 (255.7 - 333.5)
901.3 (794.5 - 1022.4)
1682.6 (1465 - 1932.5)
609.5 (489.6 - 758.9)
260.2 (231 - 293)
127 (111.9 - 144.2)
5015.1 (4137.2 - 6079.2)

UGT1A4
UGT1A6
UGT1A7
UGT1A9
UGT2A3
UGT2B10
UGT2B15
UGT2B4
UGT2B7
SULT1A1
SULT1A2
SULT1B1
SULT2A1

223.6 (187.1 - 267.1)

501.7 (369.8 - 680.7)

1771.5 (1480.4 - 2119.8)

831.9 (704.8 - 981.8)

82.8 (68.4 - 100.2)

89.8 (74.1 - 108.8)

429.9 (350.2 - 527.8)

271.2 (221.6 - 331.7)

283.3 (233.6 - 343.6)

295.1 (249.3 - 349.3)

UGT1A1

NASH

NAFL

Control

Table 4: Effect of NAFLD on the expression of NAFLD specific marker proteins. P-

value from non-parametric Kruskal-Wallis test without adjustment for multiple

comparisons. * and ** represent p-value <0.05 and <0.01, respectively.
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81.3 (62.9 - 105.1)
83.7 (63.3 - 110.8) **

72.7 (59.8 - 88.3) *
76.7 (57.1 - 103) **

105.8 (89 - 125.9)
142 (117 - 172.4)

ACSM3
ACSM5

1538.5 (1249.7 - 1894.1)
29682.5 (25883.7 - 34038.9) *

816.8 (670.2 - 995.6)
1243.3 (1033.3 - 1496)
28656.6 (25251.2 - 32521.1) *

981.4 (819.3 - 1175.6)
1238.1 (1081.7 - 1417.1)
35368.4 (31705.4 - 39454.6)

FASN
CPS1

894 (745.4 - 1072.3)

3119.4 (2646.1 - 3677.3) **

2835.3 (2477 - 3245.4) **

4330.2 (3917.2 - 4786.8)

ACADSB

GLO1

NASH

NAFL

Control
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Supplementary Table 3: Effect of NAFLD and diabetes on the expression of CYP450
proteins.
Supplementary Table 4: Effect of NAFLD and diabetes on protein expression of phase-II
proteins.
Supplementary Table 5: Effect of NAFLD and diabetes on protein expression of some
marker proteins.
Supplementary Table 6 a,b: Effect of NAFLD and diabetes on protein expression of
cytosolic and hepatic enzymes.
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16
4
1
89.1 (76.6 - 103.6)

9
12
17
4
0
78.5 (70.8 87.1)

Female
Male
Caucasian
Afro-American
Hispanic

PPGL (mg/g)

0.7 (0.6 - 0.8)
14.1 (11.6 - 17)
76 (68.2 - 84.6)

0.5 (0.4 - 0.6)
14.3 (11.8 17.3)
90.9 (84.1 98.3)

1601 (1438.5 - 1781.9)

1372.5 (1245.1
- 1513)

Liver weight (g)

Malondialdehyde
(nmol/mg
protein)
Cholesterol
(µg/g liver)

31.2 (26.4 - 36.7)

27.5 (24.7 30.7)

BMI (kg/m2)

Body weight (kg)

46.6 (40.9 - 53.2)

46.4 (39.3 54.8)

Age (y)
7
14

21

21

Diabetic

N

Non-diabetic

Control

82.6 (73.4 - 93.1)

20.1 (15.4 - 26.3)

0.9 (0.7 - 1.1)

1682.1 (1470.1 1924.7)

28.6 (25.4 - 32.3)

85.7 (74.5 - 98.6)

2

16
1

9

10

51.9 (47.3 - 56.8)

19

Non-diabetic

NAFL

74.5 (64 - 86.7)

17.8 (14.6 - 21.7)

83.1 (72 - 96)

22 (17.6 - 27.5)

1.2 (0.8 - 1.9) **

1745 (1530 1990.3)

1957.6 (1612.9 2376) **

1 (0.7 - 1.4) **

29.3 (27 - 31.8)

86.6 (78.8 - 95.1)

13
0
0

9
7

50.2 (43.9 - 57.3)

16

Non-diabetic

34.7 (28.9 - 41.7)

95.3 (80.4 - 113)

14
0
1

9
6

54.1 (49.3 - 59.3)

15

Diabetic

17

Diabetic

77.3 (67 - 89.2)

20.1 (16.5 - 24.5)

1.2 (0.9 - 1.6) **

1914.2 (1687.6 2171.3) **

34.6 (31.1 - 38.4)

97.6 (87.7 - 108.7)

15
1
1

9
8

51.2 (47.5 - 55.2)

NASH
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249.8 (133.3 - 468.4)

220.7 (110.3 - 441.7)
869 (626.2 - 1205.9)
1008 (799.9 - 1270.3)
409.5 (308.6 - 543.5)
2023.4 (1601.8 - 2556)
445.2 (257.7 - 769.2)
162.5 (88.2 - 299.4)

300 (151.3 - 594.7)

1153.7 (834.3 - 1595.4)

1140.4 (944 - 1377.6)

518.9 (402.4 - 668.9)

3474.9 (2781 - 4341.9)

1019.2 (627.2 - 1656.1)

308.5 (161.7 - 588.5)

CYP2B6

CYP2C8

CYP2C9

CYP2D6

CYP2E1

CYP3A4

CYP3A5

(11596.3 - 17397.5)

13538.8
(10827.9 - 16928.4)

19217.9 (16842.7 - 21928.2)

50.1 (37.7 - 66.6)

447.6 (372.5 - 537.9)

345.8 (295.3 - 405)

97.7 (84.1 - 113.6)

258.9 (230.9 - 290.3)

55.4 (47.1 - 65.1)

CYB5A

CYP51A1

CYP8B1

CYP27A1

CYP4F11

CYP4F2

CYP4F3
45.5 (38.6 - 53.6)

178.4 (145.2 - 219.3)

72.1 (61.6 - 84.4)

267.7 (224.4 - 319.3)

347.8 (248.5 - 486.7)

267.5 (143 - 500.4)

Diabetic

49.9 (38.6 - 64.6)

154.5 (118.5 - 201.4)

74.3 (57.9 - 95.2)

253.5 (192.1 - 334.6)

362.6 (293.3 - 448.3)

25.6 (19.6 - 33.5)

(9090.1 - 15462.6)

11855.7

1600 (1334.9 - 1917.8)

67.9 (35.2 - 131.2)

234.1 (138.3 - 396.1)

2081 (1582.4 - 2736.7)

293.5 (210.9 - 408.6)

770.7 (556.7 - 1067)

613.8 (413.7 - 910.6)

79 (52.8 - 118.3)

500.2 (233.4 - 1072.1)

Supplementary table 3

52.3 (42.3 - 64.7)

164.9 (117.7 - 231)

85.9 (70.7 - 104.3)

318.9 (264 - 385.3)

361.8 (268.9 - 486.9)

41.8 (33.8 - 51.7)

14203.7

1742.3 (1577.9 - 1923.9)

2058.4 (1803.3 - 2349.6)

1858.7 (1650.9 - 2092.7)

191.7 (94.5 - 389)

502.3 (259.1 - 974.1)

POR

38.3 (29.9 - 49.2)

NAFL

2419.8 (2026.1 - 2889.9)

448.7 (307.7 - 654.2)

994.8 (843.1 - 1173.8)

801.9 (486.7 - 1321.2)

816.1 (471.7 - 1412)

318.1 (178.1 - 568.1)

484.9 (335.1 - 701.7)
1017 (648.4 - 1595.1)

618.9 (401.2 - 954.8)

785.5 (453.9 - 1359.6)

Non-diabetic

CYP2A6

Diabetic

Non-diabetic

Control

CYP1A2

Protein

52 (41.7 - 64.7)

222.7 (187.5 - 264.6)

91 (71.9 - 115.1)

316.3 (278.8 - 358.9)

318.2 (231.9 - 436.8)

33.2 (20.5 - 53.5)

(10814 - 16808.7)

13482.2

1680.8 (1398.4 - 2020.3)

189.2 (110.2 - 324.8)

402 (208.1 - 776.7)

2614.8 (2064.6 - 3311.5)

361.8 (183.8 - 712.1)

1031.2 (806.4 - 1318.7)

820.2 (523.8 - 1284.4)

170.8 (93.2 - 313.1)

903.1 (573.9 - 1421.1)

396.9 (186.4 - 845.4)

Non-diabetic

NASH

50.8 (41.8 - 61.7)

168.4 (130.7 - 216.9)

78.9 (63.8 - 97.7)

313.5 (251.8 - 390.3)

417.1 (332.4 - 523.3)

45.6 (30.3 - 68.6)

(10921.9 - 15504.9)

13013.2

1923.9 (1650 - 2243.2)

104.7 (53.3 - 205.5)

418 (247.4 - 706.5)

2778.5 (2188.2 - 3528)

425.8 (304 - 596.5)

954.8 (722.3 - 1262.2)

932.8 (642.5 - 1354.4)

191 (98.7 - 369.4)

709.5 (434.8 - 1157.8)

260.4 (185.1 - 366.3)

Diabetic
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93 (72.5 - 119.3)
57.2 (45.7 - 71.5)
101.5 (70 - 147.2)
261.6 (215.1 - 318)
831.3 (707.5 - 976.7)
1552.5 (1307.1 1844.1)

130 (107.8 - 156.8)

70.7 (52.6 - 95.1)

166.8 (127.7 - 217.9)

326 (274.6 - 387)

977.2 (806.8 - 1183.6)

1823.6 (1469.8 2262.6)

UGT1A9

UGT2A3

UGT2B10

UGT2B15

UGT2B4

UGT2B7

SULT2A1

SULT1B1

SULT1A2
114.2 (94.1 - 138.6)
4142.1 (2994 5730.5)

6072.1 (5071.9 7269.5)

240.8 (201 - 288.3)

140.4 (120.1 - 164.1)

279 (238.9 - 326)

501.9 (355.5 - 708.7)

66.8 (55.1 - 81.1)

87.7 (72.5 - 106)

UGT1A7

740.3 (575.4 - 952.4)

270.5 (212.8 - 343.9)

333.3 (280.3 - 396.4)

379.4 (325.5 - 442.1)

UGT1A6

SULT1A1

151.9 (107.2 - 215.1)

546.4 (458.8 - 650.8)

566.7 (473.8 - 677.9)

UGT1A4

3794.3 (2522.3 - 5707.8)

123.2 (94.7 - 160.3)

215 (163.5 - 282.7)

427.8 (312.1 - 586.6)

1631.2 (1300.7 - 2045.7)

871.1 (720.9 - 1052.6)

80.7 (57.7 - 112.8)

827 (638 - 1072.1)

266.7 (200.6 - 354.5)

126.9 (84.2 - 191.2)

85 (62.6 - 115.6)

5568.8 (4164.7 - 7446.3)

126.1 (97.2 - 163.7)

253.3 (180.6 - 355.2)

587.5 (377 - 915.7)

1699.7 (1266.4 - 2281.3)

Supplementary table 4

3485.2 (2246.8 - 5406.1)

113.2 (90 - 142.3)

198.3 (173 - 227.3)

359.7 (238.8 - 541.8)

1438.5 (1102.1 - 1877.5)

721.5 (595.7 - 873.8)

272.9 (215.9 - 345.1)

100.2 (65.1 - 154.2)

76.5 (55.9 - 104.7)

98.2 (74.7 - 129)

91.8 (73.9 - 113.9)

125 (102.6 - 152.2)

80.1 (64.4 - 99.5)

68.8 (54.7 - 86.5)

438.7 (349.3 - 551)

437.6 (311.5 - 614.7)

258.4 (178.1 - 374.8)

Non-diabetic

105.7 (90.1 - 123.9)

349 (269.7 - 451.6)

239.6 (183.7 - 312.4)

Diabetic

330.8 (265.9 - 411.5)

NAFL

454.8 (377.8 - 547.5)

585 (483.8 - 707.3)

323.4 (248.1 - 421.6)

241.1 (193.7 - 300)

361.2 (286.8 - 454.9)

UGT1A1

Non-diabetic

Diabetic

Control

Non-diabetic

Protein

NASH

3106.4 (2068.4 - 4665.2)

120.1 (98.7 - 146.2)

204.8 (170 - 246.6)

441.3 (289.5 - 672.6)

1828.4 (1452.9 - 2300.9)

835.6 (669.4 - 1043.1)

345.6 (282.8 - 422.4)

153.9 (117 - 202.5)

80.9 (63.1 - 103.9)

83.8 (64 - 109.8)

78.6 (61.8 - 100)

352.9 (273.2 - 455.7)

424.2 (326.6 - 550.8)

281.4 (225 - 351.9)

Diabetic
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166.1 (128.6 214.7)
1184.7 (1039.7 1350)
1461.9 (1281.7 1667.3)
39339.9 (34682.6 44622.5)

GLO1

FASN

CPS1

137.2 (115.8 - 162.6)

4695.5 (4041.4 5455.5)

Non-diabetic

3993.3 (3516.4 4535)

Diabetic

31797.9 (26836 37677.2)

1048.6 (844.4 1302.1)

813 (589.8 1120.5)

121.4 (91.7 160.8)

81.6 (62.8 - 106.1)

Control

ACSM5

ACSM3

ACADSB

Protein

26347.9 (21647.2 32069.3)

1171.9 (913 1504.3)

752.7 (532.6 1063.6)

71.1 (47.1 - 107.4)

62.7 (52.8 - 74.5)

2685.8 (2141.2 3368.9)

Diabetic

Supplementary table 5

30621.2 (26007.8 36053)

1302.7 (994.4 1706.7)

871.3 (692.1 1097)

81 (53.2 - 123.2)

80.8 (59.4 - 109.9)

2959.2 (2507.4 3492.5)

Non-diabetic

NAFL

32715.6 (27470.5 38962.1)

1946.1 (1469.7 2577)

983.1 (742.8 1301.3)

68.2 (42.1 - 110.6)

85.8 (56.2 - 131.1)

3686.2 (3022.4 4495.7)

Non-diabetic

1285.5 (977.2 1690.9)

831.4 (653.8 1057.2)

100 (74.2 - 134.9)

77.8 (56.3 - 107.5)

2745.5 (2171.8 3470.8)

Diabetic

27554.3 (22593.2 33604.9)

NASH
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GSTZ1

GSTP1

GSTO1

GSTK1

GSTA2

GSTA1

ALDH9A1

ALDH8A1

ALDH6A1

ALDH5A1

ALDH4A1

ALDH3A2

ALDH2

ALDH1L1

ALDH1B1

ALDH1A1

Proteins

1050 (604.4 1824.1)
1918.6 (1387.2 2653.7)
3059.7 (2427.4 3856.7)
459.7 (342.8 616.6)
1104.2 (849.1 1435.9)

212.6 (148 - 305.5)

796.9 (551.8 1150.9)

418.1 (326.1 - 536)

1371.9 (814 2312.3)
2745.3 (1973.9 3818.1)

982.5 (591.9 - 1631)

316.8 (195.6 - 513)

NAFL
Non-diabetic
Diabetic
9319.6 (7593.6 8249.6 (6067.3 11437.9)
11217)
1141.1 (796.4 893.6 (601.6 1635.1)
1327.4)
3136.6 (2510.2 2523.4 (2116.5 3919.4)
3008.4)
11977.4 (10017.9 10002.4 (7627 14320.3)
13117.5)
887.1 (776.9 749 (623.4 - 899.8)
1013)
5143.6 (4393.9 4633.2 (3785.7 6021.4)
5670.4)
914.5 (769.7 808.5 (676.1 1086.6)
966.7)
4563.8 (3879.4 4478.8 (3579.2 5369)
5604.6)
810.5 (650.5 701.2 (560.5 1009.8)
877.4)
2012.7 (1670.3 1801.2 (1384.8 2425.3)
2342.7)

Supplementary table 6a

Control
Non-diabetic
Diabetic
11702.2 (9834.4 9064.8 (7565.7 13924.7)
10861)
1361.3 (1080.2 713.4 (490.2 1715.4)
1038.2)
3598.2 (2992.3 2787.2 (2271.3 4326.6)
3420.4)
15840.9 (14025.1 12153.1 (10441.2 17891.9)
14145.7)
888.7 (795.6 788.8 (706 - 881.4)
992.7)
5957.7 (5204.7 4784.6 (4211.4 6819.7)
5435.8)
1187.2 (1044.4 941.3 (826 1349.4)
1072.7)
5981.3 (5107.5 5250.6 (4203.4 7004.6)
6558.7)
1123.8 (992.3 739 (565.1 - 966.5)
1272.6)
2438.8 (2182.2 1937.7 (1675.6 2725.6)
2240.7)
301.3 (241.4 241.8 (189 - 309.3)
376.2)
1418.4 (969.3 971.9 (620.6 2075.6)
1522.1)
2632 (2417 1572.4 (1080.5 2866.1)
2288)
3740.6 (3291.4 3212.8 (2582.9 4251.1)
3996.4)
433.6 (381.6 404.5 (331 - 494.2)
492.7)
1500.1 (1313.6 1116.3 (916.8 1713.1)
1359.3)

NASH
Non-diabetic
Diabetic
10799.9 (8264.2 8699.5 (7096.8 14113.7)
10664.1)
1527.1 (1150.2 829.7 (553.6 2027.5)
1243.4)
3375 (2548.9 2844.2 (2309.3 4469)
3503)
14404.4 (11412.5 11645.8 (8968.7 18180.6)
15121.9)
747.9 (645.7 836 (700.6 - 997.7)
866.2)
5221.8 (4438.2 4727.7 (3977.6 6143.8)
5619.2)
1087.8 (906.4 933.9 (770.3 1305.5)
1132.1)
4724.4 (3869.8 4248.1 (3526.3 5767.6)
5117.7)
933.7 (613.6 749.2 (527.1 1420.7)
1065.1)
2181.9 (1679.1 1876.5 (1569 2835.2)
2244.2)
448.7 (290.8 282.4 (190.2 692.2)
419.3)
1845.9 (1048.2 653 (412.4 3250.7)
1033.9)
2556 (2166 1819.3 (1295.3 3016.2)
2555.1)
3297 (2518.7 2501.7 (1909.1 4315.8)
3278.2)
403.6 (315.5 429.3 (341.9 - 539)
516.3)
1253.9 (952.7 962.7 (742.7 1650.3)
1247.9)
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2899.2 (2399.7 3502.7)
15823.4 (13236.9 18915.3)
3284.1 (2510.7 4295.8)
24448.2 (19017.8 31429.2)
2361 (2030.9 2744.7)
3917.3 (3357.1 4571)
2940 (2505.1 3450.5)

181.9 (161.6 - 204.8)
4120.9 (3375.1 5031.6)
21513.4 (18374.8 25188.2)
5734.5 (4736.7 6942.5)
37716 (31392.3 45313.5)
2811.4 (2453.2 3221.9)
5112 (4325.7 6041.2)

XDH

ADH1A

1873.8 (1470.7 2387.3)
1149 (958.9 1376.8)

2520.7 (2190.5 2900.6)
1482.1 (1218.7 1802.5)

AKR1C4

AKR1D1

445.8 (365.7 - 543.6)

663 (568.8 - 772.7)

AKR1C3

456 (331.1 - 627.9)

768.3 (644.6 - 915.7)

AKR1C1

AKR1A1

ADH6

ADH5

ADH4

ADH1C

ADH1B

3588.7 (3210 - 4012)

127.8 (106.5 - 153.3)

970.6 (864.4 - 1090)

CES2
877.5 (779.5 - 987.9)

2674.1 (2330.4 3068.5)
21463.9 (18764.5 24551.7)

3111.6 (2714.7 3566.5)
26713.2 (23114.9 30871.8)

AOX1

CES1

Diabetic

Control
Non-diabetic

Proteins

1022.6 (791.5 1321.1)

1432 (986.3 - 2079)

401.1 (299 - 538.1)

447.1 (325.5 - 614)

3160.7 (2341.5 4266.4)
15173.5 (11984.2 19211.6)
3552.9 (2898.9 4354.6)
22479.1 (15973.7 31633.7)
2165.2 (1669 2809.1)
3480.8 (2680.6 4519.8)
2641.2 (1942.4 3591.5)

154.5 (116.6 - 204.6)

702.6 (515.6 - 957.5)

Supplementary table 6b

1638.8 (1257.6 2135.6)
1129.7 (842.8 1514.3)

523.1 (398.9 - 686)

560.7 (419.6 - 749.2)

3075.6 (2337.5 4046.7)
16002.6 (12849.9 19928.8)
3719.6 (2849.9 4854.5)
25236.1 (18488.2 34446.8)
2312.4 (1899.1 2815.7)
3776.8 (2970.1 4802.5)
2894.6 (2270.5 3690.2)

147.7 (111.9 - 195.1)

Diabetic
2281.3 (1946.2 2674.2)
20585.3 (16308.8 25983.4)

NAFL

799.2 (702.9 - 908.7)

2798 (2522.4 3103.6)
26430.5 (22727.6 30736.7)

Non-diabetic

2222.9 (1652.4 2990.4)
1644.9 (1073.7 2520.2)

581.6 (468 - 722.6)

811.7 (675.7 - 975.1)

3373.9 (2125.3 5356)
17298.5 (12266.7 24394.3)
4148.4 (2902.6 5929.1)
30823.9 (21137.4 44949.5)
2780.6 (2095.4 3689.8)
4286.2 (2958.4 6210)
3542 (2607.5 4811.3)

177.1 (125.9 - 249.1)

2417.4 (2048.5 2852.9)
24972.2 (20329 30676.1)

Diabetic

1665.2 (1252.3 2214.3)
1207.5 (921.8 1581.8)

440.9 (338.6 - 574)

3932.7 (3216.8 4807.9)
16335.8 (13329.3 20020.5)
3271.4 (2619.9 4085)
25168 (20125.7 31473.6)
2359.5 (1878.5 2963.7)
4109.4 (3341.7 5053.6)
3103.6 (2533.9 3801.3)
435.1 (307.1 - 616.4)

186.2 (154.9 - 223.8)

770.4 (601.4 - 986.8)

NASH

816.9 (708.5 - 942)

2496.2 (1914.3 3255)
24607.1 (20650.5 29321.8)

Non-diabetic
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Abstract
Hepatic xenobiotic transporters in human liver play an important role in the elimination of
drugs or toxins and significantly contribute to variability in drug response. We developed
a label-free mass spectrometry-based method to study the protein expression of 25
clinically relevant transporter proteins (12 ABC and 13 SLC) in liver tissue from 22 donors
(9 female, 12 male).

Membrane fractions were extracted from the tissue using

ProteoExtract membrane extraction kit and in-solution trypsin digestion was performed
using pressure-cycling technology. Data was acquired in data-dependent and sequential
window acquisition of all theoretical mass spectra (SWATH-MS) mode. Chromatographic
separation was achieved over a 90-min gradient on Acquity UPLC BEH C18 peptide
column, and mass spectrometer was operated in positive electrospray mode. Digested E.
coli β-galactosidase peptides were spiked in each sample before LC-MS/MS analysis, and
intensity was expressed relative to APLDNDIGVSEATR peptide. ProteinPilot (ver 5.0.1)
was used for peptide identification and Skyline (ver 4.0) was used for targeted data
extraction from SWATH files. Na+/K+ transporting subunit alpha 4 (ATP1A4), was
quantified as a cell membrane marker and its coefficient of variation was 9.7% across
different liver samples.
Significance: The work highlights the suitability of SWATH-MS for large-scale
simultaneous quantification of several xenobiotic transporters important in drug
disposition. We found that average differential expression of transporters proteins was
similar and much smaller than the inter-individual variability observed between the genders

213

1.

Introduction

Xenobiotic transporters play a crucial role in drug disposition by mediating drug uptake
and efflux. These proteins govern the absorption, distribution, metabolism, and elimination
of drugs, toxins and endogenous molecules across the cell membrane. Thus, transporters
can govern the rate-limiting step in systemic and tissue exposure of drugs. Biologically,
transporters are membrane-bound proteins which are ubiquitously expressed throughout
the body. These proteins are mostly localized on the apical or basolateral membranes of
various organs including intestine, liver, kidney, and brain and facilitate the efflux and
uptake of xenobiotics [1]. The ATP-binding cassette (ABC) family and the solute carrier
(SLC) family represent the two significant super families of membrane transporters in
human [2-4]. ABC transporters utilize ATP for transport of substrates across the
membrane, and most of efflux transporters belong to this family (Supplementary table 1a).
In contrast, SLC transporters mainly facilitate uptake which can be active or facilitated
(Supplementary table 1b). Some SLC transporters also mediate bidirectional movement of
molecules. The altered systemic exposure and organ toxicity can be related to transporters
mediated drug interactions [1, 5]. Therefore, the last decade has seen a significant amount
of research focusing on quantification and de-orphanization of these transporters as well as
elucidation of their functionality [6, 7]. Inter-individual variability in the expression and
drug response of xenobiotic transporters may arise from non-genetic (age and gender),
genetic (polymorphism), epigenetic and regulatory factors [8]. While more than 400
different transporters have been annotated in the human genome, the function of many of
these remains unknown [2, 9].
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Efflux transporters localized on the canalicular membrane (e.g., P-gp/MDR1, MRP2,
BCRP, BSEP, MDR3, and MATE1) facilitate excretion of molecules from hepatocytes
into bile [4, 6, 10]. Meanwhile, basolateral hepatic efflux transporters (e.g., MRP1, MRP3,
MRP4, MRP5, and MRP6) return molecules to hepatic blood from the hepatocyte [4, 6,
11]. Prominent uptake transporters that are localized on the sinusoidal membrane of
hepatocyte include NTCP, OATP1B1, OATP1B3, OATP2B1, OAT2, and OCT1 [12, 13].
These uptake transporters, facilitate uptake of drugs from the blood into hepatocyte thereby
facilitating metabolic clearance of drugs. Moreover, OAT7 on the sinusoidal membrane
and sterolin-1 and sterolin-2 on basolateral membrane mediate bidirectional (efflux and
uptake) transport of various substrates [14, 15].
Traditionally, researchers have relied on quantification of mRNA expression of
transporters as a surrogate to the functional activity in the tissue. However, a weak
correlation was observed between mRNA and protein expression in human livers [16, 17].
Protein abundance levels of these transporters are usually estimated by cumbersome
Western blot analyses that is semi-quantitative at best. Last decade has seen a rise in the
use of mass-spectrometry (MS) based techniques for quantification of the protein
expression [10, 18]. Available MS methods for quantification of liver transporters are
based on targeted quantitative proteomics approaches [10, 16, 17, 19, 20]. A
comprehensive cost comparison of different mass spectrometry-based techniques reported
significant cost savings with label-free based quantitative proteomics [21].

LFQ

approaches are relatively inexpensive as compared to targeted MRM methods as there is
no need to synthesize unique peptides for each protein and isotopically labeled isoforms of
these peptide as the internal standard.
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Relative label-free quantification (LFQ) using the sequential window acquisition of all
theoretical mass spectra (SWATH-MS) technique provides an alternative to targeted
approaches for protein estimation [22]. SWATH is a data-independent acquisition (DIA)
technique in which all the precursors within a predefined m/z are fragmented, and product
ions of these precursors are recorded as a digital repository [23]. The data is further
deconvoluted and extracted using software like OpenSWATH, SWATH 2.0 and Skyline
[24]. A significant advantage of SWATH-MS over the other mass spectrometry methods
is related to the ability to perform retrospective mining of the data. For instance, if the
researcher comes up with a new hypothesis in the future, SWATH-MS data would allow
interrogation of the existing data for additional protein/s of interest without the need for
sample digestion or data reacquisition. Such a strategy offers a tremendous benefit
concerning saving of sample, time and money. A high linear association between MRM
based methods with SWATH-MS has been shown in the past making it a suitable and
reliable technique for proteomics-based studies [25, 26]. Nakamura et al. also described a
SWATH-MS for quantification of drug-related transporter proteins in human liver
microsomes, however no gender specific differences were reported due to use of small
sample size (n=4) [25].
In this work, we report the development of a SWATH-MS based method to study the
gender-specific differential expression of important drug and xenobiotic transporters in
human liver (12 ABC and 13 SLC family). The transporter proteins were shortlisted based
on the recommendation made by the International Transporter Consortium (ITC), the US
Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), as
human xenobiotic transporters that play a significant role in drug discovery [6, 7, 27].
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2.

Materials and methods

2.1 Chemicals and Reagents
Protein preparation kit, TPCK-treated trypsin, trypsin digested β-galactosidase, and MS
tuning solution was obtained from SCIEX (Framingham, MA). Acquity UPLC Peptide
BEH C18 analytical column and VanGuard pre-columns were procured from Waters Corp.
(Waltham, MA). Calbiochem ProteoExtract Native Membrane Protein Extraction Kit was
purchased from EMD Millipore (Billerica, MA). 1,4-Dithiothreitol (DTT) was obtained
from Roche Diagnostics (Indianapolis, IN). Sodium deoxycholate and iodoacetamide
(IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade acetonitrile and
formic acid were purchased from ThermoFisher (Waltham, MA).
2.2 Human Liver Bank
Frozen human liver samples from brain dead donors were purchased from Sekisui
XenoTech LLC, Kansas City, KS. All the livers are from organ donors involved in
automobile accidents and therefore are IRB-exempt. The age of liver donors ranged from
21 to 64 years, with 13 males and 9 females. Most livers were from organ donors involved
in automobile accidents. The detailed demographics of the donors is given in table 1.
2.3 Human Liver Tissue Preparation
Membrane extraction from human tissue was performed as described in the ProteoExtract
kit protocol with slight modifications. Briefly, liver tissue (~100 mg) was placed in a
Dounce homogenizer with 1000 µl of extraction buffer-I (EBI) and five µl of the protease
inhibitor cocktail. All the subsequent steps were carried out at 4°C unless specified
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otherwise. Tissue was homogenized on ice with 10-15 strokes and incubated for 10 min
with gentle agitation. Samples were spun at 16,000 x g for 15 min, and the supernatant was
stored for future analysis of soluble proteins. The remaining pellet was gently resuspended
in 500 µl of extraction buffer-II (EBII) and 2.5 µl of the protease inhibitor cocktail.
Following 30 min incubation with gentle agitation, samples were centrifuged at 16,000 x
g for 15 min, and the supernatant containing the membrane-bound and associated proteins
was collected for further analysis. Total protein concentration was estimated using Pierce
BCA protein assay kit (ThermoFisher Scientific, Waltham, MA).
2.4 Pressure-Cycling Technology (PCT) aided trypsin digestion
Protein digestion was performed as described by Prasad et al. with modifications [28].
Membrane fractions (250 µg protein) were denatured with 25 µL DTT (20 mM) at 95°C
for 15 min in a shaking water bath (100 rpm). After denaturation, samples were alkylated
in the dark with 25 µL IAA (33 mM) for 30 min at room temperature. Samples were
subsequently concentrated using the cold methanol, chloroform, and water (2:1:1)
precipitation method. Samples were washed with ice-cold methanol and then resuspended
in 75 µL of 50 mM ammonium bicarbonate (pH 7.8) containing 3% w/v sodium
deoxycholate (DOC). Further, TPCK-treated trypsin was added to samples at a ratio of
1:20 (trypsin: protein) and samples were transferred into digestion tubes (PCT MicroTubes,
Pressure Biosciences Inc., Easton, MA). The barocycler was run as described previously
by our group [29]. Post tryptic digestion, 20 µL of 2.5% formic acid in 50:50 water:
acetonitrile was added to 80 µL of digested protein samples to precipitate DOC and any
undigested proteins as well as quench the trypsin digestion. Samples were spun at 5000 g
at 10°C for 5 min, and the supernatant was collected for further analysis. Each sample was
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spiked with trypsin-digested β-galactosidase peptides (15 pmol) before mass
spectrometry analysis and 15 µL was injected.
2.5 LC-MS/MS Analysis
Mass spectrometry analysis was performed as described previously with modifications
[29]. All experiments were performed on a SCIEX 5600 TripleTOF® mass spectrometer
equipped with a DuoSpray™ ion source (SCIEX, Concord, Canada) coupled to Acquity
UHPLC HClass system (Waters Corp., Milford, MA, USA). Sample separation was
achieved on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm 2, 300 Å, 1.7 µm)
attached to an Acquity VanGuard pre-column (2.1 X 5 mm 2, 300 Å, 1.7 µm).
Autosampler and analytical column were maintained at 10°C and 40°C, respectively.
The chromatographic separation was achieved over a 90-min gradient at 100 μL/min. A
linear gradient was used for chromatographic separation using mobile phase A (98%
water, 2% acetonitrile, 0.1% formic acid) and mobile phase B (98% acetonitrile, 2%
water, 0.1% formic acid). The solvent composition was 98% A from 0 to 5 min, 98%
to 75% A from 5 to 55 min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to
70 min, 20% A held from 70 to 75 min to flush the column back to 98% A at 80 min.
The gradient was held at initial conditions from 80 min until the end of the run to
equilibrate the column before the start of next run. Mass calibration of the QTOF
detector was monitored by injecting trypsin-digested β- galactosidase peptides every ten
samples during the analysis.
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2.6 Data-dependent and SWATH acquisition parameters
Data-dependent, as well as data independent (SWATH) analysis, was performed in positive
ionization mode. The method specific parameters were as follows: gas 1 (GS1) 60 psi, gas
2 (GS2) 60 psi, curtain gas (CUR) 25 psi.

The source-specific parameters were:

temperature (TEM) 450°C, ion spray voltage floating (ISVF) 5500 V, declustering
potential (DP): 120, collision energy (CE) 10, collision energy spread (CES) 5.
A maximum of 50 candidate ions with a charge state 2 to 4 was monitored every survey
scan cycle. All the ions between m/z 300-1250 which exceeded 25 cps were subjected to
MS/MS analysis. Rolling collision energy dependent on the m/z of the ion and dynamic
accumulation were used. The mass tolerance was set at 50 mDa during the initial 0.25 sec
survey scan (total cycle time: 3.90 sec).
All the parameters for SWATH acquisition were similar as described above except the
following: Source temperature (TEM) was 400°C, GS 1 was 55 psi, and TOF masses were
collected from m/z 300 to 1500. The total cycle time for SWATH acquisition was 3.95 sec.
SWATH data was acquired (m/z 400-1100) over 70 SWATH windows per cycles with a
window size of m/z 10.
2.7

Data processing and extraction

DDA samples were searched against reviewed Swiss-Prot identifiers (October 2016) using
ProteinPilot 5 (SCIEX, Concord, Canada). The search was performed using Paragon
algorithm for identification of peptides and proteins from DDA data. Thorough ID search
mode with digestion: trypsin, Cys alkylation: iodoacetamide with false discovery analysis
(1.0%) was searched against UniProt human protein database. ID focus during the
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processing was maintained on biological modifications only. Raw data files and search
results are available at Japan Proteome Standard Repository (jPOSTrepo JPST000372,
ProteomeXchange PXD008593), a publicly available data repository for proteomics data
[30]. Spectral library and SWATH data were uploaded to Skyline for peptide and transition
picking. Skyline is an opensource application for targeted extraction of peptide information
from the SWATH data. Surrogate flyable peptides were selected as previously described
[31]. For each protein, peptide correlation analysis was performed to choose surrogate
peptides with a significant correlation coefficient (Spearman r>0.500, P<0.05). Only
peptides between 6 to 25 amino acids, that were not embedded in the transmembrane
domain were included. We also excluded peptides with known posttranslational
modifications and polymorphic variations. Wherever possible, two peptides per protein
were used to estimate the relative abundance of transporter proteins.
2.8 Data normalization
The raw peptide intensity data was expressed relative to the β-galactosidase peptide
(APLDNDIGVSEATR [M + 2H]2+: 729.3652) intensity. Subsequently, these relative
values were normalized with membrane protein yield to account for the differences in
protein abundance among samples.

Relative intensity =

Raw intensity (protein)
Raw intensity (APLDNDIGVSEATR)

Normalized intensity = Relative intensity ∗ membrane protein per mg tissue
Normalized intensity = Relative intensity ∗ membrane protein per mg tissue * liver
weight
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2.9 Statistical analysis
The correlation analysis for selection of surrogate peptides and statistical analysis was
performed on Prism 6 (GraphPad Software Inc. La Jolla, Ca). Non-parametric Mann
Whitney U test was used to compare the differences in demographic data and Chi-square
test was used to compare the proportionality. Normalized intensity data were naturallogarithm transformed before statistical analysis [32]. The geometric mean was calculated
from non-transformed data using SPSS v24 (IBM Analytics, Armonk, NY). Gender
differences in the relative expression of major xenobiotic and drug transporters in human
liver were carried out using a t-test on the natural logarithmic transformed data. Nonparametric Spearman analysis was used for correlation between different transporter
proteins. P<0.05 was considered significant throughout the analysis. Demographic data
were reported as mean ± SEM unless stated otherwise.
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3. Results
SWATH-MS was used to estimate the protein expression of 25 hepatic drug transporters
(12 ABC and 13 SLC family) in membrane fractions from 22 human liver donors. A
complete list of surrogate peptides used for the relative estimation of transporters in liver
samples is given in supplementary table 2. All transporters were quantified with two
unique surrogate peptides except OATP1B1, OCT3, ENT1, NTCP, and sterolin-2 where
only one unique surrogate peptide was qualified for inclusion based on the criteria
described in 2.7.
3.1 Yield of membrane protein per gram of liver tissue
The average membrane yield (mg/g liver tissue) for all the livers was 20.33±4.42, n=22
(fig 1a). Membrane protein yield was marginally lower in females (19.05±1.44, n=9) as
compared to males (21.21±1.23, n=13). However, the gender-difference in yield was
statistically insignificant (p>0.46). The variability in sodium/potassium-transporting
ATPase subunit alpha-4 (ATP1A4, an integral membrane marker) levels was used to gauge
the quality of the membrane fractions and % coefficient of variation among the 22 samples
was 9.7% (fig 1b).
3.2 Effect of gender on drug efflux transporters
We found that none of the investigated efflux transporters was differentially expressed in
males and females (fig 2a). BCRP was detected in membrane fractions from 7/9 female
and 7/12 male donor livers. In females, BSEP was found in eight out of nine donors. Other
efflux transporters studied in this work were found in all the liver samples. Six MRP
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transporters quantified using this assay are given in fig 2b. No significant gender difference
was seen in transporter proteins with efflux/uptake function as well (fig 2c). Sterolin-1 was
detected in 8 and 9 membrane fractions from female and male donors, respectively. ENT2
was detectable in membrane fraction from 8 females and 9 male donors.
3.3 Effect of gender on drug uptake transporters
Gender was not found to influence the protein abundance of any of the uptake transporters
in this study (fig 3). All the uptake transporters included in the study except OATP
transporters were detectable in all the liver samples. In males, OATP1B3, and OATP2B1
were present in 12, and ten donor liver samples, respectively. In females, OATP1B3, and
OATP2B1 were present in 7, and 8 donor liver samples, respectively. OAT1B1 was found
in all the samples included in the study. Gender-specific expression level and male/female
ratio of transporter proteins is available at table 2-5.
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4. Discussion
Drug response, efficacy, and toxicity are dependent on the expression of drug metabolizing
enzymes and transporters in the intestine and liver. Differences in the basal expression of
these proteins in the human liver can contribute to significant changes in systemic exposure
of a drug. Extensive research in human has shown the gender-related differences which
partly explain the interindividual variability in drug disposition, toxicity and therapeutic
response [33, 34]. Gender is an essential underlying biological factor for the development
of personalized medicine. A study by the US General Accounting Office found that 80%
of FDA-approved prescription drugs withdrawn from the market between 1997-2000 were
due to higher adverse drug-related events in women [35]. While a considerable amount of
data is available on the gender differences in transporter protein expression in rat and mice,
studies are lacking in human [36, 37]. Also, limited data is available for the gender
differences in expression of transporter proteins in human since most available information
is based on gene expression [34]. Interestingly, growing body of research is suggesting that
mRNA serves as a poorer surrogate than protein expression for prediction of transporter
activity [17, 28, 38].
The availability of human liver tissue for studying the hepatic xenobiotic transporters
remains a challenge for researchers due to ethical consideration and the availability of
tissue with adequate clinical information. Most of the samples available from healthy
people come from donors who have sadly passed away in automobile accidents. Therefore,
when possible, a judicious and parsimonious use of such tissue is warranted to obtain
maximum data. MRM-based methods of protein quantification rely on customization of
processes for each target protein before quantification. Though such means can be adapted
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to quantify more than one protein at a time, the cost and method complexity increases
exponentially with an increase in the number of target proteins [21]. Despite the benefits
offered by SWATH-MS, there are some limitations to the methodology. First, a few of the
low abundance transporters were quantified using one surrogate peptide. As the window
size in SWATH increases, the noise level increases drastically and impedes the
quantification of low abundance proteins. Second, we assume that the total cellular
membrane protein expression serves as a surrogate for purified plasma membrane.
Nevertheless, the advantages of this technique outweigh its drawbacks.
We observed that the inter-individual variability seen in this study was much higher than
the average differences between the two genders. While a study with a large sample set is
desired to completely address the cofactors contributing to this variability, such studies are
often limited due to lack of availability of the liver tissue. Most of the tissue that is available
for commercial purchase is obtained from motor vehicle accidents or other brain-dead
donors and a detailed medical history is often lacking. Therefore, the potential of
conflicting effects from obesity, diabetes or any other undiagnosed disease cannot be ruled
out. Interestingly, there are currently no reports for any significant alteration of transporter
proteins in human liver. Our findings are also limited as we do not have a large enough
sample size to separately study the effect of obesity (BMI>30) or diabetes in our sample
set. Therefore, future studies with a larger sample size are currently being planned to
address the high inter-individual variability and differential effect of obesity and diabetes.
Few transporter proteins (OST, OCT3) were close to p<0.05 but failed to reach statistical
significance possibly due to sample size constraint. Based on means and standard
deviations, we calculated that would have got significance difference between two genders
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had we included a sample size of n=42. In contrast, for proteins with a very high p-value,
significantly large and practically challenging cohort of sample would be required.
Permeability glycoprotein 1 (P-gp) and multidrug and toxin extrusion protein 1 (MATE-1)
are predominantly responsible for efflux of cations from hepatocyte into the bile duct.
Prasad et al. found no association between age and gender with an expression of P-gp in
human livers (n=64) [28]. MATE-1 was reported to exhibit significant correlation with age
but not gender [38]. Li et al. found that the protein expression of breast cancer resistance
protein (BCRP) in human liver tissue was almost 10-fold lower than the bile salt export
pump (BSEP) [39]. Low levels of BCRP, as compared to other canalicular-localized
transporters, could explain why we were able to detect BCRP only 12 out of 20 samples.
The hepatic expression of BCRP in previous studies in human was independent of sex and
age [17]. Cheng et al. also found no significant gender-specific differences in human
hepatic BSEP expression [37].
Multidrug resistance protein 3 (MDR3) is expressed in canalicular membrane of
hepatocytes and plays an integral role in the transport of phospholipids into the bile [40].
Multidrug resistance-associated protein (MRP2) plays an important role in the efflux of
lyophilic conjugates (glutathione, glucuronate, sulfate) [41]. MRP2 is localized on the
apical membrane of polarized hepatocytes and expressed in kidney and intestine among
other tissues [42].
Equilibrative nucleoside transporter 1 and 2 (ENT1 and ENT2) are ubiquitously expressed
in tissues like human liver, heart, kidney, intestine, erythrocytes, and brain [43]. Higher
levels of ENT1 compared to ENT2 were observed in orthotopic liver transplantation [44].
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Organic anion transporting polypeptides (OATPs) facilitate uptake of large hydrophobic
organic anions while smaller and hydrophilic organic anions are transported by the organic
anion transporters (OATs) [45]. OATP1B1, OATP1B3, and OATP2B1 are most notable
transporters for drug uptake in the liver. OATP1B1 and OATP1B2 are expressed
predominantly in liver whereas OAT2B1 is ubiquitously expressed [46]. No genderspecific expression of hepatic OATPs was found in previous or the current studies [16, 28,
47].
OAT2 is highly expressed in the sinusoidal membrane of hepatocytes with lower
expression also seen in the kidney [45]. OAT7 is exclusively expressed in the basolateral
membrane of human hepatocytes in the liver and participate in the transport of anionic
substances in exchange for butyrate [14]. Members of the OCT family transport organic
cations down their electrochemical gradients [45]. OCT1 and OCT3 are predominantly
expressed in human liver and are localized to the basolateral membrane of hepatocyte [48].
Prasad et al. also reported no gender differences in expression of OATPs, OATs and OCTs
in human liver [49]. Even though OCT3 showed a trend towards higher expression in males
in our study (P=0.051), it failed to reach significance possibly due to sample size constraint.
Sodium/taurocholate co-transporting polypeptide (NTCP) is expressed predominantly on
the basolateral membrane of hepatocyte and facilitates the uptake of bile acids [50]. NTCP
mRNA expression was found to be higher in women than men, but the differences in the
expression were statistically insignificant [37]. Organic solute transporters, OST α/OST β
form a heterometric transporter complex which is localized on the basolateral membrane
of hepatocytes and transports bile acids, conjugated steroids and substrates with similar
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molecular structure [15]. These transporters are expressed in higher abundance in human
tissue (intestine, liver, kidney) involved in bile acid and steroid homeostasis [15].
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5. Conclusion
We developed a SWATH-MS based method for label-free, relative quantitative proteomics
analyses of drug and xenobiotic transporters in human liver. SWATH-MS based studies
can be used for comparative global proteomics analysis and large-scale relative protein
quantification, especially for studies that a limited quantity of tissue is available. We
successfully showed that the current approach could be directly applied to estimate the
protein expression of many target proteins at once and can be further applied to study the
difference in expression in relation to demographic characteristics or disease state. Future
studies with a larger sample size are in progress to address other factors (disease, alcohol
consumption, and smoking) which may contribute to differential expression of these
transporter proteins.
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Tables and figure legends:
Tables
Table 1. Donor demographics data. P value represent the significance from Mann-Whitney
U test. C: Caucasian, AA: Afro-American, H: Hispanic
Table 2. Gender-specific expression levels of hepatic efflux transporters. 1Geometric mean
(95% Confidence Interval), 2Mann-Whitney U test
Table 3. Gender-specific expression levels of hepatic efflux/uptake transporters.
1

Geometric mean (95% Confidence Interval), 2Mann-Whitney U test

Table 4. Gender-specific expression levels of hepatic uptake transporters. 1Geometric
mean (95% Confidence Interval), 2Mann-Whitney U test

Figures
Figure 1. Gender difference on membrane protein abundance and ATP1A4 (a
membrane proteins marker). Normalized intensity expressed as natural logarithm
transform relative to β-gal peptide intensity and further normalized to membrane protein
yield. The line represents the arithmetic mean for the respective group and individual
values are shown as aligned dots plot. Relative Intensity not be used for comparison
between levels of different proteins.
Figure 2. Effect of gender on hepatic 2(a) efflux, 2(b) efflux (MRPs), and 2 (c)
efflux/uptake transporters. Normalized intensity expressed as natural logarithm
transform relative to β-gal peptide intensity and further normalized to membrane protein
yield. The line represents the arithmetic mean for the respective group and individual
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values are shown as aligned dots plot. Relative Intensity not be used for comparison
between levels of different proteins.
Figure 3. Effect of gender on hepatic uptake transporters. Normalized intensity
expressed as natural logarithm transform relative to β-gal peptide intensity and further
normalized to membrane protein yield. The line represents the arithmetic mean for the
respective group and individual values are shown as aligned dots plot. Relative Intensity
not be used for comparison between levels of different proteins.

242

Table 1: Donor demographics data for transporter quantification. P-value represent the
significance from Mann-Whitney U test and * represent p<0.05; C: Caucasian, AA: AfroAmerican, H: Hispanic. #Significance from Chi-square test.
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Table 2: Gender-specific expression levels of hepatic efflux transporters. 1Geometric
mean (95% Confidence Interval), 2Mann-Whitney U test
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Table 3. Gender-specific expression levels of hepatic efflux/uptake transporters.
1

Geometric mean (95% Confidence Interval), 2Mann-Whitney U test
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Table 4. Gender-specific expression levels of hepatic uptake transporters. 1Geometric
mean (95% Confidence Interval), 2Mann-Whitney U test
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Graphical abstract: Workflow for quantification of transporter proteins in human liver
tissue using SWATH-MS
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Figure 1: Gender difference on membrane protein abundance and ATP1A4 (a
membrane proteins marker). Normalized intensity expressed as natural logarithm
transform relative to β-gal peptide intensity and further normalized to membrane protein
yield. The line represents the arithmetic mean for the respective group and individual
values are shown as aligned dots plot.
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Figure 2: Effect of gender on hepatic (a) efflux, (b) efflux (MRPs), and (c)
efflux/uptake transporters. Normalized intensity expressed as natural logarithm
transform relative to β-gal peptide intensity and further normalized to membrane protein
yield. The line represents the arithmetic mean for the respective group and individual
values are shown as aligned dots plot. Relative Intensity not to be used for comparison
between levels of different proteins.
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Figure 3: Effect of gender on hepatic uptake transporters. Normalized intensity
expressed as natural logarithm transform relative to β-gal peptide intensity and further
normalized to membrane protein yield. The line represents the arithmetic mean for the
respective group and individual values are shown as aligned dots plot. Relative Intensity
not to be used for comparison between levels of different proteins.
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Supplementary information
Supplementary figure 1: Hepatic transporters quantified using SWATH-MS and their
location and transport properties
Supplementary table 1a: Major hepatic transporters of ABC superfamily quantified in
this study
Supplementary table 1b: Major hepatic transporters of ABC superfamily quantified in
this study
Supplementary table 2: Surrogate peptide and transitions used for relative quantification
of transporter proteins
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Supplementary figure 1
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Supplementary table 1a
Sr. no

Protein

Gene name

name

Membrane localization

Primary

in hepatocyte

Function

1

MDR1/P-gp

ABCB1

Canalicular membrane

Efflux

2

MDR3

ABCB4

Canalicular membrane

Efflux

3

BCRP

ABCG2

Canalicular membrane

Efflux

4

BSEP

ABCB11

Canalicular membrane

Efflux

5

MRP1

ABCC1

Basolateral/Sinusoidal

Efflux

membrane
6

MRP2

ABCC2

Canalicular membrane

Efflux

7

MRP3

ABCC3

Basolateral/Sinusoidal

Efflux

membrane
8

MRP4

ABCC3

Basolateral/Sinusoidal

Efflux

membrane
9

MRP5

ABCC5

Basolateral/Sinusoidal

Efflux

membrane
10

MRP6

ABCC6

Basolateral/Sinusoidal

Efflux

membrane
11

Sterolin -1

ABCG5

Canalicular membrane

Efflux

12

Sterolin -2

ABCG8

Canalicular membrane

Efflux
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Supplementary table 1b

Sr. no

Protein name

Gene name

Membrane localization in

Primary

hepatocyte

Function

1

OCT1

SLC22A1

Basolateral/Sinusoidal membrane

Uptake

2

OCT3

SLC22A3

Basolateral/Sinusoidal

Uptake

membrane
3

OAT2

SLC22A7

Basolateral/Sinusoidal membrane

Uptake

4

OAT7

SLC22A9

Basolateral/Sinusoidal membrane

Uptake/Efflux

5

OATP1B1

SLCO1B1

Basolateral/Sinusoidal membrane

Uptake

6

OATP1B3

SLCO1B3

Basolateral/Sinusoidal membrane

Uptake

7

OATP2B1

SLCO2B1

Basolateral/Sinusoidal membrane

Uptake

8

NTCP

SLC10A1

Basolateral/Sinusoidal membrane

Uptake

9

ENT1

SLC29A1

Basolateral/Sinusoidal membrane

Uptake/Efflux

10

ENT2

SLC29A2

Basolateral/Sinusoidal membrane

Uptake/Efflux

11

MATE1

SLC47A1

Canalicular membrane

Efflux

12

OSTα

SLC51A

Basolateral/Sinusoidal membrane

Uptake/Efflux

13

OSTβ

SLC51B

Basolateral/Sinusoidal membrane

Uptake/Efflux
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Supplementary table 2
Protein
AT1A4
AT1A4
AT1A4
AT1A4
AT1A4
AT1A4
OATP1B3
OATP1B3
OATP1B3
OATP1B3
OATP1B3
OATP1B3
OATP1B1
OATP1B1
OATP2B1
OATP2B1
OATP2B1
OATP2B1
OATP2B1
OATP2B1
OAT2
OAT2
OAT2
OAT2
OAT2
OCT1
OCT1
OCT1
OCT1
OCT1
OCT1
MRP1
MRP1
MRP1
MRP1
MRP1
MRP1
MRP3
MRP3
MRP3
MRP3
MRP3
MRP3
MRP4

Precursor
(m/z)
643.0238
643.0238
643.0238
429.2400
429.2400
429.2400
487.9319
487.9319
487.9319
570.8060
570.8060
570.8060
587.7982
587.7982
953.9921
953.9921
953.9921
532.9579
532.9579
532.9579
705.4122
705.4122
509.5985
509.5985
509.5985
647.3158
647.3158
647.3158
440.7424
440.7424
440.7424
496.2561
496.2561
496.2561
602.6402
602.6402
602.6402
682.3605
682.3605
682.3605
531.2591
531.2591
531.2591
767.4470

Product (m/z)
886.5244
716.4189
488.3079
519.2773
404.2504
308.6687
535.7977
500.2791
408.2185
826.4458
769.4243
622.3559
961.4778
860.4301
1439.7754
720.3913
471.2638
657.3930
544.3089
445.2405
1325.7787
1212.6947
1086.5426
989.4898
860.4472
1049.4997
962.4677
849.3836
637.3919
536.3443
423.2602
962.4942
760.4352
647.3511
517.2584
460.2369
338.1747
1076.5656
977.4972
890.4652
875.4469
634.3042
374.1978
790.4417

Peptide, charge and transition (precursor
charge, fragment, fragment charge)
MQINVQEVVLGDLVEIK, +3y8
MQINVQEVVLGDLVEIK, +3y6
MQINVQEVVLGDLVEIK, +3y4
AAVPDAVSK, +2y5
AAVPDAVSK, +2y4
AAVPDAVSK, +2y6+2
MFLAALSFSYIAK, +3y10+2
MFLAALSFSYIAK, +3y9+2
MFLAALSFSYIAK, +3y7+2
NVTGFFQSLK, +2y7
NVTGFFQSLK, +2y6
NVTGFFQSLK, +2y5
NVTGFFQSFK, +2y8
NVTGFFQSFK, +2y7
ASPDPQDVRPSVFHNIK, +2y12
ASPDPQDVRPSVFHNIK, +2y12+2
ASPDPQDVRPSVFHNIK, +2y8+2
SSPAVEQQLLVSGPGK, +3y7
SSPAVEQQLLVSGPGK, +3y6
SSPAVEQQLLVSGPGK, +3y5
LTYGGIALLAAGTALLLPETR, +3y13
LTYGGIALLAAGTALLLPETR, +3y12
QAQLPETIQDVER, +3y9
QAQLPETIQDVER, +3y8
QAQLPETIQDVER, +3y7
MLSLEEDVTEK, +2y9
MLSLEEDVTEK, +2y8
MLSLEEDVTEK, +2y7
ENTIYLK, +2y5
ENTIYLK, +2y4
ENTIYLK, +2y3
QPLEGSDLWSLNK, +3y8
QPLEGSDLWSLNK, +3y6
QPLEGSDLWSLNK, +3y5
SSTVGEIVNLMSVDAQR, +3y9+2
SSTVGEIVNLMSVDAQR, +3y8+2
SSTVGEIVNLMSVDAQR, +3y6+2
SSLVSALLGEMEK, +2y10
SSLVSALLGEMEK, +2y9
SSLVSALLGEMEK, +2y8
ADGALTQEEK, +2y8
ADGALTQEEK, +2y5
ADGALTQEEK, +2y6+2
IIVFVTFTTYVLLGSVITASR, +3y8

255

MRP4
MRP4
MRP4
MRP4
MRP4
MRP5
MRP5
MRP5
MRP5
MRP5
MRP6
MRP6
MRP6
MRP6
MRP6
MRP6
BSEP
BSEP
BSEP
BSEP
BSEP
BSEP
BCRP
BCRP
BCRP
BCRP
BCRP
MATE1
MATE1
MATE1
MATE1
MATE1
MATE1
MDR1
MDR1
MDR1
MDR1
MDR1
MDR1
MDR3
MDR3
MDR3
MDR3
MDR3
MDR3
MRP2
MRP2

767.4470
767.4470
538.2851
538.2851
538.2851
738.8831
738.8831
738.8831
443.7301
443.7301
452.2665
452.2665
452.2665
694.4008
694.4008
694.4008
515.3062
515.3062
515.3062
515.2956
515.2956
515.2956
573.2846
573.2846
573.2846
478.5819
478.5819
514.7722
514.7722
514.7722
641.1041
641.1041
641.1041
438.2327
438.2327
438.2327
944.5180
944.5180
944.5180
824.4250
824.4250
824.4250
523.3037
523.3037
523.3037
777.0112
777.0112

814.4563
690.3983
875.4833
733.4090
549.2879
1276.6428
1129.5744
1016.4903
701.3729
572.3303
729.4618
616.3777
545.3406
1203.6732
1104.6048
1033.5677
841.5254
657.4042
529.3457
829.4679
715.4250
602.3409
961.4408
759.3454
527.2572
504.2453
316.1579
688.3988
617.3617
409.2243
656.4454
557.3770
628.4287
717.3890
589.3304
476.2463
819.4472
720.3787
474.2419
1288.7260
969.5096
766.9272
857.5203
756.4726
329.2058
1330.6022
1043.4752

IIVFVTFTTYVLLGSVITASR, +3y15+2
IIVFVTFTTYVLLGSVITASR, +3y13+2
AEAAALTETAK, +2y9
AEAAALTETAK, +2y7
AEAAALTETAK, +2y5
SLFLMEEVHMIK, +2y10
SLFLMEEVHMIK, +2y9
SLFLMEEVHMIK, +2y8
GQEFLHR, +2y5
GQEFLHR, +2y4
SSLASGLLR, +2y7
SSLASGLLR, +2y6
SSLASGLLR, +2y5
ALVASLPGQLQYK, +2y11
ALVASLPGQLQYK, +2y10
ALVASLPGQLQYK, +2y9
STALQLIQR, +2y7
STALQLIQR, +2y5
STALQLIQR, +2y4
SLNIQWLR, +2y6
SLNIQWLR, +2y5
SLNIQWLR, +2y4
LATTMTNHEK, +2y8
LATTMTNHEK, +2y6
LATTMTNHEK, +2y4
LAEIYVNSSFYK, +3y8+2
LAEIYVNSSFYK, +3y5+2
GGPEATLEVR, +2y6
GGPEATLEVR, +2y5
GGPEATLEVR, +2y7+2
GLLLLGVFLILLVGILVR, +3y6
GLLLLGVFLILLVGILVR, +3y5
GLLLLGVFLILLVGILVR, +3y11+2
GTQLSGGQK, +2y7
GTQLSGGQK, +2y6
GTQLSGGQK, +2y5
LSTIQNADLIVVFQNGR, +2y7
LSTIQNADLIVVFQNGR, +2y6
LSTIQNADLIVVFQNGR, +2y4
FVDTAGNFSFPVNFSLSLLNPGK, +3y12
FVDTAGNFSFPVNFSLSLLNPGK, +3y18+2
FVDTAGNFSFPVNFSLSLLNPGK, +3y14+2
STTVQLIQR, +2y7
STTVQLIQR, +2y6
STTVQLIQR, +2y5+2
AMQFSEASFTWEHDSEATVR, +3y11
AMQFSEASFTWEHDSEATVR, +3y9
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MRP2
MRP2
MRP2
MRP2
Sterolin-1
Sterolin-1
Sterolin-1
Sterolin-1
Sterolin-1
Sterolin-1
Sterolin-2
Sterolin-2
Sterolin-2
Sterolin-2
Sterolin-2
Sterolin-2
OAT7
OAT7
OAT7
OAT7
OAT7
OAT7
OCT3
OCT3
OCT3
ENT1
ENT1
ENT2
ENT2
ENT2
ENT2
ENT2
ENT2
NTCP
NTCP
NTCP

777.0112
521.2536
521.2536
521.2536
532.7739
532.7739
532.7739
588.3666
588.3666
588.3666
588.3666
588.3666
588.3666
938.4416
938.4416
938.4416
500.6011
500.6011
500.6011
523.3106
523.3106
523.3106
471.7538
471.7538
471.7538
488.9196
488.9196
440.5528
440.5528
440.5528
858.3992
858.3992
858.3992
768.0472
768.0472
768.0472

914.4326
747.3632
632.3362
430.2409
862.4451
749.3610
636.2770
864.5050
751.4209
650.3733
650.3733
482.2904
369.2063
813.3939
541.2798
410.2140
1089.5357
976.4517
861.4247
829.5393
716.4553
615.4076
559.3198
488.2827
375.1987
1079.5844
850.4781
818.4254
619.3297
490.2871
904.3795
621.2475
758.3412
1090.5891
823.4308
468.2453

AMQFSEASFTWEHDSEATVR, +3y8
FFDTTPTGR, +2y7
FFDTTPTGR, +2y6
FFDTTPTGR, +2y4
TTLLDAMSGR, +2y8
TTLLDAMSGR, +2y7
TTLLDAMSGR, +2y6
IVVLTIHQPR, +2y7
IVVLTIHQPR, +2y6
IVVLTIHQPR, +2y5
LVLISLHQPR, +2y5
LVLISLHQPR, +2y8+2
LVLISLHQPR, +2y6+2
YSNPADFYVDLTSIDR, +2y14+2
YSNPADFYVDLTSIDR, +2y9+2
YSNPADFYVDLTSIDR, +2y7+2
ISIPLDSNMRPEK, +3y9
ISIPLDSNMRPEK, +3y8
ISIPLDSNMRPEK, +3y7
DTLTLEILK, +2y7
DTLTLEILK, +2y6
DTLTLEILK, +2y5
GPSAAALAER, +2y5
GPSAAALAER, +2y4
GPSAAALAER, +2y3
DAQASAAPAAPLPER, +3y11
DAQASAAPAAPLPER, +3y8
SSQAQAQELETK, +3y7
SSQAQAQELETK, +3y5
SSQAQAQELETK, +3y4
SLTSYFLWPDEDSR, +2y7
SLTSYFLWPDEDSR, +2y5
SLTSYFLWPDEDSR, +2y12+2
MIYTAATTEETIPGALGNGTYK, +3y11
MIYTAATTEETIPGALGNGTYK, +3y8
MIYTAATTEETIPGALGNGTYK, +3y4
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